final PrograM 13th Congress of the european society for ... - ESSM
final PrograM 13th Congress of the european society for ... - ESSM
final PrograM 13th Congress of the european society for ... - ESSM
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
13 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>european</strong> <strong>society</strong><br />
<strong>for</strong> sexual Medicine<br />
14 – 17 november 2010<br />
Malaga, spain<br />
Palacio de Ferias y Congresos<br />
www.essm.org<br />
<strong>final</strong> <strong>PrograM</strong><br />
Hosted by <strong>the</strong> Asociación Española de Andrología medicina Sexual y reproductiva (ASESA)
TABLE OF CONTENT<br />
Page<br />
Welcome Addresses.....................................................3<br />
<strong>ESSM</strong> History...............................................................5<br />
<strong>ESSM</strong> Committees.......................................................6<br />
<strong>ESSM</strong> Awards .............................................................7<br />
Acknowledgements.....................................................8<br />
Palacio de Ferias y Congresos – Floor Plan.....................9<br />
General In<strong>for</strong>mation<br />
<strong>Congress</strong> Venue.......................................................10<br />
<strong>Congress</strong> Registration Counter.................................10<br />
<strong>Congress</strong> Registration Fees ......................................10<br />
<strong>Congress</strong> Language..................................................10<br />
Publication <strong>of</strong> Proceedings.......................................10<br />
<strong>Congress</strong> Documentation<br />
CO CONGRESS ONLINE ® ..........................................10<br />
Speakers Centre.......................................................11<br />
<strong>ESSM</strong> Membership Issues.........................................11<br />
Name Badges..........................................................11<br />
Technical Exhibition.................................................11<br />
Poster Exhibition .....................................................11<br />
Electronic Posters on <strong>the</strong> <strong>ESSM</strong> Website...................12<br />
Internet Centre........................................................12<br />
Wireless LAN / WIFI..................................................12<br />
C<strong>of</strong>fee and Lunch Breaks..........................................12<br />
Restaurants.............................................................12<br />
Cloakroom...............................................................12<br />
Bank........................................................................12<br />
Page<br />
Lost and Found........................................................12<br />
Mobile Phones.........................................................12<br />
Program Changes....................................................12<br />
Insurance.................................................................12<br />
Car Park...................................................................13<br />
Taxis........................................................................13<br />
Currency..................................................................13<br />
Electricity.................................................................13<br />
Climate....................................................................13<br />
Time........................................................................13<br />
Travel to Malaga......................................................13<br />
<strong>Congress</strong> Shuttles....................................................13<br />
Social Program..........................................................16<br />
Supporting Program..................................................17<br />
Introduction to <strong>the</strong> Scientific Program........................20<br />
Scientific Program Schedule.......................................22<br />
Scientific Program<br />
Sunday, 14 November 2010.....................................26<br />
Monday, 15 November 2010 ..................................28<br />
Tuesday, 16 November 2010....................................33<br />
Wednesday, 17 November 2010..............................40<br />
Poster Presentations...................................................42<br />
List <strong>of</strong> Exhibitors – Exhibition Map..............................57<br />
List <strong>of</strong> Chairpersons and Presenters.............................58<br />
<strong>Congress</strong> and Exhibition Office<br />
Office Hamburg<br />
Hanser & Co GmbH<br />
Zum Ehrenhain 34<br />
22885 Barsbüttel • Germany<br />
Phone: +49 – 40 – 670 88 20<br />
Fax: +49 –40 – 670 32 83<br />
Email: essm@cpo-hanser.de<br />
Scientific Secretariat<br />
Andrea Salonia, MD<br />
University Vita-Salute San Raffaele<br />
Via Olgettina 60<br />
20132 Milan • Italy<br />
Email: saloniaandrea@yahoo.co<br />
<strong>ESSM</strong> Secretariat<br />
Lavinia Ricci<br />
c/o AIM CONGRESS – AIM Group<br />
Via Ripamonti 129<br />
20141 Milan • Italy<br />
Phone: +39 – 025 – 660 12 89<br />
Fax: +39 – 027 – 004 85 77<br />
Email: admin@essm.org<br />
CONGRESS VENUE<br />
Palacio de Ferias y Congresos<br />
Avenida Ortega y Gasset, 201<br />
29006 Malaga, Spain<br />
www.fycma.com<br />
2
Welcome from <strong>the</strong> <strong>ESSM</strong><br />
Dear Colleagues, Dear Friends,<br />
On behalf <strong>of</strong> <strong>the</strong> Executive and Scientific committee <strong>of</strong> <strong>the</strong> European Society <strong>of</strong> Sexual<br />
Medicine, we extend to everyone in sexual medicine a warm welcome to our 2010 meeting<br />
in Malaga.<br />
Ian Eardley<br />
Andrea Salonia<br />
We have worked hard to develop an innovative scientific program <strong>for</strong> <strong>the</strong> Malaga congress<br />
where men’s, women’s, and couple’s issues will be comprehensively discussed. This year<br />
<strong>the</strong>re is a particular focus on surgical aspects <strong>of</strong> male sexual dysfunction including Peyronie’s<br />
disease, genital emergencies and penile augmentation. We have exciting Master lectures on<br />
Testosterone deficiency, Men’s Health and <strong>final</strong>ly a report on <strong>the</strong> 3 rd International Consultation<br />
on Male and Female Sexual dysfunction. Everyday clinical practice in both genders will<br />
be explored, with round tables and lectures dedicated to <strong>the</strong>mes such as <strong>the</strong> close relationship<br />
between heart disease and male’s sexual health, <strong>the</strong> sexual dysfunction that is related<br />
to urological cancer and so-called “benign” diseases in both genders. In addition we will<br />
focus on <strong>the</strong> pharmacological treatment <strong>of</strong> male and female sexual dysfunction, helping<br />
you to identify <strong>the</strong> correct treatment strategy <strong>for</strong> your everyday patients. In <strong>the</strong> field <strong>of</strong><br />
women’s sexual health <strong>the</strong>re will be a focus on <strong>the</strong> reproductive cycle, orgasmic disorders<br />
and “infertile family” matters. Finally we hope to highlight some <strong>of</strong> <strong>the</strong> less well investigated<br />
aspects <strong>of</strong> <strong>the</strong> human sexuality including issues relating to sexual torture and paedophilic<br />
violence toward adolescents. Alongside <strong>the</strong> Scientific Program, we have a comprehensive<br />
series <strong>of</strong> Educational Courses developed in conjunction with our Director <strong>of</strong> Education.<br />
Every <strong>ESSM</strong> meeting is an opportunity to meet old friends and to make new acquaintances.<br />
This meeting will be no different, and we hope that <strong>the</strong> meeting proves successful <strong>for</strong> all <strong>of</strong><br />
you as both a scientific and a social event.<br />
We are proud to welcome you to all <strong>the</strong> scientific sessions <strong>of</strong> <strong>the</strong> <strong>ESSM</strong> 2010 annual meeting.<br />
Ian Eardley, MD<br />
<strong>ESSM</strong> President<br />
Andrea Salonia, MD<br />
Chairman <strong>ESSM</strong><br />
Scientific Committee<br />
www.essm.org<br />
3
WELCOME FROM THE local congress chair<br />
Dear colleagues, dear friends,<br />
Although always said and written, be sure, it is with great pleasure and honour that Malaga,<br />
on behalf <strong>of</strong> <strong>the</strong> Spanish Association <strong>of</strong> Andrology, Reproductive and Sexual Health, ASESA,<br />
hosts this 13 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> European Society <strong>for</strong> Sexual Medicine. We had a challenge<br />
and have faced not easy times, but we at <strong>the</strong> local level have done our best to accomplish<br />
with what is written in our symbols. The motto and qualifications granted to Malaga are:<br />
“The first one in <strong>the</strong> danger <strong>of</strong> <strong>the</strong> Freedom, Very noble, Very loyal, Very hospitable, <strong>the</strong> Very<br />
charitable one and always Brave City <strong>of</strong> Malaga”.<br />
Antonio Martín Morales<br />
In <strong>the</strong> documents <strong>of</strong> <strong>the</strong> Catholic Kings, one already gives to Malaga <strong>the</strong> title <strong>of</strong> “Very noble”.<br />
It was granted in 1492, when it was determined that, considering <strong>the</strong> lineage and nobility<br />
<strong>of</strong> most <strong>of</strong> <strong>the</strong> new settlers, this title would be in all <strong>the</strong> <strong>of</strong>ficial documents. Philippe IV in<br />
1640 granted <strong>the</strong> city with <strong>the</strong> title <strong>of</strong> “Very loyal”, <strong>for</strong> <strong>the</strong> services given by <strong>the</strong> city and<br />
especially by <strong>the</strong> big quantities <strong>of</strong> money contributed to <strong>the</strong> Crown. The title <strong>of</strong> “Very illustrious”<br />
was granted in 1710 on behalf <strong>of</strong> Philippe V by <strong>the</strong> services given to <strong>the</strong> Crown by <strong>the</strong><br />
city during <strong>the</strong> War <strong>of</strong> Succession. “Always brave” by <strong>the</strong> crest <strong>of</strong> his coat <strong>of</strong> arms a civic<br />
crown and <strong>the</strong> emblem, “The first one in <strong>the</strong> danger <strong>of</strong> <strong>the</strong> freedom” were granted by<br />
Royal decree <strong>of</strong> August 21, 1843, owing to <strong>the</strong> struggles that provoked <strong>the</strong> fall <strong>of</strong> General<br />
Espartero. The title <strong>of</strong> “Very hospitable” was granted by Royal decree <strong>of</strong> January 1, 1901 by<br />
<strong>the</strong> noble and self-sacrificing conduct <strong>of</strong> <strong>the</strong> Malaga people owing to <strong>the</strong> shipwreck <strong>of</strong> <strong>the</strong><br />
frigate <strong>of</strong> German war Gneisenau. 386 out <strong>of</strong> 427 sailors were saved and 12 people among<br />
<strong>the</strong> rescuers died. And already in 1922 and in pro<strong>of</strong> <strong>of</strong> <strong>the</strong> Real appreciation, <strong>for</strong> <strong>the</strong> charitable<br />
help given to <strong>the</strong> soldiers <strong>of</strong> <strong>the</strong> Army <strong>of</strong> Africa and support <strong>of</strong> a hospital <strong>for</strong> <strong>the</strong> same<br />
ones, <strong>the</strong> title was granted to <strong>the</strong> city to Malaga <strong>of</strong> “Very charitable”.<br />
What about Sexual Medicine How can we qualify this matter Does it match somehow<br />
with Malaga’s motto and qualifications<br />
Dealing open minded with Sexual Issues has been traditionally felt as a trigger <strong>for</strong> freedom,<br />
so maybe we are in <strong>the</strong> right place, since Malaga is “The first one in <strong>the</strong> danger <strong>of</strong> <strong>the</strong> Freedom”.<br />
On <strong>the</strong> o<strong>the</strong>r hand, Sexuality, closely linked to Love, turn out as a “Very noble” and<br />
“Very loyal”, as well as Enjoyable, Human Feature. If you add hospitality and generosity, be<br />
sure that <strong>the</strong> “Very hospitable”, <strong>the</strong> “Very charitable one” and always “Brave City <strong>of</strong> Malaga”,<br />
taking advantage and, at <strong>the</strong> same time, thanking <strong>the</strong> hard work <strong>of</strong> our Scientific Committee<br />
and <strong>Congress</strong> Organizer has pursued <strong>the</strong> best <strong>of</strong>fer, which <strong>of</strong> course is what you deserve.<br />
Welcome to Malaga, feel at home and enjoy this 13 th <strong>ESSM</strong> <strong>Congress</strong>. It would be our best<br />
reward.<br />
Antonio Martín Morales, MD<br />
Chairman <strong>of</strong> <strong>the</strong> 13 th <strong>ESSM</strong> <strong>Congress</strong> 2010<br />
4
<strong>ESSM</strong> HISTORY<br />
<strong>ESSM</strong> President<br />
Ian Eardley, MD<br />
St. James’s University Hospital<br />
Leeds, UK<br />
Chairperson <strong>of</strong> <strong>the</strong> 13 th <strong>ESSM</strong> <strong>Congress</strong> 2010<br />
Antonio Martin Morales, MD, Spain<br />
Urología Andrología integradas y Medicina Sexual<br />
Carlos Haya University Hospital<br />
Málaga, Spain<br />
<strong>ESSM</strong> Presidents<br />
1993 – 1997 Gorm Wagner, Denmark<br />
1997 – 1999 Inigo Saenz de Tejada, Spain<br />
1999 – 2001 John Pryor, UK<br />
2001 – 2004 Dimitrios Hatzichristou, Greece<br />
2004 – 2007 Francesco Montorsi, Italy<br />
2007 – 2010 Ian Eardley, UK<br />
2010 – 2013 Hartmut Porst, Germany,<br />
President Elect<br />
<strong>ESSM</strong> <strong>Congress</strong>, Venues and Chairman<br />
1995 Porto Carras, Greece<br />
Dimitrios Hatzichristou, Greece<br />
1997 Madrid, Spain<br />
Inigo Saenz de Tejada, Spain<br />
2000 Barcelona, Spain<br />
Halim Hattat, Turkey<br />
2001 Rome, Italy<br />
Francesco Montorsi, Italy<br />
2002 Hamburg, Germany<br />
Hartmut Porst, Germany<br />
2003 Istanbul, Turkey<br />
Emre Akkus, Turkey<br />
2004 London, UK<br />
David Ralph, UK<br />
2005 Copenhagen, Denmark<br />
Petter Hedlund, Sweden<br />
Annamaria Giraldi, Denmark<br />
2006 Vienna, Austria<br />
Siegfried Meryn, Austria<br />
2007 Lisbon, Portugal<br />
Nuno Monteiro Pereira, Portugal<br />
2008 Brussels, Belgium<br />
Joint <strong>Congress</strong> <strong>of</strong> ISSM/<strong>ESSM</strong><br />
Eric Wespes, Belgium (ISSM)<br />
Claude Schulman, Belgium (<strong>ESSM</strong>)<br />
2009 Lyon, France<br />
Béatrice Cuzin, Lyon<br />
François Giuliano, Paris<br />
2010 Malaga, Spain<br />
Antonio Martin Morales, Malaga<br />
2011 Milan, Italy<br />
Andrea Salonia, Italy<br />
www.essm.org<br />
5
<strong>ESSM</strong> COMMITTEES<br />
<strong>ESSM</strong> EXECUTIVE COMMITTEE<br />
President Ian Eardley, UK<br />
President Elect Hartmut Porst, Germany<br />
Secretary General Antonio Martin Morales, Spain<br />
Treasurer David Ralph, UK<br />
Adv. Board<br />
Representative Carlo Bettocchi, Italy<br />
Members Carla Costa, Portugal<br />
Béatrice Cuzin, France<br />
Petter Hedlund, Sweden<br />
Manuel Mas, Spain<br />
Yacov Reisman, The Ne<strong>the</strong>rlands<br />
Jens Sønksen, Denmark<br />
Mustafa F. Usta, Turkey<br />
<strong>ESSM</strong> SCIENTIFIC COMMITTEE<br />
Chair<br />
Andrea Salonia, Italy<br />
Sub-Committees<br />
Men‘s Sexual Health<br />
Clinical: Ed<br />
Chair<br />
Kostantinos Hatzimouratidis, Greece<br />
Members Ilan Gruenwald, Isreal<br />
Muammer Kendirci, Turkey<br />
Nicola Mondaini, Italy<br />
Thierry Roumeguère, Belgium<br />
Clinical: Health Issues<br />
Chair<br />
Charalambos Vlachopoulos, Greece<br />
Members Giovanni Corona, Germany<br />
Dirk Schul<strong>the</strong>iss, Germany<br />
Clinical: Sexual Disorders<br />
Chair<br />
Francois Giuliano, France<br />
Members Nicolae Calomfirescu, Romania<br />
Juza Chen, Israel<br />
Emmanuele Jannini, Italy<br />
Marcel Waldinger, The Ne<strong>the</strong>rlands<br />
Clinical: Surgery<br />
Chair<br />
Ates Kadioglu, Turkey<br />
Members Luigi Cormio, Italy<br />
Giulio Garaffa, Italy<br />
Sukbinder Minhas, Turkey<br />
Sava C. Perovic, Serbia<br />
Women’s Sexual Health<br />
Female Sexual Health<br />
Chair<br />
Rossella E. Nappi, Italy<br />
Members Johannes Bitzer, Switzerland<br />
Selahittin Çayan, Turkey<br />
Annamaria Giraldi, Denmark<br />
Ellen Laan, The Ne<strong>the</strong>rlands<br />
The Couple<br />
Psychosexual<br />
Chair<br />
Members<br />
Basic Science<br />
Chair<br />
Members<br />
Kevan Wylie, UK<br />
Loukas Athanasiadis, Greece<br />
Stuart Brody, UK<br />
Bente Traeen, Norway<br />
Mario Maggi, Italy<br />
Javier Angulo, Spain<br />
Delphine Behr-Roussel, France<br />
Giuseppe Cirino, Italy<br />
Christian Gratzke, Germany<br />
NATIONAL ORGANIZATION COMMITTEE<br />
Chair<br />
Advisory Board<br />
Members<br />
Antonio Martin Morales<br />
Ana Ma Puigvert Martìnez<br />
Rafael Prieto Castro<br />
Manuel Mas Garcia<br />
Ignacio Moncada Iribarren<br />
Ander Astobieta Odriozola<br />
Carlos Balmori Boticario<br />
Jesus Blázquez Izquierdo<br />
Francisco Cabello Santamaría<br />
Natalio Cruz Navarro<br />
Miquel de la Peña Sanchez-Zúñiga<br />
Pedro Gutierrez Hernandez<br />
José Mª Martínez Jabaloyas<br />
José Mª Pomerol Monseny<br />
Luis Rodriguez Vela<br />
Froilán Sanchez Sanchez<br />
Ana Mª Segura Paños<br />
6
essm awards<br />
The <strong>ESSM</strong> Meeting Awards<br />
The best presentations will be awarded with EUR 2.000<br />
by <strong>ESSM</strong>’s Award Committees.<br />
1. Prize <strong>for</strong> <strong>the</strong> best presentation on FSD (preclinical)<br />
2. Prize <strong>for</strong> <strong>the</strong> best presentation on FSD (clinical)<br />
3. Prize <strong>for</strong> <strong>the</strong> best presentation on MSD (preclinical)<br />
4. Prize <strong>for</strong> <strong>the</strong> best presentation on MSD (clinical)<br />
5. Prize <strong>for</strong> <strong>the</strong> best surgical presentation<br />
The <strong>ESSM</strong> Prestige Awards<br />
The Executive Committee <strong>of</strong> <strong>ESSM</strong> decided to establish<br />
two awards to be presented during <strong>the</strong> annual meetings<br />
<strong>of</strong> <strong>the</strong> <strong>society</strong>:<br />
The <strong>ESSM</strong> Career Award<br />
This award will be presented to a senior scientist who has<br />
made an outstanding contribution in <strong>the</strong> field.<br />
The Executive and Scientific Committees will select <strong>the</strong><br />
award winner, and <strong>the</strong> award winner will be presented<br />
during <strong>the</strong> Opening Ceremony.<br />
The <strong>ESSM</strong> Award <strong>of</strong> Excellence<br />
This award is presented annually to a physician or scientist<br />
(ei<strong>the</strong>r in basic sciences or clinical practice) who has<br />
made recent exceptional achievement in <strong>the</strong> field. Special<br />
consideration will be given to applications from less-experienced<br />
researchers in Sexual Medicine.<br />
<strong>ESSM</strong> Award Winners<br />
Best Presentation Awards<br />
1995 Christian Stief, Germany<br />
1997 Paul F. Engelhardt, Germany<br />
Francois Giuliano, France<br />
Suks Minhas, UK<br />
2000 Apostolos Apostolidis, Greece<br />
F. Mumtaz, UK<br />
2002 Annamaria Giraldi, Denmark<br />
2003 Stefan Ückert, Germany<br />
Ilan Gruenwald, Israel<br />
Mustafa Usta, Turkey<br />
Alberto Briganti, Italy<br />
2004 Byoung Ahn, Republic <strong>of</strong> Korea<br />
Javier Angulo, Spain<br />
Antonio Aversa, Italy<br />
2005 Giovanni Corona, Italy<br />
Elke Gizewski, Germany<br />
Halim Hattat, Turkey<br />
Attila Kun, Hungary<br />
Sava Perovic, Serbia<br />
2006 Fotini Ferenidou, Greece<br />
Giulio Garaffa, Italy<br />
Wayne Hellstrom, USA<br />
Linda Vignozzi, Italy<br />
Guido van Wingen, The Ne<strong>the</strong>rlands<br />
2007 Stephanie Ortigue, France<br />
Dara Lazar, Austria<br />
Ignacio Moncada, Spain<br />
Jun-Kyu Suh, Republic <strong>of</strong> Korea<br />
Tolga Akman, Turkey<br />
2008 David Ralph, UK<br />
Judith Alder, Switzerland<br />
Konstantinos Rokkas, Greece<br />
K. Park, Korea<br />
H. Gelez, France<br />
2009 Andrea Russo, Italy<br />
Gert Holstege, The Ne<strong>the</strong>rlands<br />
Javier Angulo, Spain<br />
Yoram Vardi, Israel<br />
Jas Kalsi and Giulio Garaffa, UK<br />
Career Awards<br />
2002 John Pryor, UK<br />
2003 Gorm Wagner, Denmark<br />
2004 Giles Brindley, UK<br />
Ronald Virag, France<br />
2005 Karl-Erik Andersson, Sweden<br />
2007 Inigo Saenz de Tejada, Spain<br />
2008 Vaclav Michael, Czech Republic<br />
2009 Axel R. Fugl-Meyer, Sweden<br />
2010 Hans Hedlund, Sweden<br />
Award <strong>of</strong> Excellence<br />
2002 Petter Hedlund, Sweden<br />
2003 Selim Cellek, UK<br />
2004 Stefan Ückert, Germany<br />
2005 Javier Angulo, Spain<br />
Ekkehard W. Hauck, Germany<br />
2006 Andrea Salonia, Italy<br />
2007 Antonio Aversa, Italy<br />
2008 Delphine Behr-Roussel, France<br />
2009 Giovanni Corona, Italy<br />
2010 Tillmann H.C. Krüger, Germany<br />
www.essm.org<br />
7
ACKNOWLEdgEmENTS<br />
The organizers <strong>of</strong> <strong>the</strong> 13 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> European Society <strong>for</strong> Sexual Medicine gratefully acknowledge <strong>the</strong> support <strong>of</strong><br />
<strong>the</strong> following companies (as per October 2010).<br />
Major sponsors<br />
Eli Lilly and Company<br />
sponsors<br />
American Medical Systems B.V.<br />
Bayer Spain<br />
Coloplast A / S<br />
Itamar Medical Ltd.<br />
Pfizer<br />
Janssen Pharmaceutica NV.<br />
Medispec Ltd.<br />
Nature Publishing<br />
Pierre Fabre Medicament<br />
save <strong>the</strong> date!<br />
14 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>european</strong> <strong>society</strong><br />
<strong>for</strong> sexual Medicine<br />
1 – 4 December 2011<br />
Milan Convention Center | Milan, Italy<br />
8
Palacio de Ferias y Congresos – Floor plan<br />
Ground Level<br />
Main<br />
Entrance<br />
Entrance<br />
Hall<br />
Counter<br />
Central<br />
Patio<br />
Exhibition Catering Poster<br />
Exhibition<br />
Pavilion 1<br />
Cloakroom<br />
Auditorium 1 Auditorium 2<br />
Conference<br />
Room 1<br />
Restaurant<br />
Speakers<br />
Centre<br />
Level 1<br />
Fur<strong>the</strong>r meeting rooms on level 1:<br />
> <strong>ESSM</strong> Board Room<br />
> Conference Room 2<br />
> Multipurpose rooms 1 – 15<br />
www.essm.org<br />
9
general in<strong>for</strong>mation<br />
<strong>Congress</strong> Venue<br />
Palacio de Ferias y Congresos<br />
Avenida Ortega y Gasset, 201<br />
29006 Malaga, Spain<br />
www.fycma.com<br />
<strong>Congress</strong> Registration Counter<br />
All congress materials and documentation will be available<br />
at <strong>the</strong> congress registration counter located at <strong>the</strong><br />
entrance foyer <strong>of</strong> <strong>the</strong> Palacio de Ferias y Congreses de<br />
Malaga. The congress staff will be pleased to help you<br />
with all enquiries regarding registration, congress material<br />
and congress program. Please do not hesitate to contact<br />
<strong>the</strong> staff members if <strong>the</strong>re is anything <strong>the</strong>y can do to<br />
make your stay more enjoyable.<br />
Opening Hours<br />
Sunday 14 November 2010 08.00 – 19.00 h<br />
Monday 15 November 2010 07.00 – 18.00 h<br />
Tuesday 16 November 2010 06.45 – 18.00 h<br />
Wednesday 17 November 2010 07.30 – 12.30 h<br />
During <strong>the</strong> opening hours <strong>the</strong> congress counter can be<br />
reached at:<br />
Phone: +34 – 952 045653<br />
Fax: +34 –952 045654<br />
<strong>Congress</strong> Registration Fees<br />
Registration and Payment<br />
after<br />
1 Sept. 2010<br />
<strong>ESSM</strong> Members, Physicians (MD) EUR 500<br />
Non-Members, Physicians (MD) EUR 600<br />
<strong>ESSM</strong>-Members with reduced fees*:<br />
Nurses, Residents in Training,<br />
Scientists (PhD), Psychologists,<br />
Therapists, Students<br />
Non-Members with reduced fees*:<br />
Nurses, Residents in Training,<br />
Scientists (PhD), Psychologists,<br />
Therapists, Students<br />
EUR 400<br />
EUR 500<br />
Retired Delegates EUR 80<br />
Accompanying Persons EUR 85<br />
Registration fee <strong>for</strong> participants includes:<br />
> Admission to all scientific sessions<br />
> Admission to poster and technical exhibition<br />
> Admission to <strong>the</strong> <strong>ESSM</strong> Opening Ceremony and<br />
Welcome Reception on 14 November 2010<br />
> Conference materials (delegate bag, <strong>final</strong> program,<br />
abstract book, etc.)<br />
> C<strong>of</strong>fee breaks and lunches from Monday, 15 November<br />
2010 until Wednesday, 17 November 2010 ending<br />
with a c<strong>of</strong>fee break in <strong>the</strong> morning.<br />
> Use <strong>of</strong> congress bus shuttle service between <strong>the</strong> city<br />
centre and <strong>the</strong> congress venue from<br />
Sunday, 14 November 2010 to Wednesday, 17 November<br />
2010<br />
Registration fee <strong>for</strong> accompanying persons<br />
includes:<br />
> Admission to <strong>the</strong> <strong>ESSM</strong> Opening Ceremony and<br />
Welcome Reception on 14 November 2010<br />
> Half Day Walking City Sightseeing Tour <strong>of</strong> Malaga on<br />
Monday, 15 November 2010 (pre-registration<br />
necessary)<br />
> Use <strong>of</strong> congress bus shuttle service between <strong>the</strong> city<br />
cen tre and <strong>the</strong> congress venue from Sunday, 14<br />
No vember 2010 to Wednesday, 17 November 2010<br />
<strong>Congress</strong> Language<br />
The congress language is English. Simultaneous translation<br />
will not be provided.<br />
Symposia in national languages organized by <strong>the</strong> national<br />
affiliated societies ASESA / SPA will be <strong>of</strong>fered on Sunday,<br />
15 November 2010 , 09.00 – 14.00 h.<br />
Publication <strong>for</strong> Proceedings<br />
The European Society <strong>for</strong> Sexual Medicine retains <strong>the</strong><br />
right to publish all material presented at <strong>the</strong> congress in<br />
an <strong>ESSM</strong> publication.<br />
<strong>Congress</strong> Documentation<br />
The <strong>ESSM</strong> will <strong>of</strong>fer its members to view parts <strong>of</strong> <strong>the</strong> scientific<br />
schedule online through a web-based system from<br />
<strong>the</strong> <strong>ESSM</strong> homepage. There<strong>for</strong>e several lectures will be<br />
filmed during <strong>the</strong> congress, which include all Master Lectures<br />
and Round Tables, <strong>the</strong> JSM Debates and <strong>the</strong> Video<br />
Course and all Educational Courses.<br />
* A letter <strong>of</strong> <strong>the</strong> Chairman <strong>of</strong> <strong>the</strong> Department is necessary.<br />
10
general in<strong>for</strong>mation<br />
CO CONGRESS ONLINE ®<br />
Participants can benefit from <strong>the</strong> web based <strong>ESSM</strong> <strong>Congress</strong><br />
In<strong>for</strong>mation System CO CONGRESS ONLINE ® on-site<br />
at <strong>the</strong> Internet centre in <strong>the</strong> exhibition area in Pavilion 1.<br />
At www.essm-congress.org participants can set up and<br />
print out a personal congress program schedule.<br />
CO CONGRESS ONLINE ® <strong>of</strong>fers an extensive congress<br />
service and provides you with in<strong>for</strong>mation on:<br />
> Updated scientific program<br />
> Program by day<br />
> Program by <strong>for</strong>mats with accepted abstracts <strong>of</strong> chairpersons<br />
and speakers<br />
> Program search<br />
> List <strong>of</strong> participants (who is who)<br />
> List <strong>of</strong> exhibitors and sponsors<br />
> Social Events<br />
> General congress in<strong>for</strong>mation<br />
> Supporting program<br />
> City <strong>of</strong> Malaga<br />
> Hotel accommodation<br />
> Travel to Malaga<br />
> News<br />
> Private mailbox<br />
Speakers Centre<br />
The speakers centre is located on <strong>the</strong> ground level <strong>of</strong> <strong>the</strong><br />
congress centre. Speakers are asked to hand in <strong>the</strong>ir CD<br />
ROM or USB stick, containing <strong>the</strong> PowerPoint presentation<br />
(IBM <strong>for</strong>mat or compatible, no multisession) preferably<br />
one day be<strong>for</strong>e <strong>the</strong>ir presentation but at <strong>the</strong> latest<br />
90 minutes prior to <strong>the</strong> presentation. The presentation<br />
will be transferred to <strong>the</strong> central congress server and will<br />
be available afterwards on a special congress notebook<br />
in <strong>the</strong> hall <strong>of</strong> <strong>the</strong> presentation. Due to time and technical<br />
reasons we kindly ask <strong>the</strong> speakers not to use <strong>the</strong>ir own<br />
notebook. Several PC working stations are provided in<br />
<strong>the</strong> speakers’ centre where speakers can also work on<br />
<strong>the</strong>ir PC charts in a quiet area. Technical staff will be glad<br />
to assist.<br />
Opening Hours<br />
Sunday 14 November 2010 08.00 – 19.00 h<br />
Monday 15 November 2010 07.00 – 18.00 h<br />
Tuesday 16 November 2010 06.45 – 18.00 h<br />
Wednesday 17 November 2010 07.30 – 12.00 h<br />
<strong>ESSM</strong> Membership Issues<br />
For <strong>ESSM</strong> membership issues and any o<strong>the</strong>r <strong>ESSM</strong> business,<br />
please contact our <strong>ESSM</strong> booth which is situated in<br />
<strong>the</strong> exhibition area in <strong>the</strong> Pavilion 1.<br />
As an initiative <strong>of</strong> <strong>the</strong> <strong>ESSM</strong>, all <strong>ESSM</strong> members can get<br />
a free copy <strong>of</strong> <strong>the</strong> ICSM 2009 CD at <strong>the</strong> <strong>ESSM</strong> booth.<br />
The CD contains <strong>the</strong> proceedings <strong>of</strong> <strong>the</strong> 3 rd International<br />
Consultation on Sexual Medicine, 10 – 13 July 2009 –<br />
Palais des Congrès, Paris, France.<br />
Name Badges<br />
All participants are kindly requested to wear <strong>the</strong>ir name<br />
badge at all times during <strong>the</strong> congress. The colours <strong>of</strong><br />
<strong>the</strong> name badge have <strong>the</strong> following significance:<br />
Delegate:<br />
blue<br />
Accompanying person: orange<br />
Press:<br />
yellow<br />
Exhibitor:<br />
green<br />
Staff:<br />
red<br />
Technical Exhibition<br />
A technical exhibition will be organized in <strong>the</strong> Pavilion 1 <strong>of</strong><br />
<strong>the</strong> Palacio de Ferias y Congresos, Malaga next to <strong>the</strong> main<br />
meeting rooms. C<strong>of</strong>fee bars and catering stations <strong>for</strong><br />
lunch will be located in <strong>the</strong> technical exhibition as well.<br />
Opening Hours<br />
Monday 15 November 2010 09.00 – 17.00 h<br />
Tuesday 16 November 2010 09.00 – 17.00 h<br />
Wednesday 17 November 2010 09.00 – 11.00 h<br />
Poster Exhibition<br />
Posters will be sited in Pavilion 1, where <strong>the</strong> technical<br />
exhibition will take place. Special highlighted posters will<br />
be displayed in a dedicated area <strong>of</strong> <strong>the</strong> exhibition. Highlighted<br />
poster tours will take place during <strong>the</strong> lunch and<br />
afternoon c<strong>of</strong>fee breaks on Monday and Tuesday.<br />
Operated by Estensis GmbH –<br />
<strong>the</strong> Conference Company<br />
www.essm.org<br />
11
general in<strong>for</strong>mation<br />
Each poster tour includes six poster presentations chaired<br />
by a senior scientist as follows:<br />
Basic science<br />
Monday, 15 November 2010 12.00 – 12.30 h<br />
Male sexual function and dysfunction<br />
Monday, 15 November 2010 15.30 – 16.00 h<br />
Female sexual function<br />
Tuesday, 16 November 2010 12.00 – 12.30 h<br />
Different aspects <strong>of</strong> sexual health – 2<br />
Tuesday, 16 November 2010 15.30 – 16.00 h<br />
Fur<strong>the</strong>r details are given in <strong>the</strong> scientific program schedule<br />
<strong>of</strong> <strong>the</strong> congress in this program. The poster presentation<br />
will be sited in <strong>the</strong> Pavilion 1 <strong>of</strong> <strong>the</strong> congress venue.<br />
The poster exhibition is open to all participants:<br />
Poster exhibition Opening Hours<br />
Monday 15 November 2010 09.00 – 17.00 h<br />
Tuesday 16 November 2010 09.00 – 17.00 h<br />
Wednesday 17 November 2010 09.00 – 11.00 h<br />
Wednesday, 17 November 2010 free <strong>of</strong> charge to all participants<br />
wearing congress name badges. A complimentary<br />
snack buffet will be <strong>of</strong>fered during lunch time <strong>for</strong> all<br />
registered congress delegates in <strong>the</strong> exhibition area during<br />
<strong>the</strong> congress on Monday and Tuesday.<br />
Restaurants<br />
A self service restaurant is provided adjacent to <strong>the</strong> exhibition<br />
area in Pavilion 1.<br />
Cloakroom<br />
A cloakroom is available close to <strong>the</strong> <strong>Congress</strong> Counter.<br />
You can also store your luggage here.<br />
Bank<br />
An ATM machine from <strong>the</strong> Bank Unicaja is located in <strong>the</strong><br />
Palacio de Ferias y Congresos.<br />
Electronic Posters On The <strong>ESSM</strong> Website<br />
All poster presentations will be displayed on <strong>the</strong> <strong>ESSM</strong><br />
website after <strong>the</strong> congress. All poster authors who have not<br />
yet submitted <strong>the</strong>ir poster are kindly asked to do so electronically<br />
ei<strong>the</strong>r on CD ROM or on USB stick at <strong>the</strong> speakers<br />
centre on <strong>the</strong> ground level <strong>of</strong> <strong>the</strong> congress centre.<br />
Internet Centre<br />
Several Internet terminals are available to all delegates at<br />
<strong>the</strong> exhibition area in <strong>the</strong> Pavilion 1 <strong>of</strong> <strong>the</strong> Palacio de Ferias<br />
y Congresos, The Internet centre is accessible according<br />
to <strong>the</strong> opening hours <strong>of</strong> <strong>the</strong> exhibition.<br />
By courtesy <strong>of</strong> <strong>the</strong> major sponsors:<br />
Lost And Found<br />
A lost and found service is available at <strong>the</strong> registration<br />
area <strong>of</strong> <strong>the</strong> congress venue.<br />
Mobile Phones<br />
Delegates are kindly requested to keep <strong>the</strong>ir mobile<br />
phones turned <strong>of</strong>f while attending <strong>the</strong> scientific sessions<br />
in <strong>the</strong> meeting rooms.<br />
Program Changes<br />
The organisers cannot assume liability <strong>for</strong> any changes in<br />
<strong>the</strong> congress program due to external or un<strong>for</strong>eseen circumstances.<br />
Wireless LAN / WiFi<br />
Wireless LAN is installed from Sunday, 14 November until<br />
Wednesday, 17 November 2010 in <strong>the</strong> congress centre.<br />
C<strong>of</strong>fee and Lunch Breaks<br />
C<strong>of</strong>fee and tea will be served during <strong>the</strong> morning and<br />
afternoon c<strong>of</strong>fee breaks from Monday 15 November to<br />
Insurance<br />
The congress fee does not include insurance. All participants<br />
are advised to arrange <strong>for</strong> <strong>the</strong>ir own insurance.<br />
Health and accident insurance is recommended and has<br />
to be purchased in your country <strong>of</strong> origin. The organisers<br />
will not be responsible <strong>for</strong> a loss or damage <strong>of</strong> personal<br />
belongings.<br />
12
general in<strong>for</strong>mation<br />
Car Park<br />
Parking spaces are situated in <strong>the</strong> general car park <strong>of</strong> <strong>the</strong><br />
Palacio de Ferias y Congresos. Parking fees are not included<br />
in <strong>the</strong> registration fee.<br />
Taxis<br />
Taxis are available in front <strong>of</strong> <strong>the</strong> main entrance or upon<br />
demand at <strong>the</strong> registration counter.<br />
Currency<br />
The <strong>of</strong>ficial Spanish currency is EUR. Credit cards are fitly<br />
accepted.<br />
Electricity<br />
Spanish plugs use 220-240 volts.<br />
Climate<br />
Time<br />
The time zone is UTC / GMT +1 hour<br />
Travel to Malaga<br />
By plane<br />
Malaga Airport is located 8 kilometers from <strong>the</strong> capital. By<br />
car Malaga Airport can be reached within <strong>the</strong> municipality<br />
<strong>of</strong> Malaga, to <strong>the</strong> southwest <strong>of</strong> <strong>the</strong> capital, and can be<br />
accessed from <strong>the</strong> E-15 motorway, which also <strong>for</strong>ms <strong>the</strong><br />
Malaga ring road, or Avenida de Velázquez, which goes<br />
directly into <strong>the</strong> city centre. The congress centre is located<br />
between <strong>the</strong> airport and city centre. www.aena.es<br />
By train<br />
Malaga Railway Station constitutes one <strong>of</strong> <strong>the</strong> city’s most<br />
important communication nodes with <strong>the</strong> rest <strong>of</strong> <strong>the</strong><br />
province, as well as with <strong>the</strong> Andalusian region, <strong>the</strong> rest<br />
<strong>of</strong> Spain and with Europe.<br />
The climate in Malaga is extremely moderate in winter,<br />
with very mild temperatures. The average temperature<br />
during <strong>the</strong> day in November is 15 ° Celsius. Over <strong>the</strong> year<br />
Malaga enjoys an average <strong>of</strong> 330 days <strong>of</strong> sun.<br />
<strong>Congress</strong> Shuttles – Stop A and B<br />
A<br />
B<br />
www.essm.org<br />
13
gENErAL iNFOrmATiON<br />
<strong>Congress</strong> shUttles<br />
A daily congress shuttle is provided between <strong>the</strong> city centre<br />
<strong>of</strong> Malaga and <strong>the</strong> Palacio de Ferias y Congreses. With<br />
your badge you can use <strong>the</strong> shuttle free <strong>of</strong> charge according<br />
to <strong>the</strong> below time table. Busses will depart from<br />
two stops in <strong>the</strong> city centre.<br />
On Monday a direct shuttle from <strong>the</strong> Palacio to “Meet<br />
your Colleagues Evening” at <strong>the</strong> Malagueta Bullring will<br />
be arranged. For <strong>the</strong> <strong>ESSM</strong> Annual Business Meeting a<br />
shuttle will leave from <strong>the</strong> city centre, Stops A and B<br />
already on 06.30 h on Tuesday morning.<br />
<strong>the</strong> stops are:<br />
stop a: Hotel Molina Lario, Molina Lario street, 20 – 22,<br />
this hotel is opposite AC Malaga Palacio Hotel.<br />
stop b: Barceló Málaga hotel main entrance, Heroes de<br />
Sostoa street s / n.<br />
stop a: Hotel Molina Lario, Molina Lario street, 20 – 22,<br />
this hotel is opposite AC Malaga Palacio Hotel.<br />
<strong>Congress</strong> venue: Palacio de Ferias y Congresos.<br />
sunday, 14 november 2010<br />
From To Departure<br />
Stop A / B Palacio 08.30 h<br />
Stop A / B Palacio 14.30 h<br />
Stop A / B Palacio 17.30 h<br />
Palacio Stop A / B 20.30 h<br />
Monday, 15 november 2010<br />
From To Departure<br />
Stop A / B Palacio 07.20 h<br />
Palacio Stop A / B 17.45 h<br />
Palacio Stop A / B 19.15 h<br />
fur<strong>the</strong>r drive to Malagueta bullring<br />
<strong>for</strong> <strong>ESSM</strong> “Meet your Colleagues Evening”<br />
tuesday, 16 november 2010<br />
From To Departure<br />
Stop A / B Palacio 06.30 h<br />
Stop A / B Palacio 07.20 h<br />
Palacio Stop A / B 17.45 h<br />
Palacio Stop A / B 19.15 h<br />
Wednesday, 17 november 2010<br />
From To Departure<br />
Stop A / B Palacio 07.20 h<br />
Palacio Malaga Airport 11.00 h<br />
Palacio Malaga Airport 12.30 h<br />
stop b: Barceló Málaga hotel main entrance, Heroes de<br />
Sostoa street s / n<br />
next to main station Estacion Vialia Maria Zambrano<br />
stop a – hotels<br />
AC Malaga Palacio<br />
stop b – hotels<br />
Barcelo Malaga<br />
Following hotels are in walking distance to Stop A / B:<br />
Molina Larios<br />
Silken Puerta Malaga<br />
Malaga Larios<br />
Hotel Montemalaga<br />
NH Malaga<br />
Hotel Tryp Alameda<br />
Malaga Centro<br />
Hotel Husa Guadal medina<br />
MS Maestrarza<br />
Patio de Posada Vinci<br />
Zenit Hotel<br />
14
feel<br />
sexual<br />
SEXUAL CONFIDENCE MATTERS *<br />
* Alth<strong>of</strong> SE. Quality <strong>of</strong> life and erectile dysfunction. Urology 2002; 59: 803-810 (‘<strong>the</strong> inability to function sexually can erode an individual’s sense <strong>of</strong> self-esteem and lead to emotional and marital tension’).<br />
Alth<strong>of</strong> SE, O’Leary MP, Cappelleri JC, et al. Self-esteem, confi dence and relationships in men treated with sildenafi l citrate <strong>for</strong> erectile dysfunction : results <strong>of</strong> two-double-blind placebo-controlled trials. J Gen Intern Med 2006; 21:1069-1074<br />
(good evidence <strong>for</strong> improvement in SEAR scores <strong>for</strong> Viagra vs. placebo)<br />
VIAGRA ® Tablets (sildenafil citrate). Presentation: Blue fi lm-coated, rounded diamond-shaped tablets containing sildenafi l citrate equivalent to 25mg, 50mg and 100mg sildenafi l. The tablets contain lactose. Indications: Erectile dysfunction.<br />
Sexual stimulation is required <strong>for</strong> effi cacy. Dosage: Adults: 50mg approximately one hour be<strong>for</strong>e sexual activity. Adjust dose based on effi cacy and toleration. Maximum dose is 100mg. One dose per day is <strong>the</strong> maximum recommended. If taken<br />
with food, <strong>the</strong> onset <strong>of</strong> activity may be delayed. Elderly: Dosage adjustments are not required in elderly patients. Hepatic impairment, severe renal impairment: 25mg initial dose should be considered; adjust dose based on effi cacy and toleration.<br />
Children under 18 years: Not indicated. With CYP3A4 inhibitors: a starting dose <strong>of</strong> 25mg should be considered, except <strong>for</strong> ritonavir (see Warnings and precautions). With alpha-blockers: Patients should be stable on alpha-blocker <strong>the</strong>rapy prior<br />
to initiating sildenafi l treatment; starting dose <strong>of</strong> 25mg should be considered. Contra-indications: Co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any <strong>for</strong>m; patients <strong>for</strong> whom sexual activity is inadvisable (e.g.<br />
patients with severe cardiovascular disorders); patients with vision loss in one eye due to non-arteritic anterior ischaemic optic neuropathy (NAION); severe hepatic impairment; hypotension; recent stroke or myocardial infarction; known hereditary<br />
degenerative retinal disorders; hypersensitivity to sildenafi l or to any <strong>of</strong> <strong>the</strong> excipients. Pregnancy and lactation: Not indicated <strong>for</strong> women. Warnings and precautions: A medical history and physical examination should be undertaken to<br />
diagnose erectile dysfunction and determine potential underlying causes. Cardiovascular status should be assessed, as sexual activity is associated with cardiac risk. Although <strong>the</strong>ir clinical relationship to Viagra has not been established, serious<br />
cardiovascular events have been reported (see Side-effects), mostly in patients with pre-existing cardiovascular risk factors and many occurring during or shortly after intercourse. Sildenafi l has vasodilator properties, resulting in mild and<br />
transient decreases in blood pressure. Prior to prescribing sildenafi l, physicians should carefully consider whe<strong>the</strong>r <strong>the</strong>ir patients with increased susceptibility to vasodilators could be adversely affected, especially in combination with sexual<br />
activity. Sildenafi l potentiates <strong>the</strong> hypotensive effects <strong>of</strong> nitrates. Caution advised in patients with anatomical de<strong>for</strong>mation <strong>of</strong> <strong>the</strong> penis (such as angulation, cavernosal fi brosis or Peyronie’s disease) or predisposed to priapism (such as sickle<br />
cell anaemia, multiple myeloma or leukaemia) and in patients with bleeding disorders or active peptic ulceration . Not recommended in combination with o<strong>the</strong>r treatments <strong>for</strong> erectile dysfunction. As with o<strong>the</strong>r PDE5 inhibitors, visual defects and<br />
NAION cases have been reported with <strong>the</strong> intake <strong>of</strong> sildenafi l. In case <strong>of</strong> sudden visual defect, <strong>the</strong> patient should stop taking VIAGRA and consult a physician immediately. Caution is advised when sildenafi l is administered to patients taking an<br />
alpha-blocker, as coadministration may lead to symptomatic hypotension in a few susceptible individuals (see Drug Interactions) . This is most likely to occur within 4 hours post sildenafi l dosing. To minimise <strong>the</strong> potential <strong>for</strong> developing postural<br />
hypotension, patients should be hemodynamically stable on alpha-blocker <strong>the</strong>rapy prior to initiating sildenafi l treatment and a starting dose <strong>of</strong> 25 mg should be considered (see Dosage); physicians should advise patients what to do in <strong>the</strong> event <strong>of</strong><br />
postural hypotensive symptoms. Co-administration <strong>of</strong> sildenafi l with ritonavir is not advised. The fi lm coating <strong>of</strong> <strong>the</strong> VIAGRA tablet contains lactose. VIAGRA should not be administered to men with hereditary problems <strong>of</strong> galactose intolerance, Lapp<br />
lactase defi ciency or glucose-galactose malabsorption. Not <strong>for</strong> use by women. Drug interactions: In combination with inhibitors <strong>of</strong> CYP3A4 e.g. ketoconazole, erythromycin, cimetidine, a 25mg starting dose should be considered. Alpha-blockers<br />
- simultaneous co-administration may lead to symptomatic hypotension in a few susceptible individuals – See Dosage and Warnings and precautions. Ritonavir – see Warnings and precautions. Potentiates <strong>the</strong> hypotensive effects <strong>of</strong> nitrates<br />
(See Contra-indications). Nicorandil – Due to its nitrate component it has <strong>the</strong> potential to have serious interaction with sildenafi l. No potentiation <strong>of</strong> <strong>the</strong> increase in bleeding time caused by acetyl salicylic acid (150mg) or <strong>the</strong> hypotensive effects<br />
<strong>of</strong> alcohol. No data on non-specifi c phosphodiesterase inhibitors such as <strong>the</strong>ophylline or dipyridamole. Side-effects: Common and very common side-effects were fl ushing, headache, dizziness, dyspepsia, altered vision (increased perception<br />
<strong>of</strong> light, blurred vision), chromatopsia (mild and transient, predominantly colour tinge to vision) and nasal congestion. The following side-effects have also been reported; hypersensitivity reactions, eye pain, red eyes/bloodshot eyes, lacrimation<br />
disorders, tachycardia, palpitation, ventricular arrhythmia, myocardial infarction, unstable angina, sudden cardiac death, hypotension (see Warnings and precautions and Drug interactions), hypertension, epistaxis, syncope, cerebrovascular<br />
haemorrhage, atrial fi brillation, transient ischaemic attack, nausea and vomiting, dry mouth, skin rash, prolonged erection, priapism. NAION, retinal vascular occlusion and visual fi eld defect, sudden decrease or loss <strong>of</strong> hearing, vertigo, tinnitus).<br />
Seizure, seizure recurrence, somnolence, hypoaes<strong>the</strong>sia fatigue, myalgia, chest pain, Steven Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Driving and operating machinery: Caution if affected by dizziness or altered vision.<br />
Legal category: POM. Basic NHS cost: Packs <strong>of</strong> 4, 25mg tablets [EU/1/98/077/002] £16.59; Packs <strong>of</strong> 8, 25mg tablets [EU/1/98/077/003] £33.19; Packs <strong>of</strong> 4, 50mg tablets [EU/1/98/077/006] £21.27; Packs <strong>of</strong> 8, 50mg tablets [EU/1/98/077/007]<br />
£42.54; Packs <strong>of</strong> 4, 100mg tablets [EU/1/98/077/010] £23.50; Packs <strong>of</strong> 8, 100mg tablets [EU/1/98/077/011] £46.99. Marketing Authorisation Holder: Pfi zer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom.<br />
Fur<strong>the</strong>r in<strong>for</strong>mation on request: Pfi zer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS Last revised: July 2010<br />
EU.VIA.2010.53 - Date <strong>of</strong> preparation: October 2010<br />
Adverse events should be reported. Reporting <strong>for</strong>ms and in<strong>for</strong>mation can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Pfizer Medical In<strong>for</strong>mation on 01304 616161<br />
Ref: VI 18_0
social program<br />
Opening Ceremony and Welcome Reception<br />
Sunday, 14 November 2010<br />
18.30 h<br />
Auditorium I at <strong>the</strong> Palacio de Ferias y Congresos<br />
‘Meet Your Colleagues’ Evening<br />
Monday, 15 November 2010<br />
The Malagueta Bullring, Paseo de Reding<br />
20.00 h<br />
The congress will be <strong>of</strong>ficially opened by <strong>the</strong> <strong>ESSM</strong> President<br />
and <strong>the</strong> Local Organising Committee. Typical Andalucía<br />
Flamenco will be presented by <strong>the</strong> Eva Yerbabuena<br />
Ballet Flamenco.<br />
Afterwards all delegates are invited to <strong>the</strong> Welcome Reception<br />
in <strong>the</strong> foyer <strong>of</strong> <strong>the</strong> Palacio de Ferias y Congresos<br />
where local wine and typical Spanish food will be <strong>of</strong>fered.<br />
The European Society <strong>of</strong> Sexual Medicine invites all delegates<br />
to join <strong>the</strong> “meet with your Colleagues Evening”.<br />
During this evening all congress delegates can take <strong>the</strong><br />
opportunity to fur<strong>the</strong>r discuss <strong>the</strong> latest research and developmental<br />
findings in sexual medicine outside <strong>the</strong> congress<br />
sessions.<br />
The event will take place at <strong>the</strong> famous Malagueta bullring<br />
in <strong>the</strong> heart <strong>of</strong> Malaga where typical Spanish food,<br />
such as Tapas and local wines will be <strong>of</strong>fered.<br />
Built in 1874 by Joaquín Rucoba in Neo-Mudejar style,<br />
<strong>the</strong> bullring is located in Paseo de Reding, in <strong>the</strong> district<br />
<strong>of</strong> La Malagueta. It was inaugurated on 11 th June 1876<br />
and still today operates as a Bull fighting venue.<br />
Cost contribution: EUR 30 per person<br />
<strong>ESSM</strong> Members: complimentary<br />
For all <strong>ESSM</strong> members this special cultural event is complimentary.<br />
You will receive your ticket in exchange <strong>for</strong> a<br />
voucher included in your congress documents at <strong>the</strong><br />
<strong>ESSM</strong> booth in <strong>the</strong> exhibition area. Pre-registration is<br />
necessary on Monday, 15 November 2010 until 15.00 h<br />
at <strong>the</strong> <strong>ESSM</strong> booth.<br />
Best dances <strong>of</strong> Eva Yerbabuena<br />
Eva Yerbabuena is considered to be one <strong>of</strong> <strong>the</strong> most<br />
famous Flamenco dancers <strong>of</strong> our time. She founded Eva<br />
Yerbabuena Ballet Flamenco, an independent dance<br />
company in 1988. Since <strong>the</strong>n, <strong>the</strong> Company has produced<br />
five more shows and toured <strong>the</strong> world. The Company’s<br />
philosophy is to present <strong>the</strong> highest quality <strong>of</strong><br />
flamenco dance. In this special show Eva Yerbabuena<br />
Company presents a summing up <strong>of</strong> <strong>the</strong>ir best dances:<br />
Eva (1998), 5 Women 5 (2000), <strong>the</strong> Voice <strong>of</strong> Silence<br />
(2002), Four Voices (2004), <strong>the</strong> Spindle <strong>of</strong> <strong>the</strong> Memory<br />
(2006) and Wonders and Signs (2007).<br />
Many prestigious awards have honored her work, including<br />
Premio Nacional de Danza in 2001 (National Dance<br />
Award in Spain). In 2007, she received <strong>the</strong> Medal <strong>of</strong> Andalusia,<br />
as recognition to its successful pr<strong>of</strong>essional trajectory.<br />
Eva Yerbabuena has collaborated with Joaquín<br />
Cortés and Pina Bausch.<br />
16
supporting program<br />
Welcome to Malaga, Bienvenidos A Malaga !<br />
Malaga is <strong>the</strong> capital <strong>of</strong> <strong>the</strong> Costa del Sol which belongs<br />
to <strong>the</strong> sou<strong>the</strong>rn region <strong>of</strong> Andalucia which is famous <strong>for</strong><br />
its beautiful nature, typical white villages, vibrant cities,<br />
costal fishing villages, flamenco, bullfighting, fantastic<br />
outdoor activities and mild winters. Malaga is surrounded<br />
by cities like Cadiz, Marbella, Seville or Granada which<br />
all <strong>of</strong> <strong>the</strong>m have a rich history, remarkable architecture<br />
and culture. The combination <strong>of</strong> great wea<strong>the</strong>r, some <strong>of</strong><br />
<strong>the</strong> best golf courses in Europe, interesting cities with<br />
plenty <strong>of</strong> Spanish culture and history have made <strong>the</strong><br />
Costa del Sol and Malaga an attractive destination during<br />
winter time.<br />
Culture<br />
Malaga has applied <strong>for</strong> <strong>the</strong> title <strong>of</strong> “European Culture<br />
Capital” <strong>for</strong> <strong>the</strong> year 2016. This means that <strong>the</strong> city is being<br />
improving its cultural <strong>of</strong>fers in every respect. Over<br />
twenty museums, most <strong>of</strong> <strong>the</strong>m in walking distance in<br />
<strong>the</strong> historical center make Malaga <strong>the</strong> City <strong>of</strong> Museums.<br />
The city presents excellent museums ranging from historic<br />
to modern art which host some <strong>of</strong> <strong>the</strong> most interesting<br />
exhibitions as well as new projects like <strong>the</strong> Wine<br />
Museum or <strong>the</strong> Holy Week Museum. The main attractions<br />
are <strong>the</strong> Alcazaba and <strong>the</strong> Castillo de Gibralfaro,<br />
from where you have a fantastic view <strong>of</strong> <strong>the</strong> town and<br />
bay. Beside <strong>the</strong> entrance <strong>of</strong> <strong>the</strong> Alcabaza (Arabic <strong>for</strong>tress),<br />
which was a Moorish <strong>for</strong>nication <strong>of</strong> <strong>the</strong> 8 th century, <strong>the</strong>re<br />
are ruins <strong>of</strong> a Roman <strong>the</strong>atre <strong>of</strong> <strong>the</strong> 2 nd century. Gibralfaro<br />
Castle was built in <strong>the</strong> 14 th century and is one <strong>of</strong> <strong>the</strong><br />
most famous historic sites <strong>of</strong> <strong>the</strong> Costa del Sol.<br />
The famous painter and sculptor Pablo Picasso was born<br />
here (25 October 1881 – 8 April 1973). As one <strong>of</strong> <strong>the</strong><br />
most recognized artists <strong>of</strong> <strong>the</strong> 20th century he gained<br />
unique fame through his revolutionary artistic <strong>for</strong>ms <strong>of</strong><br />
expression including paintings from classical to abstract,<br />
drawings, ceramics and sculptures. His works had great<br />
influence on <strong>the</strong> modern art. His paintings from <strong>the</strong> blue<br />
and pink period marked <strong>the</strong> beginning <strong>of</strong> <strong>the</strong> cubism. His<br />
birth house is a five storeyed house which has now become<br />
<strong>the</strong> headquarters <strong>of</strong> <strong>the</strong> “The Fundacion Picasso“.<br />
The Museum contains 3500 pieces which include ceramic<br />
and graphic works <strong>of</strong> Picasso.<br />
Monday, 15 November 2010<br />
Malaga City Sightseeing<br />
Walking Tour<br />
09.30 – 12.30 h<br />
This route accompanied by an English speaking guide <strong>of</strong>fers<br />
<strong>the</strong> visitor a tour through Malaga history, from <strong>the</strong><br />
Roman period till <strong>the</strong> present time. Some <strong>of</strong> its main<br />
monuments and museums are located nearby, so <strong>the</strong><br />
visitor can witness <strong>the</strong> city’s development. Discover almost<br />
three thousand years <strong>of</strong> city’s history.<br />
Visit to <strong>the</strong> Alcazaba<br />
This impressive building, built mostly in <strong>the</strong> 11th century,<br />
was <strong>the</strong> palace-<strong>for</strong>tress <strong>of</strong> <strong>the</strong> city’s governing Muslims.<br />
It was built on <strong>the</strong> summit <strong>of</strong> a hill, adapted to <strong>the</strong> relief.<br />
This latter, within which <strong>the</strong> palace stands, is also adapted<br />
to <strong>the</strong> lines <strong>of</strong> <strong>the</strong> hill and has strong defensive elements<br />
at each end. It has a lift that runs from Calle Guillén<br />
Sotelo, behind <strong>the</strong> Town Hall.<br />
Visit to <strong>the</strong> Ca<strong>the</strong>dral<br />
The Ca<strong>the</strong>dral was built on <strong>the</strong> site where <strong>the</strong> city’s main<br />
mosque had stood during <strong>the</strong> eight centuries <strong>of</strong> Muslim<br />
domination. The building <strong>of</strong> <strong>the</strong> ca<strong>the</strong>dral began in <strong>the</strong><br />
first half <strong>of</strong> <strong>the</strong> 16th century (1528) and continued<br />
throughout <strong>the</strong> 17th and 18th century. Yet, it is still unfinished<br />
as it is missing <strong>the</strong> top part <strong>of</strong> <strong>the</strong> main façade<br />
and <strong>the</strong> south tower is incomplete.<br />
Price per person: EUR 30<br />
Incl. entrance fee <strong>for</strong> <strong>the</strong> Alcazaba and <strong>the</strong> Catedral<br />
Meeting point in front <strong>of</strong> <strong>the</strong> AC Málaga Palacio hotel,<br />
Cortina del Muelle 1.<br />
Tickets can be purchased at <strong>the</strong> congress counter.<br />
For registered accompanying persons this tour is complimentary<br />
and necessary to reserve until 14 No vember<br />
2010. Please contact <strong>the</strong> registration counter.<br />
www.essm.org<br />
17
TESTOPATCH® SMPC<br />
1. NAME OF THE MEDICINAL PRODUCT. TESTOPATCH® 1.2 mg/24 h transdermal patch.<br />
TESTOPATCH® 1.8 mg/24 h transdermal patch. TESTOPATCH® 2.4 mg/24 h transdermal patch.<br />
2. QUALITATIVE AND QUANTITATIVE COMPOSITION: One transdermal patch <strong>of</strong> 30 cm² contains 15 mg<br />
<strong>of</strong> testosterone and delivers 1.2 mg <strong>of</strong> testosterone per 24 hours. One transdermal patch <strong>of</strong> 45 cm² contains<br />
22.5 mg <strong>of</strong> testosterone and delivers 1.8 mg <strong>of</strong> testosterone per 24 hours. One transdermal patch <strong>of</strong> 60 cm²<br />
contains 30 mg <strong>of</strong> testosterone and delivers 2.4 mg <strong>of</strong> testosterone per 24 hours. For a full list <strong>of</strong> excipients,<br />
see section 6.1.<br />
3. PHARMACEUTICAL FORM. Transdermal patch. Thin, transparent transdermal patch.<br />
4. CLINICAL PARTICULARS. 4.1 Therapeutic indications. Replacement <strong>the</strong>rapy <strong>for</strong> male<br />
hypogonadism due to testosterone deficiency confirmed by laboratory and clinical signs (see section 4.4).<br />
4.2 Posology and method <strong>of</strong> administration. FOR ADULT MEN ONLY. Transdermal route. Posology.<br />
Two transdermal patches must be applied simultaneously to <strong>the</strong> skin and be replaced every 48 hours.<br />
TESTOPATCH®, transdermal patch is available in three dosage <strong>for</strong>ms: 1.2 mg / 24h, 1.8 mg / 24h and 2.4 mg<br />
/ 24h. Initiation <strong>of</strong> treatment. The initial dose generally recommended is two TESTOPATCH® 2.4 mg/24 h<br />
transdermal patches, renewed every 48 hours. This dosage may be adjusted as a function <strong>of</strong> clinical<br />
symptoms and plasma testosterone levels. Dosage adjustment. The plasma testosterone concentration is to<br />
be determined on morning time at <strong>the</strong> start <strong>of</strong> treatment and during patient follow-up between 12 and 36 hours<br />
after applying <strong>the</strong> transdermal patch. The administered dose may be adjusted by <strong>the</strong> physician on <strong>the</strong> basis <strong>of</strong><br />
clinical and laboratory responses. The testosterone levels have to be regularly monitored after dose adjustment.<br />
If <strong>the</strong> plasma testosterone concentration is higher than normal values, or in <strong>the</strong> event <strong>of</strong> symptoms <strong>of</strong><br />
hyperandrogenism, <strong>the</strong> dosage may be reduced to 2 patches TESTOPATCH® 1.8 mg/24 h or to 2 patches<br />
TESTOPATCH® 1.2 mg/24 h. Method <strong>of</strong> administration. Take care <strong>for</strong> <strong>the</strong> integrity <strong>of</strong> <strong>the</strong> pouches be<strong>for</strong>e<br />
use. Open <strong>the</strong> sachet only prior to use and apply immediately after removal from <strong>the</strong> protective sachet.<br />
TESTOPATCH® must be applied to <strong>the</strong> arms, lower back or thighs on clean, dry and healthy skin. Avoid areas<br />
<strong>of</strong> skin that are oily, perspire heavily or are covered with hair, as <strong>the</strong> patch may not stick tightly to <strong>the</strong>se areas.<br />
If necessary, hair at <strong>the</strong> application site should be cut and not shave be<strong>for</strong>e applying TESTOPATCH®. As well<br />
soaps, oils, lotions or o<strong>the</strong>r agents that may irritate <strong>the</strong> skin or affect it must not be used. A patch should not<br />
be applied twice consecutively to <strong>the</strong> same site. The transdermal patches are not to be applied to <strong>the</strong> breasts<br />
or scrotum. The patches may be worn when showering or bathing. In <strong>the</strong> rare event that a patch becomes<br />
detached from <strong>the</strong> skin, it is recommended to apply a new patch to ano<strong>the</strong>r site; <strong>the</strong> latter should be<br />
removed at <strong>the</strong> date initially scheduled. If <strong>the</strong> patient <strong>for</strong>gets to change <strong>the</strong> patches, he should replace <strong>the</strong>m<br />
as soon as he remembers. The following patches should be applied on <strong>the</strong> days initially scheduled. Children<br />
and adolescents. TESTOPATCH® is not <strong>for</strong> use in children and adolescents below 18 and no clinical study<br />
has been conducted in children and adolescents. Elderly subjects. The experience using TESTOPATCH® is<br />
limited in patients over <strong>the</strong> age <strong>of</strong> 65 years. Renal/hepatic impairment. No <strong>for</strong>mal studies have been<br />
conducted in patients with renal or hepatic impairment, but TESTOPATCH® should be used with caution in<br />
<strong>the</strong>se patients (See section4.4). 4.3 Contraindications. • Suspected or confirmed breast carcinoma or<br />
prostatic cancer, • Known hypersensitivity to testosterone or to any o<strong>the</strong>r constituent <strong>of</strong> <strong>the</strong> transdermal<br />
patch, • Presence or history <strong>of</strong> liver tumour. 4.4 Special warnings and precautions <strong>for</strong> use. •<br />
TESTOPATCH® is to be used if hypogonadism (hypo-or hypergonadrotrophic) has been clearly demonstrated<br />
and if o<strong>the</strong>r aetiologies that may be responsible <strong>for</strong> <strong>the</strong> symptoms have been ruled out be<strong>for</strong>e initiating<br />
treatment. Testosterone deficiency must be clearly demonstrated by clinical signs (regression <strong>of</strong> secondary<br />
sexual characteristics, modification <strong>of</strong> build, as<strong>the</strong>nia, decreased libido, erectile dysfunction, etc) and<br />
confirmed by two separate serum testosterone assays. At present, <strong>the</strong>re is no consensus as to normal serum<br />
testosterone values as a function <strong>of</strong> age. However, account should be taken <strong>of</strong> <strong>the</strong> fact that physiological<br />
levels <strong>of</strong> serum testosterone diminish with age. • Because <strong>of</strong> <strong>the</strong> variability <strong>of</strong> results between different<br />
laboratories, all assays should be per<strong>for</strong>med by <strong>the</strong> same laboratory <strong>for</strong> a given patient. • TESTOPATCH® is not<br />
indicated in <strong>the</strong> treatment <strong>of</strong> male sterility and impotence. • Androgens can accelerate <strong>the</strong> development <strong>of</strong><br />
infraclinical prostate cancer or <strong>of</strong> benign prostatic hyperplasia. • Be<strong>for</strong>e initiating testosterone-based<br />
<strong>the</strong>rapy, it is essential that patients undergo a detailed examination so as to eliminate any risks related to<br />
pre-existing prostate cancer. • Attentive and regular monitoring <strong>of</strong> <strong>the</strong> prostate and breasts is to be<br />
conducted, using <strong>the</strong> recommended methods (rectal touch and determination <strong>of</strong> prostate-specific antigen<br />
(PSA))at least once a year in any patient under testosterone treatment. In hypogonadal subjects aged over<br />
40 and in patients at risk (clinical or familial factors), a regular monitoring is recommended every 3 months<br />
<strong>for</strong> <strong>the</strong> first year, <strong>the</strong>n twice a year subsequently. • In addition to monitoring serum testosterone levels in<br />
patients receiving long-term androgen <strong>the</strong>rapy, <strong>the</strong> following laboratory parameters should also be<br />
monitored regularly: haemoglobin, hematocrit (to detect any polyglobulia) liver function parameters and<br />
lipid pr<strong>of</strong>ile. TESTOPATCH® is to be used with caution: • in patients suffering from renal or liver failure. No<br />
efficacy and safety study on this medicinal product has been conducted in <strong>the</strong>se patients, • in patients<br />
presenting with severe heart, liver or kidney failure, or ischemic heart disease, Testosterone treatment may<br />
induce complications, characterized by oedema, which may or may not be accompanied by congestive heart<br />
failure. The treatment must be discontinued immediately if such complications occur. Adapted treatment<br />
may be initiated fur<strong>the</strong>r to physician’s decision. • in patients presenting with cancer at risk <strong>of</strong> hypercalcemia<br />
/ hypercalciuria due to bone metastases. Regular serum calcium monitoring is to be conducted in such<br />
patients, • in hypertensive patients, testosterone may induce an increase in blood pressure, • in patients presenting<br />
with epilepsy or suffering from migraine since those disorders may be exacerbated. Enhanced insulin<br />
sensitivity may be observed in patients receiving androgens and in whom normal plasma testosterone levels<br />
have been induced by treatment. Testosterone treatment <strong>of</strong> hypogonadal subjects may increase <strong>the</strong> risk <strong>of</strong><br />
sleep apnoea, particularly in subjects with risk factors such as obesity or chronic respiratory disease.Certain<br />
clinical signs such as irritability, nervousness, weight gain and prolonged or frequent erections, nausea,<br />
vomiting or ankle swelling, breathing disturbances, including those associated with sleep may reflect<br />
excessive testosterone exposure and require dosage adjustment. The attention <strong>of</strong> sportsmen and athletes is<br />
to be drawn to <strong>the</strong> fact that this product contains an active substance (testosterone) liable to induce positive<br />
results to tests <strong>for</strong> prohibited substances. Androgens are not suitable <strong>for</strong> enhancing muscular development<br />
in healthy individuals or <strong>for</strong> increasing physical ability. If <strong>the</strong> patient develops a severe application site<br />
reaction, treatment should be reviewed and discontinued if necessary. TESTOPATCH® should not be used in<br />
women due to possible virilising effects (see also section 4.6). 4.5 Interaction with o<strong>the</strong>r medicinal<br />
products and o<strong>the</strong>r <strong>for</strong>ms <strong>of</strong> interaction. Precautions <strong>for</strong> use. Interactions studies have only been<br />
per<strong>for</strong>med in adults. + Oral anticoagulants: variation in <strong>the</strong> anticoagulant effect through modification to<br />
<strong>the</strong> hepatic syn<strong>the</strong>sis <strong>of</strong> coagulation factors, with a tendency towards an increase in <strong>the</strong> effect <strong>of</strong> <strong>the</strong> oral<br />
anticoagulant. More frequent controls <strong>of</strong> <strong>the</strong> INR, and possible adjustment <strong>of</strong> <strong>the</strong> dosage <strong>of</strong> <strong>the</strong> oral<br />
anticoagulant during treatment with TESTOPATCH® and <strong>for</strong> 8 days following its discontinuation, are<br />
recommended. + The concurrent administration <strong>of</strong> testosterone with ACTH or corticosteroids may increase<br />
<strong>the</strong> likelihood <strong>of</strong> oedema; thus <strong>the</strong>se drugs should be administered with caution, particularly in patients with<br />
cardiac, renal or hepatic disease. + Laboratory tests interactions : androgens may decrease levels <strong>of</strong><br />
thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increase resin uptake <strong>of</strong><br />
T3 and T4. Free thyroid hormone concentrations remain unchanged, however and <strong>the</strong>re is no clinical<br />
evidence <strong>of</strong> thyroid dysfunction. 4.6 Pregnancy and lactation. TESTOPATCH® is <strong>for</strong> men only. It is not<br />
indicated in women. Testosterone may induce virilising effects on <strong>the</strong> female foetus. Testosterone must not<br />
be administered in women who are pregnant or breastfeeding. 4.7 Effects on ability to drive and use<br />
machines. No studies on <strong>the</strong> effects on <strong>the</strong> ability to drive and use machines have been per<strong>for</strong>med. 4.8.<br />
Undesirable effects. During clinical trials per<strong>for</strong>med with different doses <strong>of</strong> TESTOPATCH®, 47.9% <strong>of</strong><br />
patients presented with at least one undesirable effect which was probably treatment-related. The<br />
undesirable effects most frequently observed in clinical trials with <strong>the</strong> various strengths <strong>of</strong> TESTOPATCH® are<br />
reactions at <strong>the</strong> application site, <strong>of</strong>ten at <strong>the</strong> beginning <strong>of</strong> treatment. Application site reactions occurred in<br />
approximately 23% <strong>of</strong> patients. At <strong>the</strong> recommended dosage <strong>of</strong> two 2.4 mg/24 h patches every 48 hours,<br />
<strong>the</strong> possibly treatment-related adverse events observed in a total <strong>of</strong> 253 patients, treated <strong>for</strong> a maximum <strong>of</strong><br />
one year, are indicated in <strong>the</strong> table below:<br />
Metabolism and nutrition disorders<br />
Psychiatric disorders<br />
Nervous system disorders<br />
Gastrointestinal disorders<br />
Hepato-biliary disorders<br />
Skin and subcutaneous disorders<br />
Musculoskeletal and connective tissue disorders<br />
General disorders and administration site<br />
conditions<br />
COMMON (>1/100,
Low testosterone levels<br />
SAFELY RESTORING TESTOSTERONE<br />
(1, 2)<br />
within <strong>the</strong> physiological range<br />
1- Raynaud J.P. et al., Pharmacokinetic study <strong>of</strong> a new testosterone-in-adhesive matrix patch applied<br />
every two days to hypogonadal men. JSBMB 2008; 109: 177-184.<br />
2- Raynaud J.P. et al., Sustained efficacy and safety <strong>of</strong> a novel testosterone-in-adhesive matrix patch<br />
applied every two days to hypogonadal men over at least four years. Eur Urol Suppl 2008; 7 (3); 297.<br />
September 2010
introduction to <strong>the</strong> scientific program<br />
Structure <strong>of</strong> <strong>the</strong> Scientific Program<br />
The scientific program is structured according to days.<br />
Per day it is structured by time and room. All presenters<br />
are listed by name and <strong>the</strong> title <strong>of</strong> <strong>the</strong>ir presentation.<br />
Structure <strong>of</strong> <strong>the</strong> Abstract Book<br />
The abstract book is structured by session <strong>for</strong>mat. The<br />
listing starts with <strong>the</strong> podium session followed by <strong>the</strong><br />
highlighted poster sessions. Hereafter <strong>the</strong> poster presentations<br />
are listed according to topics.<br />
Master Lectures<br />
Each lecture <strong>of</strong> 30 minutes will be given by a distinguished<br />
and renowned expert and will be devoted to a<br />
specific topic <strong>of</strong> major interest.<br />
Round Tables<br />
These sessions will usually last 60 to 90 minutes. They<br />
will focus on a particular topic and present <strong>the</strong> very latest<br />
data related to it. The round tables will include a maximum<br />
<strong>of</strong> four papers and time <strong>for</strong> discussion.<br />
Debates<br />
The JSM debate lasts <strong>for</strong> 60 minutes and is designed to<br />
cover controversial issues <strong>of</strong> a particular topic. The moderator<br />
will allow a short introduction <strong>for</strong> each topic by<br />
<strong>the</strong> respective opponents followed by a discussion on <strong>the</strong><br />
arguments proposed. Comments, arguments, and questions<br />
from <strong>the</strong> floor are welcome during <strong>the</strong> discussion.<br />
Educational Courses<br />
These 90 minutes sessions present a detailed account <strong>of</strong><br />
a chosen topic. Courses are designed to provide learning<br />
experiences that actively involve participants and will include<br />
an opportunity <strong>for</strong> in<strong>for</strong>mal exchange with <strong>the</strong> faculty.<br />
Attendees will be given <strong>the</strong> possibility to interact actively<br />
via a voting system with <strong>the</strong> faculty <strong>of</strong> <strong>the</strong> session.<br />
Video Surgery Course<br />
The Video surgery Course will last 90 minutes, each video<br />
has a duration <strong>of</strong> 10 minutes. A panel <strong>of</strong> selected experts<br />
will present surgical videos showing different techniques<br />
and approaches and will discuss <strong>the</strong> details with <strong>the</strong> participants.<br />
Podium Sessions<br />
Podium sessions will present <strong>the</strong> best abstracts accepted<br />
<strong>for</strong> <strong>the</strong> <strong>Congress</strong> by <strong>the</strong> Scientific Committee and will focus<br />
on specific topics presenting <strong>the</strong> very latest findings<br />
in this field. The sessions will last 30 to 90 minutes. Presentations<br />
are limited to 6 minutes followed by 2 minutes<br />
<strong>of</strong> discussion.<br />
Highlighted Poster Tours<br />
Authors were invited to submit abstracts on <strong>the</strong>ir latest<br />
research findings or important ongoing research. The<br />
highlighted poster tours were selected by <strong>the</strong> Scientific<br />
Committee based on a review <strong>of</strong> all abstract submissions.<br />
The most interesting posters are grouped by topic and<br />
presented in a 30-minute moderated tour. Each tour will<br />
consist <strong>of</strong> a maximum <strong>of</strong> 6 posters in <strong>the</strong> same general<br />
field and will take place during <strong>the</strong> c<strong>of</strong>fee breaks on<br />
15 and 16 November 2010.<br />
Symposia in National Language<br />
The affiliated national societies <strong>of</strong> <strong>the</strong> <strong>ESSM</strong> have been<br />
invited to organize symposia in national language during<br />
<strong>the</strong> first congress day <strong>of</strong> <strong>the</strong> annual <strong>ESSM</strong> congress. One<br />
symposium in Spanish will be held on Sunday, 15 November<br />
2010, 09.00 – 14.00 h.<br />
Symposia organized by <strong>the</strong> Industry<br />
Symposia organized by <strong>the</strong> Industry in consultation with<br />
<strong>the</strong> Scientific Committee will be presented on Tuesday,<br />
16 November 2010 during lunchtime.<br />
20
introduction to <strong>the</strong> scientific program<br />
CME (Continuing Medical Education)<br />
The 13 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> European Society <strong>for</strong> Sexual<br />
Medicine is seeking <strong>for</strong> accreditation by <strong>the</strong> European<br />
Council <strong>for</strong> Continuing Education (EACCME) to provide<br />
continuing medical education (CME) credits to physicians.<br />
The EACCME is an institution <strong>of</strong> <strong>the</strong> European Union <strong>of</strong><br />
Medical Specialists (UEMS). EACCME credits are recognised<br />
Europe-wide and in North America. EACCME credits<br />
can be exchanged <strong>for</strong> <strong>the</strong>ir national equivalent by contacting<br />
<strong>the</strong> respective National CME authority. EACCME credits<br />
are recognised by <strong>the</strong> American Medical Association (AMA)<br />
towards <strong>the</strong> Physician’s Recognition Award (AMA).<br />
Please hand in <strong>the</strong> evaluation <strong>for</strong>m you find enclosed in<br />
your congress documents at <strong>the</strong> <strong>ESSM</strong> booth in <strong>the</strong> exhibition<br />
area. The <strong>ESSM</strong> Secretariat will send <strong>the</strong> certificate<br />
after <strong>the</strong> congress.<br />
This congress has been submitted <strong>for</strong> CME accreditation<br />
to <strong>the</strong> Italian Ministry <strong>of</strong> Health. Physicians will be accredited.<br />
Italian delegates will find <strong>the</strong> CME evaluation <strong>for</strong>ms<br />
in <strong>the</strong>ir personal congress documents. You are asked to<br />
fill <strong>the</strong>m in and leave <strong>the</strong>m at <strong>the</strong> <strong>ESSM</strong> booth in <strong>the</strong> exhibition<br />
area at <strong>the</strong> end <strong>of</strong> <strong>the</strong> congress. The <strong>ESSM</strong> Secretariat<br />
will send <strong>the</strong> certificate after <strong>the</strong> congress.<br />
www.essm.org<br />
21
program schedule<br />
Sunday, 14 November 2010<br />
Time<br />
Room<br />
Auditorium I Auditorium II Conference Room 1 Foyer<br />
09.00<br />
Registration<br />
08.00 – 19.00 h<br />
10.00<br />
11.00<br />
12.00<br />
SN-01<br />
ASESA/SPA<br />
Symposium in<br />
national language<br />
Spanish<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
VC-01<br />
Video Surgery<br />
Course<br />
17.00<br />
18.00<br />
D-01<br />
JSM Debate<br />
Sexual interest and sexual<br />
arousal in men<br />
19.00<br />
Opening Ceremony<br />
20.30<br />
Get Toge<strong>the</strong>r in <strong>the</strong> Foyer<br />
Abbreviations<br />
SN – Symposia in national language<br />
SA – Satellite Symposia<br />
D – JSM Debate<br />
VC – Video Surgery Course<br />
RT – Round Table<br />
EC – Educational Course<br />
ML – Master Lecture<br />
PS – Podium Session<br />
HP – Highlighted Posters<br />
22
program schedule<br />
Monday, 15 November 2010<br />
Time<br />
Room<br />
Auditorium I Auditorium II Conference Room 1 Foyer / Pavilion 1<br />
08.00<br />
09.00<br />
10.00<br />
RT-01<br />
Sexually transmitted diseases:<br />
challenges in <strong>the</strong> “real life” world<br />
ML-01<br />
ED – What is <strong>the</strong> place <strong>for</strong> penile<br />
implants in 2010 <br />
RT-02<br />
What should we know about<br />
PDE5-IS in 2010<br />
ML-02<br />
The Registry <strong>of</strong> Hypogonadism in<br />
Men (RHYME)<br />
C<strong>of</strong>fee Break<br />
EC-01<br />
Contemporary clinical management<br />
<strong>of</strong> ejaculatory and orgasmic<br />
disorders<br />
Foyer<br />
Registration<br />
07.30 – 18.00 h<br />
Pavilion 1<br />
Technical and<br />
Poster Exhibition<br />
09.00 – 17.00 h<br />
11.00<br />
12.00<br />
RT-03<br />
Is sexual health <strong>of</strong> importance in<br />
patients with heart failure The<br />
case <strong>for</strong> erectile dysfunction<br />
ML-03<br />
The history@<strong>ESSM</strong> lectures<br />
RT-04<br />
Who, where and why The<br />
demography <strong>of</strong> female sexual<br />
dysfunction throughout <strong>the</strong><br />
reproductive cycle<br />
EC-02<br />
What <strong>the</strong> sexual physician<br />
needs to know about genital<br />
dermatology<br />
Pavilion 1<br />
HP-01<br />
Basic Science<br />
Lunch Break<br />
13.00<br />
14.00<br />
RT-05<br />
Postoperative sexual function<br />
following radical prostatectomy:<br />
which approach is better in 2010<br />
RT-06<br />
Do women become orgasmic<br />
EC-03<br />
Gender reassignment surgery<br />
15.00<br />
ML-04<br />
Reports from <strong>the</strong> 3 rd International<br />
Consultation on Sexual Medicine<br />
PS-01<br />
Conservative ED treatment<br />
PS-02<br />
Psychosexual issues<br />
and management<br />
Pavilion 1<br />
16.00<br />
17.00<br />
RT-07<br />
The real world is running quickly<br />
– who is in charge <strong>of</strong> ed patients<br />
in 2010<br />
C<strong>of</strong>fee Break<br />
RT-08<br />
Translational science: How to<br />
translate preclinical discoveries<br />
into clinical applications<br />
EC-04<br />
What <strong>the</strong> sexual physician needs<br />
to know about sexually<br />
transmitted infection<br />
HP-02 / Male sexual<br />
function and dysfunction<br />
18.00<br />
RT-09<br />
Adolescentology – is anyone out<br />
<strong>the</strong>re who may help me<br />
19.00<br />
20.00<br />
Meet your Colleagues Evening<br />
Venue Bullring, Malaga, please see page 16<br />
www.essm.org<br />
23
program schedule<br />
Tuesday, 16 November 2010<br />
Room<br />
Time<br />
08.00<br />
09.00<br />
10.00<br />
Auditorium I Auditorium II Conference Room 1 Foyer / Pavilion 1<br />
RT-10<br />
Peyronie’s disease: still a pain in<br />
<strong>the</strong> neck! A critical reappraisal<br />
ML-05<br />
SMSNA Lecture: Penile augmentation<br />
surgery – Quo vadis<br />
<strong>ESSM</strong> Annual<br />
Business Meeting<br />
Members only<br />
PS-03<br />
Ejaculatory disorders<br />
PS-04<br />
Is ED a proxy <strong>of</strong> men’s health<br />
C<strong>of</strong>fee Break<br />
EC-05<br />
Contraception and HRT <strong>for</strong> women<br />
in contemporary clinical practice<br />
Foyer<br />
Registration<br />
07.30 – 18.00 h<br />
Pavilion 1<br />
Technical and<br />
Poster Exhibition<br />
09.00 – 17.00 h<br />
11.00<br />
RT-11<br />
Who deserves what A more<br />
focused pharmacological approach<br />
<strong>for</strong> sexual dysfunctions<br />
RT-12<br />
Gender differences – a novel<br />
biopsychological paradigm<br />
EC-06<br />
The role <strong>of</strong> penile pros<strong>the</strong>sis in<br />
contemporary sexual medicine<br />
practice<br />
12.00<br />
ML-06<br />
New medical insights into restless<br />
genital syndrome<br />
Lunch Break<br />
Pavilion 1<br />
HP-03<br />
Female sexual function<br />
13.00<br />
SA-02<br />
Case discussions between <strong>the</strong><br />
contradictory contexts <strong>of</strong><br />
evidence-based medicine and<br />
experts’ experience (Lilly LLC)<br />
14.00<br />
RT-14<br />
Premature ejaculation in <strong>the</strong> real<br />
life setting<br />
RT-15<br />
Is testosterone dangerous <strong>for</strong><br />
prostate health<br />
EC-07<br />
Contemporary clinical management<br />
<strong>of</strong> erectile dysfunction<br />
15.00<br />
ML-07<br />
Science <strong>for</strong> men’s health – it is not<br />
a marketing hype!<br />
PS-05<br />
Surgery and Peyronie’s disease<br />
Pavilion 1<br />
16.00<br />
17.00<br />
RT-16<br />
How to approach sexual<br />
dysfunction in 2010 – Sharing <strong>the</strong><br />
experience <strong>of</strong> different European<br />
countries<br />
C<strong>of</strong>fee Break<br />
RT-17<br />
Prevention and management <strong>of</strong><br />
male genital emergencies<br />
EC-08<br />
Contemporary clinical management<br />
<strong>of</strong> women’s sexual problems<br />
HP-04 / Different aspects<br />
<strong>of</strong> sexual health-2<br />
18.00<br />
RT-18<br />
The “bull fighting experience”: My<br />
surgery works better in severe<br />
cases <strong>of</strong> Peyronie’s disease!<br />
PS-06<br />
Preclinical sexual medicine<br />
19.00<br />
24
PrOgrAm SCHEduLE<br />
WEDNESDAY, 17 NOVEMBER 2010<br />
time<br />
room<br />
auditorium i auditorium ii Conference room 1 foyer / Pavilion 1<br />
08.00<br />
09.00<br />
10.00<br />
rt-19<br />
Testosterone, who hates you<br />
Master lecture-08<br />
Award <strong>of</strong> Excellence 2010 Winner<br />
Ps-07<br />
Women’s sexual health<br />
Ps-08<br />
Different aspects <strong>of</strong><br />
sexual health-1<br />
C<strong>of</strong>fee Break<br />
eC-09<br />
Gynaecological disorders<br />
in sexual medicine<br />
Foyer<br />
registration<br />
07.30 – 12.30 h<br />
Pavilion 1<br />
technical and<br />
Poster exhibition<br />
09.00 – 11.00 h<br />
11.00<br />
rt-20<br />
Is sexuality a family matter within<br />
<strong>the</strong> infertile couple<br />
esha session<br />
Premature ejaculation:<br />
The couple’s perspective<br />
12.00<br />
Closing Ceremony<br />
www.essm.org<br />
25
scientific program<br />
Sunday, 14 November 2010<br />
SN-01<br />
National Symposium<br />
09.00 – 14.00 h auditorium II<br />
La Salud Sexual se encuentra de nuevo en el Mediterráneo<br />
Symposium <strong>of</strong> Asociacion Espanola de Andrología (Spain)<br />
and Sociedade Portuguesa de Andrología (Portugal)<br />
09:00 – 09:15 Presentación<br />
Presidenta ASESA: Ana Puigvert Martínez<br />
Presidente SPA: Jorge Rocha Mendes<br />
09:15 – 10:45 Mesa Redonda:<br />
Temas de Especial Interés<br />
Moderadores: Jorge Rocha Mendes /<br />
Ander Astobieta Odriozola<br />
10:45 – 11:15 Pausa café<br />
“Implicaciones andrológicas del abuso<br />
de anabolizantes esteroideos”<br />
José Ferran García<br />
la Seducción antes de la Erección<br />
José Luis Arrondo Arrondo<br />
a Andrologia numa consulta de reabilitação<br />
Cardiaca<br />
Nuno Louro<br />
Cirugía Cosmética del pene, la demanda<br />
sin fin, ¿dónde debemos situarnos<br />
Ana Puigvert Martínez<br />
¿Que pasa con la Eyaculación Precoz<br />
Juan Ignacio Martínez Salamanca<br />
11:15 – 11:45 Conferencia:<br />
del Órgano al Organismo:<br />
Del Pene a la Medicina Sexual<br />
Moderador: José Mª Pomerol Montseny<br />
Ponente: Manuel Mas<br />
11:45 – 13:00 Mesa Redonda:<br />
Temas de Rabiosa Actualidad<br />
Moderadores: Rafael Prieto Castro /<br />
Ignacio Moncada Iribarren<br />
Medicina Sexual como ventana a la<br />
Salud del Varón<br />
Natalio Cruz Navarro<br />
tratamiento de la patología en Medicina<br />
Sexual, mucho más que iPDE5<br />
y Testosterona<br />
Eduardo García Cruz<br />
rehabilitación sexual tras prostatectomía<br />
radical<br />
Luis Rodríguez Vela<br />
13:00 – 14:00 Asamblea General Ordinaria<br />
VC-01<br />
Video Surgery Course<br />
15.30 – 17.00 h Conference Room 1<br />
Video surgery course<br />
Chairpersons: David Ralph, United Kingdom<br />
Ates Kadioglu, Turkey<br />
VC-01-001<br />
VC-01-002<br />
VC-01-003<br />
VC-01-004<br />
VC-01-005<br />
VC-01-006<br />
VC-01-007<br />
VC-01-008<br />
Inflatable penile pros<strong>the</strong>sis insertion<br />
in actue priapism<br />
Omidreza Sedigh, Italy<br />
Albuginea reconstruction <strong>for</strong> complex<br />
penile pros<strong>the</strong>sis re-implant<br />
Carlo Bettocchi, Italy<br />
Use <strong>of</strong> scrotal flap <strong>for</strong> penile skin lost<br />
as a complications <strong>of</strong> penile augmentation<br />
Ahmad Shamsodini, Qatar<br />
Distally staged Urethroplasty <strong>for</strong> Lichen<br />
Sclerosis Atrophicus<br />
Paul Anderson, United Kingdom<br />
Modified Nesbit Procedure <strong>for</strong> treating<br />
ventral penile curvature: Comparison<br />
<strong>of</strong> two different dissection techniques<br />
<strong>of</strong> neurovascular bundle<br />
Ates Kadioglu, Turkey<br />
Subcoronal incision <strong>for</strong> three pieces penile<br />
pros<strong>the</strong>sis implant plus dorsal corporoplasty<br />
with pericardium graft <strong>for</strong><br />
severe Peyronie‘s disease correction<br />
Antonio Martin Morales, Spain<br />
Penile reconstruction <strong>for</strong> cancer-organ<br />
preserving surgery<br />
Rados Djinovic, Serbia<br />
Genital recostruction <strong>for</strong> advanced<br />
malignancy<br />
Suks Minhas, United Kingdom<br />
VC-01-009 Assisted ejaculatory techniques<br />
Mikkel Fode, Denmark, Dana Ohl, United<br />
States, Jens Sonksen, Denmark<br />
Supported by an educational grant from Coloplast A / S<br />
26
SCiENTiFiC PrOgrAm<br />
SUNDAY, 14 NOVEMBER 2010<br />
d-01 JsM debate<br />
17.15 – 18.15 h auditorium ii<br />
since sexual interest and sexual arousal in men<br />
cannot be separated, hsdd in men should be<br />
treated by treating <strong>the</strong> erectile dysfunction<br />
Chairperson: Irwin Goldstein , USA<br />
d-01-001<br />
d-01-002<br />
Pro-speaker<br />
Andrea Salonia , Italy<br />
Con-speaker<br />
John Dean , United Kingdom<br />
oPening CereMony<br />
18.30 – 19.30 h auditorium i<br />
www.essm.org<br />
27
Scientific Program<br />
Monday, 15 November 2010<br />
RT-01<br />
Round Table<br />
EC-01<br />
Educational Course<br />
08.00 – 09.30 h auditorium I<br />
Sexually transmitted diseases: Challenges in <strong>the</strong><br />
“real life” world<br />
Chairpersons: David Goldmeier, United Kingdom<br />
Suks Minhas, United Kingdom<br />
RT-01-001<br />
RT-01-002<br />
Sexual behaviour and risk assessment<br />
in different age cohorts: Risky-sex is<br />
not only an issue <strong>for</strong> <strong>the</strong> younger<br />
generations!<br />
Mark A. Bellis, United Kingdom<br />
High-risk human papillomavirus infection<br />
in sexually-active women:<br />
A critical reappraisal<br />
Santiago Melon, Spain<br />
08.00 – 09.30 h Conference Room 1<br />
Contemporary management <strong>of</strong> ejaculatory and orgasmic<br />
disorders<br />
Chairperson: Hartmut Porst, Germany<br />
EC-01-001<br />
EC-01-002<br />
EC-01-003<br />
Anatomic and physiologic basics <strong>of</strong><br />
ejaculation and orgasm<br />
Hartmut Porst, Germany<br />
Diagnosis and <strong>the</strong>rapy <strong>of</strong> premature<br />
ejaculation<br />
Emmanuele Jannini, Italy<br />
Management <strong>of</strong> delayed, absent and<br />
painful ejaculation<br />
Chris McMahon, Australia<br />
RT-01-003<br />
RT-01-004<br />
HIV and female sexual dysfunction<br />
David Goldmeier, United Kingdom<br />
Is erectile dysfunction equal to endo<strong>the</strong>lial<br />
dysfunction in HIV-infected<br />
patients<br />
Mattia Beggi, Italy<br />
ML-01 Master Lecture<br />
09.30 – 10.00 h auditorium I<br />
ED – What is <strong>the</strong> place <strong>for</strong> penile implants in 2010<br />
Moderator: Fulvio Colombo, Italy<br />
Lecturer: Ignacio Moncada, Spain<br />
RT-02<br />
Round Table<br />
08.00 – 09.30 h auditorium II<br />
What should we know about PDE5-IS in 2010<br />
Chairpersons: Antonio Martin Morales, Spain<br />
Dimitris Hatzichristou, Greece<br />
RT-02-001<br />
Are <strong>the</strong>re any differences between<br />
<strong>the</strong> PDE5-Is The translational science<br />
perspective<br />
Javier Angulo, Spain<br />
ML-02<br />
Master Lecture<br />
09.30 – 10.00 h auditorium II<br />
Long term outcomes <strong>of</strong> testosterone deficiency on<br />
prostate and sexual health: The Registry <strong>of</strong> Hypogonadism<br />
in Men (RHYME)<br />
Moderator: Antonio Martin Morales, Spain<br />
Lecturer: Raymond Rosen, USA<br />
RT-02-002<br />
RT-02-003<br />
RT-02-004<br />
Is it possible to improve a patient’s<br />
compliance with PDE5-Is in <strong>the</strong> real<br />
life setting<br />
Ilan Gruenwald, Israel<br />
Do <strong>the</strong> PDE5i‘s affect fertility<br />
Nikolaos S<strong>of</strong>ikitis, Greece<br />
PDE5-Is and <strong>the</strong> female sexual response:<br />
Faulty protocols or paradigms<br />
Raymond Rosen, USA<br />
28
scientific program<br />
Monday, 15 November 2010<br />
RT-03<br />
Round Table<br />
EC-02<br />
Educational Course<br />
10.30 – 11.30 h auditorium I<br />
Is sexual health <strong>of</strong> importance in patients with<br />
heart failure The case <strong>for</strong> erectile dysfunction<br />
Chairpersons: Antonio Aversa, Italy<br />
Charalambos Vlachopoulos, Greece<br />
RT-03-001<br />
RT-03-002<br />
RT-03-003<br />
RT-04<br />
Erectile dysfunction in hypertension<br />
and heart failure: When HTN and HF<br />
met ED<br />
Margus Viigimaa, Estonia<br />
Algorithm <strong>for</strong> <strong>the</strong> management <strong>of</strong> a<br />
heart failure patient with erectile<br />
dysfunction: “Pumping up” HF patient’s<br />
sex life<br />
Gabriele Fragasso, Italy<br />
PDE5 inhibitors in heart failure patients:<br />
Killing two birds with one<br />
stone<br />
Charalambos Vlachopoulos, Greece<br />
Round Table<br />
10.30 – 12.00 h auditorium II<br />
Who, where and why The demography <strong>of</strong> female<br />
sexual dysfunction throughout <strong>the</strong> reproductive<br />
cycle<br />
Chairpersons: Aslan Ergul, Turkey<br />
Rossella Nappi, Italy<br />
RT-04-001<br />
RT-04-002<br />
RT-04-003<br />
RT-04-004<br />
Bo<strong>the</strong>rsome and distress are <strong>of</strong> paramount<br />
importance in defining <strong>the</strong><br />
prevalence and predictors <strong>of</strong> female<br />
sexual dysfunction<br />
Annamaria Giraldi, Denmark<br />
Sexual dysfunction is frequent in reproductive-aged<br />
women<br />
Rossella Nappi, Italy<br />
The effect <strong>of</strong> <strong>the</strong> menopause<br />
Anneliese Schwenkhagen, Germany<br />
Sexuality and health in older women<br />
Johannes Bitzer, Switzerland<br />
10.30 – 12.00 h Conference Room 1<br />
What <strong>the</strong> sexual physician needs to know about<br />
genital dermatology<br />
Chairperson: Asif Muneer, United Kingdom<br />
EC-02-001<br />
EC-02-002<br />
EC-02-003<br />
ML-03<br />
Male genital dermatoses and <strong>the</strong> impact<br />
on sexual and urinary function<br />
Chris Bunker, United Kingdom<br />
Premalignant penile lesions – diagnosis<br />
and management<br />
Asif Muneer, United Kingdom<br />
Female genital dermatology<br />
Goldstein Andrew, USA<br />
Master Lecture<br />
11.30 – 12.00 h auditorium I<br />
The history@<strong>ESSM</strong> lectures<br />
Moderator: Manuel Mas, Spain<br />
ML-03-001<br />
ML-03-002<br />
HP-01<br />
Picasso: Art can only be erotic!<br />
Dirk Schul<strong>the</strong>iss, Germany<br />
Dali: Eroticism in surrealism<br />
Beatrice Cuzin, France<br />
Highlighted<br />
Poster Session<br />
12.00 – 12.30 h Pavilion 1<br />
Basic science<br />
Chairpersons: Mario Maggi, Italy<br />
Ulf Simonsen, Denmark<br />
HP-01-001<br />
Brain activations in patients with psychogenic<br />
erectile dysfunction: An fMRI<br />
study<br />
Ezio Domenico Di Pierro, Italy<br />
G. Paradiso Galatioto, N. Cera, G. Pace,<br />
A. Del Rosso, G. Sepede, F. Gambi, A. Tar -<br />
taro, C. Del Gratta, G. L. Romani, C. Vicentini<br />
www.essm.org<br />
29
Scientific Program<br />
Monday, 15 November 2010<br />
HP-01-002<br />
HP-01-003<br />
HP-01-004<br />
HP-01-005<br />
HP-01-006<br />
Effects <strong>of</strong> repeated flibanserin treatment<br />
on appetitive sexual behaviors<br />
in male and female rats<br />
Jonathan Greggain, Canada<br />
K. Allers, B. Sommer, J. Pfaus<br />
Effect <strong>of</strong> mescenchymal derived stem<br />
cell transplantation with BDNF on <strong>the</strong><br />
erectile function in <strong>the</strong> rat model<br />
with cavernous nerve injury<br />
Su Jin Kim, Republic <strong>of</strong> Korea<br />
S.-K. Yang, T. Y. Ahn, J. H. Hong, B. I. Yoon,<br />
H. J. Cho, S.-H. Hong, J. Y. Lee, T.-K. Hwang,<br />
S. W. Kim<br />
Relaxation induced by hydrogen sulfide<br />
signaling is impaired in human<br />
corpus cavernosum and penile arteries<br />
from men with erectile dysfunction<br />
José María La Fuente, Portugal<br />
J. I. Martínez-Salamanca, P. Cuevas,<br />
A. Fernández, P. Cardoso, J. Angulo<br />
Effect <strong>of</strong> vardenafil treatment in <strong>the</strong><br />
plasma proteome <strong>of</strong> patients with<br />
erectile dysfunction and diabetes<br />
mellitus<br />
San Jose Luis, Spain<br />
A. J. Lopez Fabre, R. Brime, I. Galante,<br />
P. Mateos Caceres, P. Lanzat, E. Mahillo,<br />
J. Carballido, A. Silmi, C. Macaya,<br />
C. Oliver<br />
Chronic administration <strong>of</strong> sildenafil<br />
improves erectile function in a rat<br />
model <strong>of</strong> chronic renal failure<br />
Mustafa Faruk Usta, Turkey<br />
N. Gurbuz, A. Kol<br />
RT-05<br />
Round Table<br />
13.30 – 14.30 h auditorium I<br />
Postoperative sexual function following radical<br />
prostatectomy: Which approach is better in 2010<br />
Chairperson: Mustafa Faruk Usta, Turkey<br />
RT-05-001<br />
RT-05-002<br />
RT-06<br />
Open radical prostatectomy per<strong>for</strong>ms<br />
better!<br />
Markus Graefen, Germany<br />
Robotic-assisted laparoscopic radical<br />
prostatectomy, mon amour!<br />
Francesco Montorsi, Italy<br />
Round Table<br />
13.30 – 15.00 h auditorium II<br />
Do women become orgasmic<br />
Chairpersons: Talli Rosenbaum, Israel<br />
Annamaria Giraldi, Denmark<br />
RT-06-001<br />
RT-06-002<br />
RT-06-003<br />
RT-06-004<br />
Preclinical issues involved in <strong>the</strong> female<br />
orgasm<br />
Helene Gelez, France<br />
Functional imaging <strong>of</strong> <strong>the</strong> brain in relation<br />
to <strong>the</strong> female orgasm<br />
Janniko Georgiadis, The Ne<strong>the</strong>rlands<br />
The peripheral assessment <strong>of</strong> orgasmic<br />
women<br />
Emmanuele Jannini, Italy<br />
What are <strong>the</strong> clinical implications <strong>of</strong><br />
vaginal versus non-vaginal orgasm<br />
Stuart Brody, United Kingdom<br />
EC-03<br />
Educational Course<br />
13.30 – 15.00 h Conference Room 1<br />
Gender reassignment surgery<br />
Chairperson: David Ralph, United Kingdom<br />
EC-03-001<br />
EC-03-002<br />
EC-03-003<br />
Early management <strong>of</strong> transition<br />
Kevan Wylie, United Kingdom<br />
Male-female reassignment surgery<br />
Carlo Bettocchi, Italy<br />
Female-male reassignment surgery<br />
Giulio Garaffa, United Kingdom<br />
30
scientific program<br />
Monday, 15 November 2010<br />
ML-04<br />
Master Lecture<br />
PS-02<br />
Podium Session<br />
14.30 – 15.00 h auditorium I<br />
Reports from <strong>the</strong> 3 rd international consultation on<br />
sexual medicine<br />
Moderator: Edouard Amar, France<br />
ML-04-001<br />
PS-01<br />
Reports from <strong>the</strong> 3 rd international<br />
consultation on sexual medicine<br />
Francesco Montorsi, Italy<br />
Podium Session<br />
15.00 – 15.30 h auditorium I<br />
Conservative ED treatment<br />
Chairpersons: Thierry Roumeguere, Belgium<br />
Natalio Cruz Navarro, Spain<br />
PS-01-001<br />
PS-01-002<br />
PS-01-003<br />
PS-01-004<br />
The effect <strong>of</strong> low intensity shock<br />
wave <strong>the</strong>rapy in severe ED patients<br />
not responding to oral medication<br />
Yoram Vardi, Israel<br />
B. Appel, O. Massarwa, E. Sprecher,<br />
I. Gruenwald<br />
A randomized, double-blind, placebo-controlled,<br />
parallel-group study<br />
to assess <strong>the</strong> efficacy and safety <strong>of</strong><br />
tadalafil once daily in subjects with<br />
erectile dysfunction who are naive to<br />
phosphodiesterase type 5 inhibitors<br />
Ignacio Moncada, Spain<br />
A. Aversa, H. Porst, P. Perimenis,<br />
C. Barker, M. A. Shane, S. Sorsaburu,<br />
F. Montorsi<br />
The POTENT I randomised trial: Efficacy<br />
and safety <strong>of</strong> an orodispersible<br />
tablet <strong>for</strong>mulation <strong>of</strong> vardenafil <strong>for</strong><br />
<strong>the</strong> treatment <strong>of</strong> erectile dysfunction<br />
Frans Debruyne, The Ne<strong>the</strong>rlands<br />
H. Sperling, A. Boermans, M. Beneke,<br />
E. Ulbrich, S. Ewald<br />
The HelpED study: Impact <strong>of</strong> change<br />
in erection hardness on <strong>the</strong> sexual<br />
function and quality <strong>of</strong> life <strong>of</strong> female<br />
partners <strong>of</strong> men with erectile dysfunction<br />
Robert Andrianne, Belgium<br />
H. Claes, R. Opsomer, S. Patel, K. Commers<br />
15.00 – 15.30 h auditorium II<br />
Psychosexual issues and management<br />
Chairpersons: Stuart Brody, United Kingdom<br />
Chris McMahon, Australia<br />
PS-02-001<br />
PS-02-002<br />
PS-02-003<br />
PS-02-004<br />
HP-02<br />
Men use different sexual response<br />
models during <strong>the</strong>ir lifespan: The role<br />
<strong>of</strong> erectile dysfunction and sexual<br />
motives<br />
Evangelia Nakopoulou, Greece<br />
A. Macaskill, K. Wylie, D. Hatzichristou<br />
Dimensional pr<strong>of</strong>iles <strong>of</strong> male to female<br />
gender identity disorder: An exploratory<br />
research<br />
Alessandra Daphne Fisher, Italy<br />
E. Bandini, V. Ricca, G. Corona, E. Jannini,<br />
M. C. Meriggiola, C. Manieri, J. Ristori,<br />
G. Forti, E. Mannucci, M. Maggi<br />
Masturbation: What do women get<br />
from it – The subjective feeling <strong>of</strong> sexual<br />
satisfaction from masturbation<br />
Susanne Philippsohn, Germany<br />
Women’s motivation <strong>for</strong> sexual activity<br />
Annamaria Giraldi, Denmark<br />
M. Sand, E. Kristensen<br />
Highlighted<br />
Poster Session<br />
15.30 – 16.00 h Pavilion 1<br />
Male sexual function and dysfunction<br />
Chairpersons: Konstantinos Hatzimouratidis, Greece<br />
Muammer Kendirci, Turkey<br />
HP-02-001<br />
HP-02-002<br />
Evaluation <strong>of</strong> patient’s sexual function<br />
be<strong>for</strong>e and after renal transplantation<br />
Mohammad Reza Darabi Mahboub,<br />
Islamic Republic <strong>of</strong> Iran<br />
M. H. Shakibi<br />
Prolactin levels independently predict<br />
major cardiovascular events in<br />
patients with erectile dysfunction<br />
Giovanni Corona, Italy<br />
G. Rastrelli, V. Boddi, M. Monami, A.<br />
S<strong>for</strong>za, G. Forti, E. Mannucci, M. Maggi<br />
www.essm.org<br />
31
Scientific Program<br />
Monday, 15 November 2010<br />
HP-02-003<br />
HP-02-004<br />
HP-02-005<br />
HP-02-006<br />
Impact <strong>of</strong> LUTS /BPH treatment by<br />
tamsulosin and solifenacin combination<br />
<strong>the</strong>rapy on erectile function<br />
Jae-Seog Hyun, Republic <strong>of</strong> Korea<br />
D.-H. Seo, J.-M. Do, S.-C. Kam, K. H. Moon<br />
Comorbidities in men with erectile<br />
dysfunction, with and without hypogonadism<br />
José María Martinez-Jabaloyas, Spain<br />
O. Cardeñosa, L. Gooren<br />
IPASS: Interim data from a large international<br />
study <strong>of</strong> injectable testosterone<br />
undecanoate on sexual health<br />
and o<strong>the</strong>r parameters <strong>of</strong> male hypogonadism<br />
Michael Zitzmann, Germany<br />
J. U. Hanisch, A. Mattern, M. Maggi<br />
Male circumcision decreases genital<br />
sensitivity as measured by self-assessment<br />
in a large cohort<br />
Guy Bronselaer, Belgium<br />
H. F. L. Meyer-Bahlburg, J. M. Schober,<br />
P. Hoebeke<br />
RT-08<br />
Round Table<br />
16.00 – 17.30 h auditorium II<br />
Translational science: How to translate preclinical<br />
discoveries into clinical applications<br />
Chairpersons: Javier Angulo, Spain<br />
Carla Costa, Portugal<br />
RT-08-001 Soluble guanylate cyclase stimulators /<br />
activators and erectile dysfunction<br />
Peter Sandner, Germany<br />
RT-08-002<br />
RT-08-003<br />
RT-08-004<br />
EC-04<br />
Cannabinoid and friends – potentiallynovel<br />
targets <strong>for</strong> pharmaco<strong>the</strong>rapy<br />
Christian Gratzke, Germany<br />
How to create a novel animal model<br />
<strong>of</strong> sexual function<br />
Petter Hedlund, Sweden<br />
„Flibanserin“ – what do hops and darts<br />
have to do with women with HSDD<br />
Michael Sand, USA<br />
Educational Course<br />
RT-07<br />
Round Table<br />
16.00 – 17.30 h auditorium I<br />
The real world is running quickly – who is in charge<br />
<strong>of</strong> ED patients in 2010<br />
Chairpersons: Dimitris Hatzichristou, Greece<br />
Francesco Montorsi, Italy<br />
RT-07-001<br />
RT-07-002<br />
RT-07-003<br />
RT-07-004<br />
When, how and why do ED patients<br />
so frequently bypass <strong>the</strong> healthcare<br />
system<br />
Tara Symonds, United Kingdom<br />
What‘s <strong>the</strong> role <strong>of</strong> <strong>the</strong> pharmacist in<br />
developing <strong>the</strong> culture <strong>of</strong> male sexual<br />
health<br />
Ema Paulino, Portugal<br />
Mr. GP, what are you actually doing<br />
to promote male sexual health<br />
John Dean, United Kingdom<br />
The real world is running quickly! Are<br />
we keeping up with it<br />
Raymond Rosen, USA<br />
Supported by an educational grant from Pfizer<br />
16.00 – 17.30 h Conference Room 1<br />
What <strong>the</strong> sexual physician needs to know about<br />
sexually transmitted infection<br />
Chairperson: Philip Kell, United Kingdom<br />
Speaker: W. Wallace Dinsmore, United Kingdom<br />
Philipp Kell, United Kingdom<br />
RT-09<br />
Round Table<br />
17.30 – 19.00 h auditorium I<br />
Adolescentology – is anyone out <strong>the</strong>re who may<br />
help me<br />
Chairpersons: Mark A. Bellis, United Kingdom<br />
Chiara Simonelli, Italy<br />
RT-09-001<br />
RT-09-002<br />
RT-09-003<br />
What shall we do with <strong>the</strong> pedophiles<br />
Hartmut Bosinski, Germany<br />
Understanding emotional abuse is a<br />
critical matter <strong>for</strong> sexual health<br />
Corinne A. Rees, United Kingdom<br />
The impact <strong>of</strong> child sexual abuse on<br />
general health<br />
Roberto Maniglio, Italy<br />
RT-09-004<br />
Is childhood sexual abuse “biologically-linked”<br />
to future sexual function<br />
impairment<br />
Adriaan Tuiten, The Ne<strong>the</strong>rlands<br />
32
scientific program<br />
tuesday, 16 November 2010<br />
07.00 – 08.00 h Auditorium II<br />
<strong>ESSM</strong> Annual Business Meeting<br />
– members only –<br />
RT-10<br />
Round Table<br />
08.00 – 09.30 h auditorium I<br />
Peyronie’s disease: Still a pain in <strong>the</strong> neck! A critical<br />
reappraisal<br />
Chairpersons: Emre Akkus, Turkey<br />
Javier Romero-Otero, Spain<br />
PS-03-003<br />
PS-03-004<br />
The role <strong>of</strong> peripheral 5-Hydroxytryptamine<br />
(5-HT) receptors in mediating<br />
seminal vesicle contraction induced<br />
by electrical nerve stimulation in anaes<strong>the</strong>tized<br />
rats<br />
Chen-Hsun Ho, Taiwan<br />
C.-T. Chien, J.-T. Hsieh<br />
Escitalopram treatment <strong>for</strong> premature<br />
ejaculation has a negative effect<br />
on semen parameters<br />
Hakan Koyuncu, Turkey<br />
E. C. Serefoglu, E. Yencilek, H. Atalay,<br />
N. B. Akbas, K. Sarıca<br />
RT-10-001<br />
RT-10-002<br />
RT-10-003<br />
RT-10-004<br />
Latest news from <strong>the</strong> preclinical<br />
world. Are <strong>the</strong>re any new possible options<br />
<strong>for</strong> men with peyronie’s disease<br />
Nestor F. Gonzalez-Cadavid, USA<br />
Is <strong>the</strong>re a place <strong>for</strong> “currently available”<br />
conservative treatments in men<br />
with peyronie‘s disease<br />
Yoram Vardi, Israel<br />
Translational science in peyronie‘s<br />
disease: Applying novel findings in<br />
<strong>the</strong> real-life setting<br />
Wayne Hellstrom, USA<br />
Implants and mechanical devices:<br />
What, when and how in peyronie‘s<br />
disease<br />
Carlo Bettocchi, Italy<br />
PS-03-005<br />
PS-03-006<br />
Associations <strong>of</strong> single nucleotide polymorphisms<br />
in <strong>the</strong> oxytocin and vasopressin<br />
receptor genes with premature<br />
ejaculation<br />
Patrick Jern, Finland<br />
L. Westberg, P. Santtila, A. Johansson,<br />
J. Corander, E. Eriksson, N. K. Sandnabba<br />
The bi<strong>of</strong>eedback training in patients<br />
with premature ejaculation<br />
Valeriy Zaitsev, Ukraine<br />
A. Sytenko, M. Gafsi<br />
PS-03-007 The relationship between lower uri<strong>for</strong>mer<br />
PS-08-005 nary tract symptoms and ejaculatory<br />
dysfunction among men initiating<br />
BPH medical <strong>the</strong>rapies<br />
Raymond Rosen, USA<br />
R. Dunn, J. Wei, A. Seftel, M. Miner, W.<br />
Carman, D. Pasta, C. Spino, C. Roehrborn<br />
PS-03<br />
Podium Session<br />
08.00 – 09.00 h auditorium II<br />
Ejaculatory disorders<br />
Chairpersons: Marcel D. Waldinger, The Ne<strong>the</strong>rlands<br />
Jens Sonksen, Denmark<br />
PS-03-001<br />
PS-03-002<br />
Premature ejaculation in men with<br />
lower spinal cord lesions<br />
Frédérique Courtois, Canada<br />
K. Charvier, J.-G. Vézina, S. Carrier, N. Morel<br />
Journel, G. Jacquemin, I. Côté<br />
Perceived ejaculate volume reduction<br />
in subjects with erectile dysfunction:<br />
Psycho-biological correlates<br />
Giovanni Corona, Italy<br />
V. Boddi, M. Gacci, A. S<strong>for</strong>za, G. Forti,<br />
E. Mannucci, M. Maggi<br />
EC-05<br />
Educational Course<br />
08.00 – 09.30 h Conference Room 1<br />
Contraception and HRT <strong>for</strong> women in contemporary<br />
clinical practice<br />
Chairperson: Rossella Nappi, Italy<br />
EC-05-001<br />
EC-05-002<br />
EC-05-003<br />
How to tailor contraceptive options<br />
Johannes Bitzer, Switzerland<br />
Non-contraceptive benefits <strong>of</strong> contraceptive<br />
choice<br />
Anneliese Schwenkhagen, Germany<br />
Tips to select <strong>the</strong> best HRT <strong>for</strong> postmenopausal<br />
women<br />
Rossella Nappi, Italy<br />
www.essm.org<br />
33
Scientific Program<br />
tuesday, 16 November 2010<br />
PS-04<br />
Podium Session<br />
09.00 – 10.00 h auditorium II<br />
Is ED a proxy <strong>of</strong> men‘s health<br />
Chairpersons: Graham Jackson, United Kingdom<br />
Konstantinos Rokkas, Greece<br />
PS-04-001<br />
PS-04-002<br />
PS-04-003<br />
PS-04-004<br />
PS-04-005<br />
PS-04-006<br />
Severe depressive symptoms and cardiovascular<br />
risk in subjects with erectile<br />
dysfunction<br />
Elisa Bandini, Italy<br />
F. Lotti, G. Corona, V. Ricca, V. Boddi, M.<br />
Monami, C. Melani, G. Forti, E. Manucci,<br />
M. Maggi<br />
C-reactive protein is a better early predictor<br />
<strong>of</strong> coronary artery disease than<br />
low testosterone in men less than<br />
60 years with erectile dysfunction<br />
Nikolaos Ioakeimidis, Greece<br />
C. Vlachopoulos, A. Aggelis, A. Samentzas,<br />
I. Dima, K. Baou, K. Rokkas, T. Askitis,<br />
A. Rembelakos, C. Stefanadis<br />
Prostate safety over 6 year transdermal<br />
testosterone treatment in hypogonadal<br />
men<br />
Jean Pierre Raynaud, France<br />
J. Gardette, J. Rollet, J. J. Legros<br />
The effect <strong>of</strong> statin <strong>the</strong>rapy on testosterone<br />
levels in subjects consulting<br />
<strong>for</strong> erectile dysfunction<br />
Giovanni Corona, Italy<br />
V. Boddi, G. Balercia, G. Rastrelli, G. de<br />
Vita, A. S<strong>for</strong>za, G. Forti, E. Mannucci,<br />
M. Maggi<br />
Triglyceride / HDL-C ratio is associated<br />
with penile vascular disease in apparently<br />
healthy men with erectile dysfunction<br />
Konstantinos Rokkas, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, A. Aggelis,<br />
A. Samentzas, K. Siama, G. Sakellariou,<br />
T. Askitis, A. Rembelakos, C. Stefanadis<br />
Pulse pressure independently predicts<br />
major cardiovascular events in<br />
younger but not in older subjects<br />
with erectile dysfunction<br />
Giovanni Corona, Italy<br />
M. Monami, V. Boddi, G. Rastrelli, A. S<strong>for</strong>za,<br />
G. Forti, E. Mannucci, M. Maggi<br />
PS-04-007<br />
ML-05<br />
Men’s endorsement <strong>of</strong> models <strong>of</strong> sexual<br />
response and motivation <strong>for</strong> sexual<br />
activity<br />
Michael Sand, USA<br />
A. Giraldi, E. Kristensen<br />
Master Lecture<br />
09.30 – 10.00 h auditorium I<br />
SMSNA lecture: Penile augmentation surgery – quo<br />
vadis<br />
Moderator: Juan Ignacio Martinez-Salamanca, Spain<br />
Lecturer: Wayne Hellstrom, USA<br />
RT-11<br />
Round Table<br />
10.30 – 12.00 h auditorium I<br />
Who deserves what A more focused pharmacological<br />
approach <strong>for</strong> sexual dysfunctions<br />
Chairpersons: Pedro Simoes Vendeira, Portugal<br />
Petter Hedlund, Sweden<br />
RT-11-001<br />
RT-11-002<br />
RT-11-003<br />
RT-11-004<br />
RT-12<br />
Modification <strong>of</strong> treatment protocol;<br />
simple in appearance! The case <strong>for</strong> hypertension-related<br />
sexual dysfunction<br />
Michalis Doumas, Greece<br />
Genetic polymorphisms and association<br />
with sexual dysfunction<br />
Bulent Erol, Turkey<br />
Are pharmacogenetics and pharmacogenomics<br />
applicable to sexual dysfunction<br />
Ibrahim A Abdel-Hamid, Egypt<br />
The pharmacogenetics <strong>of</strong> testosterone<br />
replacement <strong>the</strong>rapy<br />
Giovanni Corona, Italy<br />
Round Table<br />
10.30 – 11.30 h auditorium II<br />
Gender differences – a novel biopsychological paradigm<br />
Chairpersons: Raymond Rosen, USA<br />
Zdravko Asenov Kamenov, Bulgaria<br />
RT-12-001<br />
Exploring possible genetic links to<br />
sexual orientation<br />
Ellis Lee, USA<br />
34
scientific program<br />
tuesday, 16 November 2010<br />
RT-12-002<br />
The epigenetics <strong>of</strong> sex differences in<br />
<strong>the</strong> brain<br />
Bridget Nugent, USA<br />
HP-03-002<br />
Mediators <strong>of</strong> sexual functions in diabetic<br />
females<br />
Krzyszt<strong>of</strong> Nowosielski, Poland<br />
RT-12-003<br />
EC-06<br />
A sex difference in <strong>the</strong> specificity <strong>of</strong><br />
sexual response<br />
Stephan Hamann, USA<br />
Educational Course<br />
10.30 – 12.00 h Conference Room 1<br />
The role <strong>of</strong> penile pros<strong>the</strong>sis in contemporary sexual<br />
medicine practice<br />
Chairperson: Carlo Bettocchi, Italy<br />
EC-06-001<br />
EC-06-002<br />
EC-06-003<br />
EC-06-004<br />
Penile pros<strong>the</strong>sis implant: Tips and<br />
tricks<br />
David Ralph, United Kingdom<br />
Patient counselling and follow up<br />
Amanda Spillings, United Kingdom<br />
Penile pros<strong>the</strong>sis implants: Results and<br />
major concerns<br />
Antoine Faix, France<br />
Penile pros<strong>the</strong>sis complications<br />
Carlo Bettocchi, Italy<br />
HP-03-003<br />
HP-03-004<br />
HP-03-005<br />
SA-02<br />
Women do not constantly follow <strong>the</strong><br />
same sexual response model during<br />
<strong>the</strong>ir lifespan: The role <strong>of</strong> sexual function<br />
and satisfaction<br />
Fotini Ferenidou, Greece<br />
L. Athanasiadis, P.-S. Kirana, F. Konstantinos,<br />
K. Wylie, D. Hatzichristou<br />
Epidemiology and recognition <strong>of</strong> sexual<br />
problems in <strong>the</strong> gynecologist’s<br />
<strong>of</strong>fice – first results from <strong>the</strong> EROS-<br />
Gyne study<br />
Michael Berner, Germany<br />
J. Bertelmann, L. Schmedes, L. Kriston,<br />
G. Naumann, K. Renezeder, C. Günzler<br />
The ultrasound study <strong>of</strong> <strong>the</strong> genitals<br />
vessels with <strong>the</strong> use <strong>of</strong> <strong>the</strong> method <strong>of</strong><br />
doppler sonography in <strong>the</strong> diagnostics<br />
<strong>of</strong> female sexual dysfunctions<br />
Igor Gorpynchenko, Ukraine<br />
O. Romashchenko, S. Melnykov, V. Bilogolovskaya<br />
Satellite Symposium<br />
ML-06<br />
Master Lecture<br />
11.30 – 12.00 h auditorium II<br />
New medical insights into restless genital syndrome<br />
Moderator: Beate Korda, Germany<br />
Lecturer: Marcel D. Waldinger, The Ne<strong>the</strong>rlands<br />
HP-03<br />
Highlighted<br />
Poster Session<br />
12.00 – 12.30 h Pavilion 1<br />
Female sexual function<br />
Chairpersons: Johannes Bitzer, Switzerland<br />
Selahittin Cayan, Turkey<br />
HP-03-001<br />
Rectosigmoid vaginoplasty: Our experience<br />
in 85 cases<br />
Marta Bizic, Serbia<br />
M. Majstorovic, V. Kojovic, A. Milosevic,<br />
M. Djordjevic<br />
12.30 – 13.30 h auditorium I<br />
Case discussions between <strong>the</strong> contradictory contexts<br />
<strong>of</strong> evidence-based medicine and experts‘ experience<br />
Chairperson: Hartmut Porst, Germany<br />
SA-02-001<br />
SA-02-002<br />
SA-02-003<br />
SA-02-004<br />
Evidence-based medicine – The basis<br />
<strong>for</strong> case-by-case-decisions<br />
Hartmut Porst, Germany<br />
A hypogonadal patient beyond <strong>the</strong><br />
textbook<br />
Hartmut Porst, Germany<br />
Unspeakable or speechless Disclosing<br />
sexual history<br />
Hartmut Bosinski, Germany<br />
ED – never easy<br />
Ignacio Moncada, Spain<br />
Supported by an educational grant from Lilly LLC<br />
www.essm.org<br />
35
Scientific Program<br />
tuesday, 16 November 2010<br />
RT-14<br />
Round Table<br />
PS-05<br />
Podium Session<br />
13.30 – 15.00 h auditorium I<br />
Premature ejaculation in <strong>the</strong> real life setting<br />
Chairpersons: Juza Chen, Israel<br />
Hartmut Porst, Germany<br />
14.30 – 15.30 h auditorium II<br />
Surgery and Peyronie‘s disease<br />
Chairpersons: Mustafa Faruk Usta, Turkey<br />
Suks Minhas, United Kingdom<br />
RT-14-001<br />
RT-14-002<br />
RT-14-003<br />
New insights into <strong>the</strong> clinical aspects<br />
<strong>of</strong> premature ejaculation<br />
Ege Can Serefoglu, Turkey<br />
Endocrine aspects <strong>of</strong> ejaculatory disorders<br />
Emmanuele Jannini, Italy<br />
Psychometric tools and measurements<br />
<strong>for</strong> PE: Are <strong>the</strong>y a waste <strong>of</strong><br />
time or should <strong>the</strong>y be part <strong>of</strong> <strong>the</strong><br />
standard clinical work-up<br />
Patrick Jern, Finland<br />
RT-14-004 Treatment options <strong>for</strong> PE – <strong>the</strong> new<br />
kids on <strong>the</strong> block<br />
François Giuliano, France<br />
Supported by an educational grant from Janssen Pharmaceutica<br />
NV.<br />
RT-15<br />
Round Table<br />
13.30 – 14.30 h auditorium II<br />
Is testosterone dangerous <strong>for</strong> prostate health<br />
Chairperson: Claude Schulman, Belgium<br />
RT-15-001<br />
RT-15-002<br />
EC-07<br />
Pro-Speaker<br />
Mario Maggi, Italy<br />
Con-Speaker<br />
Mohit Khera, USA<br />
Educational Course<br />
13.30 – 15.00 h Conference Room 1<br />
Contemporary clinical management <strong>of</strong> erectile disorders<br />
Chairperson: Ian Eardley, United Kingdom<br />
EC-07-001<br />
EC-07-002<br />
Assessment <strong>of</strong> men with ED<br />
Ian Earley, United Kingdom<br />
Therapy <strong>of</strong> men with ED: Case discussions<br />
Ge<strong>of</strong>frey Hackett, United Kingdom<br />
PS-05-001<br />
PS-05-002<br />
PS-05-003<br />
PS-05-004<br />
PS-05-005<br />
PS-05-006<br />
PS-05-007<br />
Prospective comparison <strong>of</strong> different<br />
methods <strong>of</strong> measurement <strong>of</strong> penile<br />
curvature in patients with peyronie‘s<br />
disease<br />
Alejandra Egui, Spain<br />
J. I. Martínez-Salamanca, L. Osorio, E. Linares,<br />
I. Sola, C. Martinez-Ballesteros, L. del<br />
Portillo, C. Joaquin<br />
Results in improvement in neoclitoris<br />
sensitivity in male to female sex reassignment<br />
Fulvio Colombo, Italy<br />
A. Franceschelli, M. Soli, C. V. Pultrone,<br />
E. Brunocilla, G. Martorana<br />
Do topical androgens and <strong>the</strong>ir timing<br />
affect <strong>the</strong> survival <strong>of</strong> buccal mucosa<br />
grefts in hypospadias repair<br />
Berk Burgu, Turkey<br />
O. Aydogdu, H. Talas, C. Demirel, D. Kankaya,<br />
A. Sertcelik, T. Soygur<br />
Efficacy and safety <strong>of</strong> penile extensor<br />
in <strong>the</strong> treatment <strong>of</strong> <strong>the</strong> acute phase<br />
<strong>of</strong> peyronie‘s disease: A pilot study<br />
Juan Ignacio Martínez-Salamanca, Spain<br />
A. Egui, L. Osorio, E. Linares, I. Sola, L. del<br />
Portillo, I. Moncada, J. Carballido<br />
The effect <strong>of</strong> treatment <strong>of</strong> non bacterial<br />
chronic prostatitis with TURF on<br />
sexual disorders: a pilot study<br />
Yacov Reisman, The Ne<strong>the</strong>rlands<br />
R. Kropman<br />
Current surgical techniques <strong>for</strong> penile<br />
curvatures, evaluation <strong>of</strong> results and<br />
subjective satisfaction rating by patients<br />
Cristian Palma Ceppi, Spain<br />
C. Rojas-Cruz, M. Sobron, J. Sarquella, M.<br />
Peraza, J. R. Sanchez Curbelo, H. T. Suarez<br />
Penile plastics with polypropylene<br />
mesh and ligamentotomy – a new<br />
method <strong>of</strong> surgical treatment <strong>of</strong> penile<br />
dysmorphophobic disorder<br />
Maksym Romaniuk, Ukraine<br />
O. Kornienko, A. Gurzhenko<br />
36
scientific program<br />
tuesday, 16 November 2010<br />
ML-07 Master Lecture<br />
15.00 – 15.30 h auditorium I<br />
Science <strong>for</strong> men’s health – it is not a marketing<br />
hype!<br />
Moderator: Ian Eardley, United Kingdom<br />
Lecturer: Frans Debruyne, The Ne<strong>the</strong>rlands<br />
HP-04-006<br />
Overweight is affecting <strong>the</strong> quality<br />
and parameters <strong>of</strong> sexual life, especially<br />
in men but also in women.<br />
Weight loss should have a positive<br />
consequence on sexuality<br />
Dana Bucuras, Romania<br />
D. Anastasiu, M. Craina<br />
HP-04<br />
Highlighted<br />
Poster Session<br />
15.30 – 16.00 h Pavilion 1<br />
Different aspects <strong>of</strong> sexual health-2<br />
Chairpersons: Giovanni Corona, Italy<br />
Nicolae Calomfirescu, Romania<br />
HP-04-001<br />
HP-04-002<br />
HP-04-003<br />
HP-04-004<br />
HP-04-005<br />
The impact <strong>of</strong> pelvic shape on <strong>the</strong><br />
genesis <strong>of</strong> erectile dysfunction after<br />
intramedullary femoral nailing<br />
Martin Sutory, Czech Republic<br />
T. Sramkova, J. Laitl<br />
Androgen deficiency and insulin resistance<br />
in obese male patients<br />
Shota Janjgava, Georgian<br />
E. Giorgadze<br />
Evaluation and interpretation <strong>of</strong> intracavernous<br />
injections at <strong>the</strong> <strong>of</strong>fice<br />
basis and during color Doppler ultrasonography<br />
Emre Akkus, Turkey<br />
H. Ozkara, B. Alici, H. Hattat<br />
Erectile dysfunction and cardiovascular<br />
risk: Investigating fibrin clot structure.<br />
A controlled study<br />
Omer Baldo, United Kingdom<br />
I. Eardley, L. Summmers, R. West, K. Standeven,<br />
R. Ajjan, J. Mcguinness<br />
Analysing by decade, testosterone<br />
undecanoat depot injectable does<br />
not increases prostate volume. Study<br />
on over 110 hypogonadic patients<br />
without prostatic cancer<br />
Dan Peretianu, Romania<br />
M. Carsote, C. Poiana, C. D. Staicu<br />
RT-16<br />
Round Table<br />
16.00 – 17.30 h auditorium I<br />
How to approach sexual dysfunction in 2010 – sharing<br />
<strong>the</strong> experience <strong>of</strong> different <strong>european</strong> countries<br />
Chairperson: Santiago de Quiroga, Spain<br />
RT-16-001<br />
RT-16-002<br />
RT-16-003<br />
RT-16-004<br />
RT-16-005<br />
United Kingdom<br />
Ian Eardley, United Kingdom<br />
Germany<br />
Hartmut Porst, Germany<br />
Italy<br />
Vincenzo Mirone, Italy<br />
France<br />
François Giuliano, France<br />
Spain<br />
Antonio Martin Morales, Spain<br />
Supported by an educational grant from Bayer, Spain<br />
RT-17<br />
Round Table<br />
16.00 – 17.30 h auditorium II<br />
Prevention and management <strong>of</strong> male genital emergencies<br />
Chairpersons: Nicolae Calomfirescu, Romania<br />
Ates Kadioglu, Turkey<br />
RT-17-001<br />
RT-17-002<br />
RT-17-003<br />
Priapism<br />
Ates Kadioglu, Turkey<br />
Penile fracture<br />
Miroslav L. Djordjevic, Serbia<br />
Fournier’s gangrene<br />
Bulent Erol, Turkey<br />
RT-17-004<br />
RT-17-005<br />
Genital trauma with severe urethral<br />
injuries<br />
Enzo Palminteri, Italy<br />
Emergent “dramas” in penile pros<strong>the</strong>sis<br />
surgery<br />
David Ralph, United Kingdom<br />
www.essm.org<br />
37
Scientific Program<br />
tuesday, 16 November 2010<br />
EC-08<br />
Educational Course<br />
PS-06<br />
Podium Session<br />
16.00 – 17.30 h Conference Room 1<br />
Contemporary clinical management <strong>of</strong> women‘s<br />
sexual problems<br />
Chairpersons: Annamaria Giraldi, Denmark<br />
Johannes Bitzer, Switzerland<br />
EC-08-001<br />
EC-08-002<br />
EC-08-003<br />
EC-08-004<br />
RT-18<br />
Womens sexual problems and barriers<br />
<strong>for</strong> seeking help<br />
Annamaria Giraldi, Denmark<br />
Assessment-questionnaires, clinical, labo<br />
ratory and GY<br />
Annamaria Giraldi, Denmark<br />
Johannes Bitzer, Switzerland<br />
Treatment options<br />
Johannes Bitzer, Switzerland<br />
Treatment <strong>of</strong> orgasm problems<br />
Annamaria Giraldi, Denmark<br />
Round Table<br />
17.30 – 19.00 h auditorium I<br />
The “bull fighting experience”: My surgery works<br />
better in severe cases <strong>of</strong> Peyronie´s Disease!<br />
Chairpersons: Miroslav L. Djordjevic, Serbia<br />
Luigi C. Cormio, Italy<br />
RT-18-001<br />
RT-18-002<br />
RT-18-003<br />
RT-18-004<br />
Do it Brazilian!<br />
Paulo H. Egydio, Brazil<br />
The British aplomb<br />
David Ralph, United Kingdom<br />
Let’s go with <strong>the</strong> New Orleans Hornets!<br />
Wayne Hellstrom, USA<br />
The Arabic way<br />
Osama Kamal Zaki Mahmoud Shaeer,<br />
Egypt<br />
17.30 – 19.00 h auditorium II<br />
Preclinical sexual medicine<br />
Chairpersons: Petter Hedlund, Sweden<br />
Carla Costa, Portugal<br />
PS-06-001<br />
PS-06-002<br />
PS-06-003<br />
PS-06-004<br />
PS-06-005<br />
Activation <strong>of</strong> L-cysteine / H2S pathway<br />
involves hyperpolarization and guanylyl<br />
cyclase stimulation in human<br />
corpus cavernosum and penile arteries.<br />
Interference with NO / cGMP pathway<br />
José María La Fuente, Portugal<br />
J. I. Martínez-Salamanca, P. Cuevas, A. Fernández,<br />
F. Rolo, J. Angulo<br />
Pentoxifylline promotes recovery <strong>of</strong><br />
erectile function after cavernous<br />
nerve injury in rats<br />
Maarten Albersen, USA<br />
T. Fandel, H. Zhang, L. Banie, G. Lin, C.-S.<br />
Lin, T. F. Lue<br />
Farnesoid x receptor activation improves<br />
erectile function in animal<br />
models <strong>of</strong> metabolic syndrome and<br />
diabetes<br />
Linda Vignozzi, Italy<br />
A. Morelli, S. Filippi, P. Comeglio, A. Chavalmane,<br />
R. Yehiely-Cohen, G. B. Vannelli,<br />
L. Adorini, M. Maggi<br />
Effects <strong>of</strong> resveratrol on <strong>the</strong> alterations<br />
<strong>of</strong> cavernosal eNOS and LOX-1<br />
expression in hypercholesterolemic<br />
condition<br />
Ozan Bozkurt, Turkey<br />
A. Kefi, O. Demir, N. Murat, S. Gidener,<br />
A. Esen<br />
Sildenafil and rolipram enhance clitoral<br />
and vaginal blood flow responses<br />
to dorsal clitoral nerve stimulation in<br />
anes<strong>the</strong>tized female rats<br />
Fabio Castiglione, Italy<br />
A. Russo, A. Bergamini, A. Salonia, P. Rigatti,<br />
F. Montorsi, P. Hedlund<br />
38
scientific program<br />
tuesday, 16 November 2010<br />
PS-06-006<br />
PS-06-008<br />
Oxidative stress-induced molecular<br />
alterations in diabetic erectile tissue<br />
Angela Castela, Portugal<br />
T. Rodrigues, P. Gomes, P. Vendeira, R. Virag,<br />
C. Costa<br />
Evidence <strong>of</strong> cross talk between Hydrogen<br />
Sulphide and Nitric Oxide in<br />
erectile response and <strong>the</strong> possible involvement<br />
<strong>of</strong> testosterone<br />
Roeswita Leono Liaw, Singapore<br />
S. Balasubramanian, G. Adaikan<br />
PS-06-010<br />
Unfavourable effect <strong>of</strong> poor penile<br />
arterial inflow and long standing<br />
erectile dysfunction on treadmill exercise<br />
per<strong>for</strong>mance in men with hypertension<br />
Konstantinos Rokkas, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, D. Ter en -<br />
tes-Printzios, A. Aggelis, P. Xaplanteris,<br />
N. Alexopoulos, C. Fassoulakis, T. Askitis,<br />
C. Stefanadis<br />
PS-06-009<br />
Endo<strong>the</strong>lial pre-conditioning – sildenafil<br />
prior to cavernous nerve injury<br />
in <strong>the</strong> rat model: defining <strong>the</strong> optimal<br />
dosing and timing regimen<br />
Alexander Muller, Switzerland<br />
J. Donohue, R. Tal, D. Paduch, P. Scardino,<br />
J. Mulhall<br />
www.essm.org<br />
39
Scientific Program<br />
Wednesday, 17 November 2010<br />
RT-19<br />
Round Table<br />
08.00 – 09.30 h auditorium I<br />
Testosterone, who hates you<br />
Chairpersons: Selahittin Cayan, Turkey<br />
Mario Maggi, Italy<br />
RT-19-001<br />
RT-19-002<br />
RT-19-003<br />
RT-19-004<br />
PS-07<br />
Who are you, testosterone How preclinical<br />
studies can in<strong>for</strong>m <strong>the</strong> daily<br />
clinical practise<br />
Mario Maggi, Italy<br />
Testosterone is linked to cognition in<br />
both health and disease<br />
David M. Lee, United Kingdom<br />
The prevalence and role <strong>of</strong> androgen<br />
deficiency in young male cancer survivors<br />
Diana M. Greenfield, United Kingdom<br />
The age related decline in male serum<br />
testosterone. What does it mean<br />
Michael Zitzmann, Germany<br />
Podium Session<br />
08.00 – 09.00 h auditorium II<br />
Women‘s sexual health<br />
Chairpersons: Ana Carvalheira, Portugal<br />
Dana Bucuras, Romania<br />
PS-07-002<br />
PS-07-001<br />
PS-07-004<br />
Efficacy <strong>of</strong> Flibanserin in premenopausal<br />
women with hypoactive sexual<br />
desire disorder: Remitter analyses<br />
Michael Berner, Germany<br />
R. Nappi, J. M. Thorp, E. Jolly, M. Sand,<br />
R. Pyke<br />
Putative gene loci <strong>for</strong> female sexual<br />
dysfunction in females: Results <strong>of</strong> a<br />
genome-wide association study in an<br />
unselected population<br />
Andrea Burri, United Kingdom<br />
L. Cherkas, T. Spector<br />
A high resolution 3D study <strong>of</strong> <strong>the</strong><br />
(foetal) female pelvis reveals important<br />
anatomical details <strong>of</strong> <strong>the</strong> innervation<br />
<strong>of</strong> <strong>the</strong> clitoris<br />
Milou Bekker, The Ne<strong>the</strong>rlands<br />
C. Wallner, H. Elzevier, M. DeRuiter<br />
PS-07-005<br />
PS-07-006<br />
PS-07-007<br />
EC-09<br />
The relationship between attachment<br />
styles, marital satisfaction and sex<br />
guilt with sexual desire in women<br />
Negar Teimourpour, Islamic Republic <strong>of</strong> Iran<br />
N. Moshtagh Bidokhti, A. Pourshahbaz<br />
Prevalence and predictors <strong>of</strong> vestibulodynia<br />
in reproductive-aged women<br />
with recurrent uncomplicated e. coliassociated<br />
urinary tract infections<br />
Andrea Salonia, Italy<br />
A. Graziottin, R. E. Nappi, A. Saccà, M.<br />
Ghezzi, L. Rocchini, M. Ferrari, F. Castiglione,<br />
P. Rigatti, F. Montorsi<br />
Addressing anxiety in-vivo in physio<strong>the</strong>rapy<br />
treatment <strong>of</strong> women with severe<br />
vaginismus: A clinical approach<br />
Talli Rosenbaum, Israel<br />
Educational Course<br />
08.00 – 09.30 h Conference Room 1<br />
Gynaecological disorders in sexual medicine<br />
Chairpersons: Johannes Bitzer, Switzerland<br />
Annamaria Giraldi, Denmark<br />
How can gynaecological disorders influence sexual<br />
function<br />
Benign gynaecological disorders and <strong>the</strong>ir treatment:<br />
The impact <strong>of</strong> hysterectomy and unilateral or bilateral<br />
oophorectomy; Impact <strong>of</strong> vulva, vagina, cervix, uterine<br />
and ovarian cancers and <strong>the</strong>ir treatment on female sexual<br />
function.<br />
PS-08<br />
Podium Session<br />
09.00 – 10.00 h auditorium II<br />
Different aspects <strong>of</strong> sexual health-1<br />
Chairpersons: Yacov Reisman, The Ne<strong>the</strong>rlands<br />
Athanasios Askitis, Greece<br />
PS-08-001<br />
Premature ejaculation patients‘ adherence<br />
to treatment and follow-up<br />
visits<br />
Juza Chen, Israel<br />
N. J. Mabjeesh, M. S<strong>of</strong>er, H. Matzkin,<br />
A. Green stein<br />
40
scientific program<br />
Wednesday, 17 November 2010<br />
PS-08-003<br />
PS-08-004<br />
Screening <strong>for</strong> coronary artery disease<br />
in asymptomatic obese patients with<br />
erectile dysfunction<br />
Charalambos Vlachopoulos, Greece<br />
K. Rokkas, N. Ioakeimidis, A. Aggelis,<br />
D. Te rentes-Printzios, K. Baou, C. Aggeli,<br />
C. Fassoulakis, T. Askitis, C. Stefanadis<br />
Behavioral modification and medical<br />
treatment in men with primary intravaginal<br />
anejaculation<br />
Igor Sorokin, USA<br />
A. Bolyakov, J. Kiper, D. Paduch<br />
RT-20<br />
Round Table<br />
10.30 – 12.00 h auditorium I<br />
Is sexuality a family matter within <strong>the</strong> infertile<br />
couple<br />
Chairpersons: Kevan Wylie, United Kingdom<br />
Kerstin Fugl-Meyer, Sweden<br />
RT-20-001<br />
Sexual ecology within <strong>the</strong> infertile<br />
couple – <strong>the</strong> importance <strong>of</strong> <strong>the</strong> biological<br />
clock<br />
Fabio Pasqualotto, Brazil<br />
PS-08-005 Changes in reproductive hormones<br />
<strong>for</strong>mer PS-03-007 and neurotransmitters during arousal,<br />
ejaculation and orgasm in normal<br />
volunteers can be measured in peripheral<br />
blood<br />
Darius Paduch, USA<br />
L. Vaucher, J. Kiper, A. Bolyakov<br />
PS-08-006<br />
PS-08-007<br />
ML-08<br />
PDE5 inhibitors in <strong>the</strong> treatment <strong>of</strong><br />
ED – Why do men dropout A qualitative<br />
study<br />
Ana Carvalheira, Portugal<br />
N. Monteiro Pereira<br />
Over ten years follow up <strong>of</strong> ED patients<br />
under self intracavernous injections<br />
Ronald Virag, France<br />
H. Sussman, C. Costa<br />
Master Lecture<br />
09.30 – 10.00 h auditorium I<br />
The “Inigo Saenz De Tejada” Award <strong>of</strong> Excellence<br />
2010 and Presentation <strong>of</strong> <strong>ESSM</strong> Grant 2010<br />
Moderator: Ana M a Puigvert Martinez, Spain<br />
ML-08-001<br />
ML-08-002<br />
Award <strong>of</strong> Excellence 2010 lecture<br />
Tillmann H. Krüger, Germany<br />
Urotensin-II as a new biomarker in<br />
erec tile function<br />
Bianca d’Emmanuele di Villa, Italy<br />
RT-20-002<br />
RT-20-003<br />
RT-20-004<br />
RT-ESHA<br />
Sexual ecology within <strong>the</strong> infertile<br />
couple – <strong>the</strong> socio-cultural impact<br />
Afsaneh Khademi, Islamic Republic <strong>of</strong> Iran<br />
Sexual health in female partners <strong>of</strong><br />
infertile couples<br />
Rossella Nappi, Italy<br />
Sex and <strong>the</strong> infertile men<br />
Giorgio Franco, Italy<br />
Round Table<br />
10.30 – 11.30 h auditorium II<br />
Premature ejaculation: The couple’s perspective<br />
Chairperson: Irem Hattat, Spain<br />
RT-ESHA-001 The ‚Pe Confidential‘ survey reveals:<br />
Men slow to talk about fast sex<br />
Irem Hattat, Spain<br />
RT-ESHA-002 Listening to PE patient<br />
John Dean, United Kingdom<br />
RT-ESHA-003 Main goals and processes <strong>of</strong> <strong>the</strong> clinical<br />
assessment <strong>for</strong> PE<br />
Ignacio Moncada, Spain<br />
Closing Ceremony<br />
12.00 – 12.30 h auditorium I<br />
ML-08-003<br />
Farnesoid X receptor: A new androgen-dependent<br />
signaling pathway regulating<br />
metabolic syndrome-associated<br />
sexual dysfunction<br />
Mario Maggi, Italy<br />
www.essm.org<br />
41
poster presentations<br />
Poster presentations will be displayed in <strong>the</strong> poster exhibition in Pavilion 1<br />
from Monday 15 November to Wednesday 17 November 2010<br />
P-01 Posters<br />
Basic Science<br />
P-01-001<br />
P-01-002<br />
P-01-003<br />
P-01-004<br />
P-01-005<br />
P-01-006<br />
P-01-007<br />
Morphologic changes in <strong>the</strong> penis <strong>of</strong><br />
a novel, nongenetic rat model <strong>for</strong><br />
lean type 2 diabetes associated ED<br />
Maarten Albersen, USA<br />
H. Zhang, X. Qiu, T. Fandel, L. Guiting,<br />
C.-S. Lin, T. F. Lue<br />
Use <strong>of</strong> ‘Near Infrared Spectrophotometry’<br />
in <strong>the</strong> differential diagnosis<br />
<strong>of</strong> testicular torsion in comparison<br />
with doppler ultrasound scan in animal<br />
model<br />
Ozgu Aydogdu, Turkey<br />
B. Burgu, P. Uyar Gocun, E. Ozden, O. Yaman,<br />
T. Soygur, A. Dursun, K. Aydos<br />
IGF-1 is differentially expressed in diabetic<br />
erectile tissue – results from a<br />
microarray analysis<br />
Angela Castela, Portugal<br />
R. Soares, R. Medeiros, R. Ribeiro, C. Monteiro,<br />
P. Gomes, P. Vendeira, R. Virag, C.<br />
Costa<br />
Evaluation <strong>of</strong> vascular smooth muscle<br />
and corpus cavernosum on hypercholesterolemia.<br />
Is resveratrol promising<br />
on erectile dysfunction<br />
Omer Demir, Turkey<br />
C. Soner, N. Murat, S. Gidener<br />
From lab to clinical activity: Adrenergic<br />
receptors and human uro-genital<br />
tissue<br />
Angelica Grasso, Italy<br />
C. Lania, S. Blanco, F. Berardinelli<br />
Decreased C-Type natriuretic peptide<br />
and increased asymmetric dimethylarginine<br />
have an additive unfavourable<br />
effect on penile and systemic vascular<br />
function<br />
Nikolaos Ioakeimidis, Greece<br />
C. Vlachopoulos, K. Rokkas, A. Aggelis,<br />
A. Samentzas, P. Xaplanteris, K. Siama,<br />
C. Fassoulakis, T. Askitis, C. Stefanadis<br />
Usefulness <strong>of</strong> an abnormal aortic / penile<br />
index to predict <strong>the</strong> presence <strong>of</strong><br />
ischemic heart disease in men with<br />
erectile dysfunction<br />
Nikolaos Ioakeimidis, Greece<br />
C. Vlachopoulos, K. Rokkas, D. Terentes-<br />
Printzios, A. Samentzas, E. Christ<strong>of</strong>oratou,<br />
G. Sakellariou, C. Fassoulakis, T. Askitis,<br />
C. Stefanadis<br />
P-01-008<br />
P-01-009<br />
P-01-010<br />
P-01-011<br />
P-01-012<br />
P-01-013<br />
P-01-014<br />
The effects <strong>of</strong> anthocyanin extracted<br />
from black soybean on benign prostatic<br />
hyperplasia-induced rat model<br />
Su Jin Kim, Republic <strong>of</strong> Korea<br />
S.-K. Yang, T. Y. Ahn, J. H. Hong, H. Jang,<br />
B. I. Yoon, H. J. Cho, S.-H. Hong, J. Y. Lee,<br />
T.-K. Hwang, S. W. Kim<br />
Role <strong>of</strong> large-conductance Ca2+-activated<br />
K+ channels in endo<strong>the</strong>liumdependent<br />
vasodilation <strong>of</strong> human<br />
penis small arteries<br />
István ElQd Király, Hungary<br />
A. Varro, U. Simonsen, J. Pataricza, J. G.<br />
Papp, L. Pajor, A. Kun<br />
Influence <strong>of</strong> paradoxical sleep deprivation<br />
and sleep recovery on testosterone<br />
level in rats <strong>of</strong> different ages<br />
association with LH and FSH<br />
Du Geon Moon, Republic <strong>of</strong> Korea<br />
M. Oh, J. H. Bae, J. J. Kim, D. Y. Yang, W.<br />
K. Lee<br />
A new experimental rat model <strong>of</strong><br />
erectile dysfunction and lower urinary<br />
tract symptoms associated with benign<br />
prostate hyperplasia: The testosterone-supplemented<br />
spontaneously<br />
hypertensive rat<br />
Alexandra Oudot, France<br />
S. Oger, D. Behr-Roussel, S. Caisey, J. Bernabé,<br />
F. Giuliano<br />
Extraordinary phenomenon in relaxation<br />
by electrical field stimulation in<br />
penile corpus cavernosum<br />
Jong Kwan Park, Republic <strong>of</strong> Korea<br />
K. Park, C. Zhao<br />
Oxytocin may regulate <strong>the</strong> expression<br />
<strong>of</strong> aquaporins in human vaginal mucosal<br />
cells<br />
Kwangsung Park, Republic <strong>of</strong> Korea<br />
H.-S. Lee, S. O. Kim, J. K. Park<br />
Histological and immunohistochemical<br />
study on human penile cavernosal<br />
tissue with viewpoints <strong>of</strong> venogenic<br />
erectile dysfunction<br />
Dina Radwan, Egypt<br />
E. Kamel<br />
42
poster presentations<br />
P-01-015<br />
A study comparing estrogen receptors,<br />
androgen receptors, and glucocorticoid<br />
receptors in penile skin and<br />
penile scar tissue in boys with and<br />
without hypospadias<br />
Nieves Martin-Alguacil, USA<br />
L. Mayoglou, C. Dupre, D. Pfaff, J. Schober<br />
P-01-023<br />
Characteristics <strong>of</strong> perpetrators <strong>of</strong> crimes<br />
<strong>of</strong> pedophilia. A preliminary report<br />
Marek Pacholski, Poland<br />
J. Heitzman, Z. Lew-Starowicz, M. Lew-<br />
Starowicz<br />
P-01-016<br />
P-01-017<br />
P-01-018<br />
P-01-019<br />
P-01-020<br />
P-01-021<br />
P-01-022<br />
Pilot study <strong>of</strong> estrogens receptors,<br />
androgen receptors, glucocorticoid<br />
receptors and relaxin receptors in penile<br />
epi<strong>the</strong>lium<br />
Nieves Martin-Alguacil, USA<br />
L. Mayoglou, C. Dupre, N. Aardsma, B. Anderson,<br />
D. Pfaff, T. Cooney, J. Schober<br />
Sex steroid receptors in male human<br />
bladder: Expression and biological<br />
function<br />
Linda Vignozzi, Italy<br />
A. Chavalmane, P. Comeglio, A. Morelli,<br />
S. Filippi, P. Sandner, F. Saad, M. Gacci, G.<br />
B. Vannelli, M. Maggi<br />
The value <strong>of</strong> systemic endo<strong>the</strong>lial dysfunction<br />
and increased arterial stiff<br />
ness <strong>for</strong> identifying wall motion abnormalities<br />
during stress echo car diography<br />
testing in hypertensive men<br />
with vascular erectile dysfunction<br />
Charalambos Vlachopoulos, Greece<br />
N. Ioakeimidis, D. Terentes-Printzios,<br />
A. Ag gelis, K. Aznaouridis, P. Xaplanteris,<br />
K. Rokkas, T. Askitis, C. Stefanadis<br />
Spontaneous recovery <strong>of</strong> erectile<br />
function in cavernous nerve crush injury<br />
rat model<br />
Dae Yul Yang, Republic <strong>of</strong> Korea<br />
S. H. Lee, W. K. Lee, D. G. Moon, J. H. Bae,<br />
H. Kim, S. Kim<br />
Pheromones in sex and reproduction<br />
Ashraf Hassan, Egypt<br />
T. Mostafa<br />
Influence <strong>of</strong> paradoxical sleep deprivation<br />
and sleep recovery on ADH<br />
(anti diuretic hormone), Na+ level in<br />
rats <strong>of</strong> different ages<br />
Du Geon Moon, Republic <strong>of</strong> Korea<br />
M. Oh, J. J. Kim, J. H. Bae, M. G. Park<br />
Sclareol molecule isolated from salvia<br />
sclarea regulates immune responses<br />
and selectively inhibits tumor growth<br />
in vivo<br />
Shoko<strong>of</strong>e Noori, Islamic Republic <strong>of</strong> Iran<br />
P-02 Posters<br />
Psychosexual issues and management<br />
P-02-002 Untouchable glans penis / PGH /<br />
Ferenc Fekete, Hungary<br />
P-02-003<br />
P-02-004<br />
P-02-005<br />
P-02-006<br />
Sexual health and overall wellness<br />
(show) survey in men and women in<br />
europe<br />
Arik Shechter, Israel<br />
J. Dean, A. Vertkin, P. Weiss, O. Yaman,<br />
M. Hodik<br />
Median raphe (parameatal) cyst <strong>of</strong><br />
<strong>the</strong> penis as precipitating and maintaining<br />
factor in impaired sexual behavior<br />
Djordje Nale, Serbia<br />
C. Tulic, N. Bojanic, S. Dragicevic<br />
Family and marriage counseling and<br />
HIV / Aids pandemic in Nigeria<br />
Christopher Kalu Okwun, Malaysia<br />
S. Siraj, S. Siraj<br />
The incidence <strong>of</strong> enuresis and dysfunctional<br />
elimination in children<br />
who present with allegations <strong>of</strong> sexual<br />
abuse<br />
Benjamin Anderson, USA<br />
S. Carstater, J. Schober<br />
P-03 Posters<br />
ED epidemiology and risk factors<br />
P-03-001<br />
The effect <strong>of</strong> cardiopulmonary bypass<br />
in coronary artery bypass surgeries<br />
(on pump versus <strong>of</strong>f-pump) on erectile<br />
function and endo<strong>the</strong>lium-derived<br />
nitric oxide levels<br />
Onder Canguven, Turkey<br />
A. Sasmazel, R. Horuz, A. Selimoglu, M. Balaban,<br />
A. Erkılıç, O. Akça, A. Baysal, S. Albayrak<br />
www.essm.org<br />
43
poster presentations<br />
P-03-002<br />
P-03-003<br />
P-03-004<br />
P-03-006<br />
P-03-007<br />
P-03-008<br />
Low testosterone and increased fibrinogen<br />
levels have an additive detrimental<br />
effect on vascular function<br />
and structure in essential hypertensive<br />
patients with erectile dysfunction<br />
Charalambos Vlachopoulos, Greece<br />
N. Ioakeimidis, D. Terentes-Printzios, A.<br />
Ag gelis, N. Alexopoulos, A. Samentzas, K.<br />
Baou, K. Rokkas, T. Askitis, C. Stefanadis<br />
The effects <strong>of</strong> sexual dysfunction problems<br />
and sexual stress on <strong>the</strong> quality<br />
<strong>of</strong> relationship in married couples<br />
Irem Hattat, Turkey<br />
H. Hattat, E. Hattat, E. Akkus<br />
Prevalence <strong>of</strong> erectile dysfunction in<br />
diabetic patients<br />
Mustafa Burak Hoþcan, Turkey<br />
Y. Hoşcan, M. Ekinci, A. Tunçkıran, C. Dilmen,<br />
A. Koşar<br />
Characteristics <strong>of</strong> men below 45 years<br />
seeking help <strong>for</strong> erectile dysfunction<br />
José María Martinez-Jabaloyas, Spain<br />
O. Cardeñosa, L. Gooren<br />
Impacts <strong>of</strong> symptoms and treatments<br />
<strong>of</strong> BPH on sexual functions<br />
Mehmet Tahmaz, Turkey<br />
A. Gür, K. Erten, M. Dayanc<br />
Storage lower urinary tract symptoms<br />
are pronounced in men with<br />
erectile dysfunction<br />
Pai-Kai Chiang, Taiwan<br />
J.-M. Hsu, W.-K. Tsai<br />
P-04 Posters<br />
ED and co-morbidities<br />
P-04-001<br />
P-04-002<br />
P-04-004<br />
P-04-005<br />
Coronary a<strong>the</strong>rosclerosis distribution<br />
in relation to global arterial function<br />
and early structural changes in patients<br />
with erectile dysfunction<br />
Athanasios Aggelis, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, A. Samentzas,<br />
K. Rokkas, P. Xaplanteris, G. Sakellariou,<br />
T. Askitis, A. Rembelakos, C. Stefanadis<br />
Effects <strong>of</strong> administration <strong>of</strong> testosterone<br />
on <strong>the</strong> metabolic syndrome<br />
and on scores <strong>of</strong> <strong>the</strong> Aging Males’<br />
Symptoms scale in men with late onset<br />
hypogonadism<br />
Jordi Cortada, Spain<br />
A. Becerra, L. Gooren<br />
Erectile dysfunction in infertile couples<br />
– is <strong>the</strong>re any correlation between<br />
classical sperm parameters and <strong>the</strong><br />
severity <strong>of</strong> sexual dysfunction<br />
Zsolt Kopa, Hungary<br />
P. Riesz, A. Kokeny<br />
Epidemiology and co-morbidities in<br />
45 – 75 year old males with erectile<br />
dysfunction<br />
Luis Labairu Huerta, Spain<br />
J. L. Arrondo Arrondo, I. Losada Álvarez,<br />
A. Teyrouz Belliot, O. Gorría Cardesa, V.<br />
Grasa Lanau, J. Aldave Villanueva, A. Solchaga<br />
Martínez<br />
P-03-009<br />
P-03-010<br />
P-03-011<br />
Effects <strong>of</strong> nebivolol and metoprolol<br />
on erectile functions <strong>of</strong> <strong>the</strong> patients<br />
with phase 1 hypertension<br />
Ahmet Tunçkiran, Turkey<br />
D. Ciçek, b. Hoscan, M. Ekinci<br />
Erectile dysfunction in diabetic men<br />
Mohammad Reza Darabi Mahboub,<br />
Islamic Republic <strong>of</strong> Iran<br />
R. Taghavi<br />
As a new factor <strong>for</strong> <strong>the</strong> development<br />
<strong>of</strong> varicocele: Chronic cough<br />
Ahmet Ali Sancaktutar, Turkey<br />
Y. Bozkurt, G. Kalkan, C. Kiliç, A. Tepeler,<br />
N. Penbegül, G. Kalkan<br />
P-04-006<br />
P-04-007<br />
Does daily intake <strong>of</strong> sildenfine preserve<br />
<strong>the</strong> histological integrity <strong>of</strong> corpus<br />
cavernosum afterandrogen deprivation(experimental<br />
study)<br />
Fathy Moossa, Egypt<br />
F. Torad, M. Mansy<br />
Is self report <strong>of</strong> erectile dysfunction<br />
associated with severity, cardiovascular<br />
risk factors, and depression<br />
Hyun-Jun Park, Republic <strong>of</strong> Korea<br />
N. C. Park, K. Min<br />
44
poster presentations<br />
P-04-008<br />
P-04-009<br />
P-04-010<br />
P-04-011<br />
P-04-012<br />
P-04-013<br />
P-04-014<br />
Satisfaction <strong>of</strong> sexual partners <strong>of</strong> <strong>the</strong><br />
patients with chronic renal failure<br />
Ahmet Tunçkiran, Turkey<br />
M. Ekinci, B. Hoscan<br />
Is IIEF-EF a proxy <strong>of</strong> general male<br />
health status<br />
Andrea Salonia, Italy<br />
A. Saccà, M. Ferrari, L. Rocchini, U. Capitanio,<br />
A. Briganti, G. Zanni, F. Castiglione,<br />
P. Rigatti, F. Montorsi<br />
Double-blind, cross-over, randomised,<br />
placebo controlled clinical trial to assess<br />
efficacy <strong>of</strong> vardenafil in subjects<br />
with erectile dysfunction and stable<br />
multiple sclerosis<br />
Joaquim Sarquella, Spain<br />
C. Nos, J. Castilló, L. Ramió-Torrentà,<br />
L. Brieva, X. Montalban, M. Tintoré, L.<br />
Gooren<br />
Characterisitics <strong>of</strong> men with erectile<br />
dysfunction and / or benign prostatic<br />
hyperplasia in US and Canadian clinical<br />
studies examining PDE5-inhibition:<br />
A retrospective analysis <strong>of</strong> more<br />
than 6,000 subjects<br />
Sebastian Sorsaburu, USA<br />
K. McVary, R. Rosen, L. S. Chan, T. Shu,<br />
L. Viktrup<br />
Cardiovascular pr<strong>of</strong>ile in patients<br />
with erectile dysfunction<br />
Tatana Sramkova, Czech Republic<br />
J. Meluzin, R. Panovsky, E. Dragomirecka,<br />
L. Chvatalova, K. Sramkova, M. Sutory,<br />
M. Pesl<br />
Non-invasive evaluation <strong>of</strong> endo<strong>the</strong>lial<br />
function in patients with metabolic<br />
syndrome and different levels<br />
<strong>of</strong> erectile dysfunction severity. A pilot<br />
study<br />
Nuno Tomada, Portugal<br />
L. Figueiredo, T. Lopes, I. Tomada, J. Queirós,<br />
J. Baptista, M. Pestana, F. Cruz, P. Vendeira<br />
Priapism induced by injection <strong>of</strong> 1 tablet<br />
(!) <strong>of</strong> papaverine (50 mg) dissolved<br />
in saline fluid<br />
Dan Peretianu, Romania<br />
M. Carsote, C. D. Staicu, S. Suba<br />
P-05 Posters<br />
Male sexual health – aging man, hormones, lifestyle<br />
factors<br />
P-05-001<br />
P-05-002<br />
Low testosterone and high asymmetric<br />
dimethylarginine levels are additively<br />
associated with carotid intima<br />
media thickness and progression <strong>of</strong><br />
coronary artery disease in middleaged<br />
men with vasculogenic erectile<br />
dysfunction<br />
Athanasios Aggelis, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, K. Rokkas,<br />
A. Samentzas, K. Aznaouridis, K. Siama,<br />
C. Fassoulakis, T. Askitis, C. Stefanadis<br />
Is <strong>the</strong>re a correlation between testosterone<br />
levels and <strong>the</strong> severity <strong>of</strong> <strong>the</strong><br />
disease in male patients with obstructive<br />
sleep apnea<br />
Onder Canguven, Turkey<br />
B. Salepci, A. Selimoglu, M. Balaban, S. Albayrak<br />
P-05-003 Testosterone and metabolic syndrome:<br />
A meta-analysis study<br />
Giovanni Corona, Italy<br />
M. Monami, G. Rastrelli, A. Aversa, Y. Tis<br />
hova, F. Saad, A. Lenzi, G. Forti, E. Ma n-<br />
nucci, M. Maggi<br />
P-05-004<br />
P-05-005<br />
P-05-006<br />
Is obesity a fur<strong>the</strong>r cardiovascular<br />
risk factor in patients with erectile<br />
dysfunction<br />
Giovanni Corona, Italy<br />
M. Monami, V. Boddi, A. S<strong>for</strong>za, G. Forti,<br />
E. Mannucci, M. Maggi<br />
Low testosterone is associated with<br />
an increased risk <strong>of</strong> MACE lethality in<br />
subjects with erectile dysfunction<br />
Giovanni Corona, Italy<br />
M. Monami, A. Fisher, V. Boddi, G. de<br />
Vita, A. S<strong>for</strong>za, G. Forti, E. Mannucci,<br />
M. Maggi<br />
The relationship <strong>of</strong> testosterone to<br />
PSA in men with sexual dysfunction<br />
Giovanni Corona, Italy<br />
V. Boddi, F. Lotti, M. Gacci, M. Carini, G.<br />
de Vita, A. S<strong>for</strong>za, G. Forti, E. Mannucci,<br />
M. Maggi<br />
www.essm.org<br />
45
poster presentations<br />
P-05-007<br />
P-05-008<br />
P-05-009<br />
P-05-010<br />
P-05-011<br />
P-05-012<br />
P-05-013<br />
P-05-014<br />
Type 2 diabetes mellitus and testosterone:<br />
A meta-analysis study<br />
Giovanni Corona, Italy<br />
M. Monami, R. Giulia, A. Aversa, A. S<strong>for</strong>za,<br />
A. Lenzi, G. Forti, E. Mannucci, M. Maggi<br />
Metabolic syndrome is a useless category<br />
in subjects with high cardiovascular<br />
risk: Results from a cohort study<br />
in men with erectile dysfunction<br />
Giovanni Corona, Italy<br />
M. Monami, G. Rastrelli, G. Forti, E. Mannucci,<br />
M. Maggi<br />
Psychobiological correlates <strong>of</strong> women’s<br />
sexual interest as perceived by<br />
patients with erectile dysfunction<br />
Giovanni Corona, Italy<br />
E. Bandini, A. Fisher, E. Maseroli, V. Boddi,<br />
G. Balercia, A. S<strong>for</strong>za, G. Forti, E. Mannucci,<br />
M. Maggi<br />
An innovative concept <strong>for</strong> integrated<br />
urogenital care <strong>of</strong> <strong>the</strong> aging male<br />
Frans Debruyne, The Ne<strong>the</strong>rlands<br />
Characterization <strong>of</strong> Hypoactive Sexual<br />
Desire Disorder (HSDD) in men<br />
Leonard DeRogatis, USA<br />
R. Rosen, I. Goldstein, B. Werneburg,<br />
J. Kempthorne-Rawson, M. Sand<br />
Does gepirone-ER have a pro-sexual effect<br />
in men with major depressive disorder<br />
MDD and sexual dysfunction<br />
Louis F Fabre, USA<br />
S. J. Kramer, L. C. Smith<br />
Low testosterone levels correlate with<br />
markers <strong>of</strong> insulin resistance and subclinical<br />
a<strong>the</strong>rosclerosis in a group <strong>of</strong><br />
severely obese young male patients<br />
Simona Fica, Romania<br />
A. Sirbu, C. Barbu, R. Olaru, S. Florea,<br />
H. Nicolae<br />
Influence <strong>of</strong> tribestan on male sexual<br />
hormones metabolism<br />
Igor Gorpynchenko, Ukraine<br />
M. Romaniuk, Y. Gurzhenko, L. Im shinetskaja<br />
P-05-015<br />
P-05-016<br />
P-05-017<br />
P-05-018<br />
P-05-019<br />
P-05-020<br />
P-05-021<br />
Testosterone Deficiency Syndrome<br />
(TDS) in 45-75 year old males with<br />
Erectile Dysfunction (ED). Prevalence<br />
and associations<br />
Luis Labairu Huerta, Spain<br />
J. L. Arrondo Arrondo, I. Losada Álvarez,<br />
O. Gorría Cardesa, A. Teyrouz Belliot,<br />
S. Napal Lecumberri, J. Campá Bortoló,<br />
A. Solchaga Martínez<br />
Scores on <strong>the</strong> aging males’ symptoms<br />
scale are correlated with testosterone<br />
levels<br />
José María Martinez-Jabaloyas, Spain<br />
O. Cardeñosa, L. Gooren<br />
Male factor infertility and sexual dysfunctions<br />
Radu Mihalca, Romania<br />
C. Belinski, S. Fica, N. Calomfirescu<br />
The penile augmentation combined<br />
with autologous fat injection and Lyoplant<br />
implantation simultaneously<br />
Il Moon, Republic <strong>of</strong> Korea<br />
I. Moon<br />
Subcutaneous testosterone implant<br />
<strong>the</strong>rapy <strong>for</strong> men with testosterone<br />
deficiency<br />
Raj Nigam, United Kingdom<br />
M. Ismail, N. Chauhan, C. Leaver<br />
Circular buccal mucosal greft <strong>for</strong><br />
treatment <strong>of</strong> urethral meatal balanitis<br />
xerotica obliterans<br />
Sinasi Yavuz Önol, Turkey<br />
F. F. Onol, Ö. Kurt, A. Simsek, R. Topaktas<br />
Our experience in cordi without hypospadias;<br />
102 cases<br />
Sinasi Yavuz Onol, Turkey<br />
O. Kurt, E. C. Polat, R. Topaktas, M. R.<br />
Erdem<br />
P-05-022 Reproductive hormone levels in<br />
healthy men with normal ejaculatory,<br />
erectile, and orgasmic function<br />
Ray Sultan, USA<br />
A. Bolyakov, L. Vaucher, A. Mielnik, J. Kiper,<br />
D. Paduch<br />
46
poster presentations<br />
P-05-023<br />
P-05-024<br />
P-05-025<br />
P-05-026<br />
P-05-027<br />
P-05-028<br />
P-05-029<br />
P-05-030<br />
Reconstitution and maintenance <strong>of</strong><br />
<strong>the</strong> sex hormone pr<strong>of</strong>ile in hypogonadal<br />
men by transdermal testosterone<br />
Jean Pierre Raynaud, France<br />
J. Fiet, J. Gardette, J. Rollet<br />
Unfavourable effect <strong>of</strong> heavy smoking<br />
and obesity on erectile function<br />
and aortic stiffness in middle aged<br />
men without clinical a<strong>the</strong>rosclerosis<br />
Konstantinos Rokkas, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, A. Aggelis,<br />
A. Samentzas, D. Terentes-Printzios,<br />
K. Baou, K. Siama, T. Askitis, C. Stefanadis<br />
Hypoactive Sexual Desire Disorder<br />
(HSDD) in men: Qualitative findings<br />
from a multi-center, diagnostic study<br />
Raymond Rosen, USA<br />
L. DeRogatis, M. Connor, B. Werneburg,<br />
M. Sand<br />
The aging process and erectile dysfunction:<br />
Clinical trial <strong>for</strong> overcome<br />
hyperproduction <strong>of</strong> endogenous methyl<br />
arginines<br />
Romil Stanislavov, Bulgaria<br />
V. Nikolova<br />
Early detection <strong>of</strong> combination <strong>of</strong> hypogonadism<br />
and sexual disorders<br />
Vladimir Startsev, Russia<br />
E. Kiseliov<br />
Aldosterone and plasma renin activity<br />
in hypertensive patients with erectile<br />
dysfunction<br />
Dimitrios Terentes-Printzios, Greece<br />
C. Vlachopoulos, N. Ioakeimidis, K. Rok kas,<br />
K. Aznaouridis, A. Samentzas, N. Alexopoulos,<br />
A. Aggelis, A. Siama, C. Ste fanadis<br />
Help-seeking perceptions regarding<br />
sexually transmitted infections symptoms:<br />
Exploratory approach with Portuguese<br />
men<br />
Alexandra Tereso, Portugal<br />
P. Parreira<br />
Effect <strong>of</strong> alpha tocopheryl acetate on<br />
cryopreserved semen quality <strong>of</strong> heat<br />
stressed Bos taurus bulls<br />
Paola Alemida de Araujo Goes, Brazil<br />
M. Nichi, E. Gualtieri de Andrade Perez,<br />
R. Otavio C. Silva, A. Dalmazzo, C. Rocha,<br />
R. Campanarut Barnabe, R. Pimenta Bertolla,<br />
V. Hyppolito Barnabe<br />
P-05-031 Transdermal testosterone replacement<br />
<strong>the</strong>rapy in male hypogonadism<br />
Corina Galesanu, Romania<br />
V. Mocanu<br />
P-05-032<br />
P-05-033<br />
Effect <strong>of</strong> Vitamin E, C, B12 and folic<br />
acid on male fertility in hypercholesterolemic<br />
rats<br />
Mustafa Burak Hoþcan, Turkey<br />
Y. Hoşcan, T. Oksay, M. Özgül, M. Ekinci,<br />
A. Tunçkıran<br />
Priapus is happier with Venus than<br />
with Bacchus<br />
Valentina Boddi, Italy<br />
G. Corona., M. Monami, A. Fisher., E. Bandini.,<br />
C. Melani., D. Balzi., A. S<strong>for</strong>za., V. Pa -<br />
tussi., G. Forti., E. Mannucci., M. Maggi<br />
P-06 Posters<br />
ED diagnosis<br />
P-06-001<br />
P-06-002<br />
P-06-003<br />
P-06-004<br />
Virtual cavernoscopy compared with<br />
CT angiography<br />
Kazuyoshi Izumi, Japan<br />
Y. Kawanishi, Y. Kusuhara, M. Komori,<br />
M. Yamanaka, A. Yamamoto, A. Numata,<br />
T. Kishimoto, H.-O. Kanayama<br />
Endo<strong>the</strong>lial function in patients with<br />
erectile dysfunction: Evaluation with<br />
Endopat-2000<br />
Ignacio Moncada, Spain<br />
I. Lopez, A. Fraile, N. Carballo<br />
Is public interest in erectile dysfunction<br />
really heightened during <strong>the</strong><br />
PDE5-is’ generation<br />
Andrea Salonia, Italy<br />
F. Pellucchi, L. Rocchini, A. Saccà, M. Ferrari,<br />
F. Castiglione, A. Briganti, A. Gallina, U. Capitanio,<br />
P. Rigatti, F. Montorsi<br />
Age specified sleep investigation during<br />
<strong>the</strong> night with <strong>the</strong> NEVA system<br />
in erectile function capable men within<br />
<strong>the</strong> age in between 20 – 60 years<br />
Ali Tok, Germany<br />
U. Engelmann, B. Lothar, Ö. Enver, F. Meier,<br />
S. Wille, A. Ilgar<br />
www.essm.org<br />
47
poster presentations<br />
P-07 Posters<br />
ED medical treatment<br />
P-07-001<br />
P-07-002<br />
P-07-003<br />
P-07-004<br />
P-07-005<br />
P-07-007<br />
P-07-008<br />
Effect <strong>of</strong> PDE5 inhibitor in <strong>the</strong> management<br />
<strong>of</strong> erectile dysfunction post<br />
TURP<br />
Konstantinos Bratsas, United Kingdom<br />
W. Hurn, M. Eylert, R. Persad<br />
The benefits <strong>of</strong> on-demand vardenafil<br />
administration in <strong>the</strong> rehabilitation<br />
<strong>of</strong> sexual function <strong>of</strong> patients after<br />
nerve-sparing radical prostatectomy<br />
Viorel Bucuras, Romania<br />
R. Bardan, A. Muresan, M. Goergiadis,<br />
C. Secasan, C. Balarie<br />
A qualitative study on patterns <strong>of</strong> use<br />
<strong>of</strong> PDE5 inhibitors in <strong>the</strong> treatment<br />
<strong>of</strong> ED<br />
Ana Carvalheira, Portugal<br />
N. Monteiro Pereira, V. Forjaz<br />
The HelpED study: Degree <strong>of</strong> agreement<br />
between patients, partners,<br />
and physicians on <strong>the</strong> erection hardness<br />
score <strong>of</strong> men with erectile dysfunction<br />
Hubert Claes, Belgium<br />
R. Andrianne, R. Opsomer, S. Patel, K. Commers<br />
Botox treatment and its impact on<br />
ejaculation and fertility in men with<br />
spinal cord injury<br />
Frédérique Courtois, Canada<br />
R. Caremel, K. Charvier, A. Ruffion, N. Morel<br />
Journel<br />
Treating erectile dysfunction with a<br />
new natural compound made <strong>of</strong> Alga<br />
Ecklonia Cava, Tribulus Terrestris and<br />
Biovis and its antioxidant, antifibrotic<br />
and antiaging action<br />
Fabrizio Iacono, Italy<br />
D. Prezioso, G. Iapicca, A. Ruffo, G. Di<br />
Lauro, L. Romis<br />
Comparison <strong>of</strong> <strong>the</strong> first intake <strong>of</strong> vardenafil<br />
and tadalafil in patients with<br />
diabetic neuropathy and diabetic<br />
erectile dysfunction<br />
Zdravko Asenov Kamenov, Bulgaria<br />
P-07-009<br />
P-07-010<br />
P-07-011<br />
P-07-012<br />
P-07-013<br />
P-07-014<br />
P-07-015<br />
A ten year review <strong>of</strong> erectile dysfunction<br />
treatment<br />
Emma Mccarty, United Kingdom<br />
W. Dinsmore<br />
A randomized, double-blind, placebo-controlled,<br />
parallel-group study<br />
to assess spontaneous morning and<br />
nocturnal erections after tadalafil<br />
once daily in subjects with erectile<br />
dysfunction but naive to phosphodiesterase<br />
type 5 inhibitors<br />
Ignacio Moncada, Spain<br />
K. Kula, C. Barker, K. Kinchen<br />
A penile rehabilitation protocol <strong>of</strong><br />
combination <strong>the</strong>rapy <strong>for</strong> PDE5 inhibitor<br />
non-responder with TDS; Monthly<br />
short-acting testosterone with daily<br />
low-dose PDE5 inhibitor<br />
Du Geon Moon, Republic <strong>of</strong> Korea<br />
M. Oh, J. H. Bae, J. Kim, M. G. Park<br />
The HelpED study: Impact <strong>of</strong> change<br />
in erection hardness on <strong>the</strong> self-esteem,<br />
confidence, and quality <strong>of</strong> life<br />
<strong>of</strong> men with erectile dysfunction<br />
Reinier Opsomer, Belgium<br />
R. Andrianne, H. Claes, S. Patel, K. Commers<br />
Factors associated with ejaculatory<br />
dysfunction and orgasmic dysfunction<br />
in men with erectile dysfunction<br />
Darius Paduch, USA<br />
A. Bolyakov, A. Beardsworth, S. Watts<br />
A randomized, double-blind, placebo-controlled,<br />
parallel-group study<br />
to assess treatment satisfaction after<br />
tadalafil once daily in subjects with<br />
erectile dysfunction but naïve to<br />
phosphodiesterase type 5 inhibitors<br />
Hartmut Porst, Germany<br />
G. Brock, C. Barker, K. Kinchen<br />
Evaluation <strong>of</strong> erectile function after<br />
hyperbaric oxygen <strong>the</strong>rapy in patients<br />
with diabetic foot ulcer<br />
Kemal Simsek, Turkey<br />
H. C. Irkilata, A. Sancaktutar, Z. Demirer,<br />
H. Ay, I. Yildirim, L. Tahmaz, S. Yildiz,<br />
M. Dayanc<br />
48
poster presentations<br />
P-08 Posters<br />
ED surgical treatment<br />
P-09 Posters<br />
ED, pelvic surgery, LUTS<br />
P-08-001<br />
P-08-002<br />
P-08-003<br />
P-08-004<br />
P-08-005<br />
P-08-006<br />
The concealable one-piece penile<br />
pros<strong>the</strong>sis – an underused device<br />
Michael Foster, United Kingdom<br />
A. Glackin, N. Rukin, R. Abraham<br />
The role <strong>of</strong> virtual cavernoscopy and<br />
3D-CT cavernosography in <strong>the</strong> surgical<br />
treatment <strong>of</strong> <strong>the</strong> mixed vasculogenic<br />
ED<br />
Yasuo Kawanishi, Japan<br />
K. Izumi, H. Muguruma, Y. Kusuhara, M.<br />
Ko mori, M. Yamanaka, A. Yamamoto, A.<br />
_Numata, T. Kishimoto, H. Kanayama<br />
Penile revascularization in vasculogenic<br />
erectile dysfunction: Long-term<br />
follow up<br />
Önder Kayigil, Turkey<br />
E. Okulu, M. Aldemir, E. Önen<br />
Sacral roots neuromodulation in neurological<br />
patients with dysfunction<br />
erectile<br />
Antonio Melchor Galán, Spain<br />
Comparison <strong>of</strong> <strong>the</strong> blood flow in <strong>the</strong><br />
cavernous tissue around <strong>the</strong> penile<br />
pros<strong>the</strong>sises with various diameters<br />
Yakov Mirkin, Russia<br />
G. Taruashvili, I. Taruashvili, V. Voloshin<br />
Abdominoplasty and scrotal z-plasty<br />
associated to penile pros<strong>the</strong>sis implantation<br />
in patients with buried penis<br />
Ignacio Moncada, Spain<br />
J. I. Martinez-Salamanca, I. Lopez, A. Fraile<br />
P-09-001<br />
P-09-002<br />
P-09-003<br />
P-09-004<br />
P-09-005<br />
PDE-5 inhibitors in treating men with<br />
erectile dysfunction and lower urinary<br />
tract symptoms<br />
Safail Gamidov, Russia<br />
O. Tazhetdinov, A. Pavlovichev<br />
Effect <strong>of</strong> tamsulosin on lower urinary<br />
tract symptoms and sexual function<br />
related to ureteric stenting<br />
Hussein Hussein, Egypt<br />
A. Bedair, A. El Shenoufy, H. El Fayoumy,<br />
A. Hussein<br />
Dedication <strong>of</strong> patients <strong>for</strong> penile rehabilitation<br />
after radical prostatectomy:<br />
Qualitative study<br />
Yacov Reisman, The Ne<strong>the</strong>rlands<br />
R. Lazarov, R. Kropman<br />
Comparison <strong>of</strong> two different techniques<br />
<strong>of</strong> hemostasis during nervesparing<br />
radical perineal prostatectomy:<br />
Harmonic scalpel versus hemoclips<br />
Florian Wimpissinger, Austria<br />
A. Cadirci, C. Hammer, W. Stackl<br />
Tadalafil (Cialis ® ) 5mg once daily improves<br />
lower urinary tract symptoms<br />
in patients with erectile dysfunction<br />
Sangjun Yoo, Republic <strong>of</strong> Korea<br />
D. You, S. W. Kim, T. Y. Ahn<br />
P-10 Posters<br />
Peyronie‘s disease and congenital penile disorders<br />
P-08-007<br />
P-08-008<br />
P-08-009<br />
Our experiences in penile fractures:<br />
Surgery and follow-up<br />
Sinasi Yavuz Onol, Turkey<br />
O. Kurt, E. C. Polat, B. Antar, O. Fikri<br />
New classification <strong>of</strong> anomalous venous<br />
drainage using caverno-CT in<br />
men with erectile dysfunction<br />
Ronald Virag, France<br />
J. F. Paul, C. Costa<br />
Sleep-related painful nocturnal erections<br />
treated with cavernosaphenous<br />
shunt: case report<br />
Asterios Fotas, Greece<br />
G. Salpigidis, C. Karkos, C. Theoharidis,<br />
S. Charalambous, A. Papathanasiou, V.<br />
Rombis<br />
P-10-001<br />
P-10-002<br />
Porcine dermal acellular collagen matrix<br />
(PELVICOL © -BARD) <strong>for</strong> albugineal<br />
substitution in <strong>the</strong> surgical <strong>the</strong>rapy<br />
<strong>of</strong> peyronie’s disease<br />
Fulvio Colombo, Italy<br />
C. V. Pultrone, P. Orciari, G. Martorana,<br />
A. Franceschelli<br />
Short-term outcome <strong>of</strong> SIS graft versus<br />
vein graft <strong>for</strong> incision and grafting<br />
procedure <strong>for</strong> Peyronie‘s Disease<br />
Isa Edhem, United Kingdom<br />
M. Malki, J. Farrell<br />
www.essm.org<br />
49
poster presentations<br />
P-10-003<br />
P-10-004<br />
P-10-005<br />
P-10-006<br />
P-10-007<br />
P-10-008<br />
P-10-009<br />
P-10-010<br />
Rehabilitation protocol after surgery<br />
<strong>for</strong> Peyronie’s disease: Preliminary<br />
study in four patients with <strong>the</strong> systematic<br />
utilisation <strong>of</strong> traction <strong>the</strong>rapy<br />
in case <strong>of</strong> graft surgery<br />
Antoine Faix, France<br />
Combination <strong>of</strong> Andropenis ® penile<br />
extender and oral <strong>the</strong>rapy (Peironi-<br />
MEV ® ) versus intralesional verpamil<br />
<strong>for</strong> penile curvature due to peyronie’s<br />
disease: Preliminary results <strong>of</strong> a randomised<br />
phase ii trial<br />
Paolo Gontero, Italy<br />
M. Di Marco, P. Gontero, G. Giubilei, F. Pisano,<br />
F. Soria, C. Fiorito, A. Zitella, R. Bartoletti,<br />
A. Tizzani, N. Mondaini<br />
Spontaneous straightening <strong>of</strong> <strong>the</strong><br />
penis after “s<strong>of</strong>t” penile pros<strong>the</strong>sis<br />
implantation in patients affected by<br />
Peyronie’s Disease<br />
Marco Grasso, Italy<br />
C. Lania, S. Blanco, F. Berardinelli, M. Castelli<br />
Qualitative analysis <strong>of</strong> psycho genital<br />
lived in Italian sample <strong>of</strong> patients<br />
with Peyronie‘s disease treated with<br />
shock-wave <strong>the</strong>rapy<br />
Fabrizio Quattrini, Italy<br />
S. Romano, S. Travaglia, F. d´Ottavio, S. R.<br />
Calabrò<br />
The combination <strong>of</strong> vein grafting and<br />
two different types <strong>of</strong> corporeal plication<br />
in complex curvature due to<br />
Peyronie’s disease<br />
Önder Kayigil, Turkey<br />
M. Aldemir, E. Okulu<br />
Tadalafil as a prophylaxis in prevention<br />
<strong>of</strong> postoperative graft retraction<br />
in severe Peyronie‘s disease<br />
Vladimir Kojovic, Serbia<br />
M. Bizic, M. Majstorovic, A. Milosevic,<br />
M. Djordjevic<br />
Radical approach in epispadias redo<br />
surgery in adulthood<br />
Marko Majstorovic, Serbia<br />
V. Kojovic, M. Bizic, A. Milosevic, M.<br />
Djordjevic<br />
Does testosterone deficiency exaggerate<br />
<strong>the</strong> clinical symptoms <strong>of</strong> Peyronie‘s<br />
disease<br />
Hyun-Jun Park, Republic <strong>of</strong> Korea<br />
N. C. Park, K. Min<br />
P-10-011<br />
P-10-012<br />
P-10-013<br />
Penile pros<strong>the</strong>ses implantations during<br />
corporoplasties in Peyronie‘s disease<br />
Fabio Pezzoni, Italy<br />
R. Vaccari<br />
Penile pros<strong>the</strong>sis placement in patients<br />
with peyronie’s disease<br />
Panagiotis Kartsaklis, Greece<br />
V. Vossos, E. Soufis, P. Zontos, C. Thomas,<br />
C. Konstantinidis, S. Andreadakis, A. Gekas<br />
Heparin-induced priapism in patient<br />
with acute coronary syndroma, erectile<br />
dysfunction and metabolic syndroma<br />
Djordje Nale, Serbia<br />
D. Djordjevic, C. Tulic<br />
P-11 Posters<br />
Penile reconstructive surgery<br />
P-11-001<br />
P-11-002<br />
P-11-003<br />
P-11-004<br />
P-11-005<br />
P-11-006<br />
Reconstructive surgery <strong>for</strong> vaselineinduced<br />
granulomas <strong>of</strong> <strong>the</strong> penile<br />
skin<br />
Zoltan Bajory, Hungary<br />
L. Pajor<br />
Penile fractures repair with a midline<br />
ventral approach: Technique and results<br />
Paolo Usai, Italy<br />
M. Fanari, A. De Lisa, G. Caddeo<br />
Sex-related penile injury-our 5 years<br />
experience<br />
Dragan Crnomarkovic, Serbia<br />
S. Micic<br />
Efficiency <strong>of</strong> surgical treatment in patients<br />
with peyronie’s disease with<br />
plication <strong>of</strong> tunica albuginea membrane<br />
in <strong>the</strong> modification <strong>of</strong> nesbit<br />
Igor Gorpynchenko, Ukraine<br />
Y. Gurzhenko, O. Kornienko, M. Romaniuk<br />
Staged urethroplasty <strong>for</strong> urethral<br />
strictures following previous hypospadias<br />
repair in childhood<br />
Badri Gvasaliya, Russia<br />
A. Grinev<br />
Follow-up <strong>for</strong> reconstruction <strong>of</strong> strictures<br />
<strong>of</strong> fossa navicularis a single<br />
technique<br />
Badri Gvasaliya, Russia<br />
A. Grinev<br />
50
poster presentations<br />
P-11-007<br />
P-11-008<br />
Evaluation <strong>of</strong> surgical safety <strong>of</strong> simultaneous<br />
<strong>for</strong>eign material removal in<br />
penis and penile enhancement surgery<br />
Su-Yeon Jang, Republic <strong>of</strong> Korea<br />
Evaluation <strong>of</strong> important factors considered<br />
by men who wish to have penile<br />
enhancement surgery<br />
Su-Yeon Jang, Republic <strong>of</strong> Korea<br />
P-11-009 Fournier’s gangrene – a review <strong>of</strong> 131<br />
cases <strong>for</strong> 18 years<br />
Tiago Lopes, Portugal<br />
R. Pinto, A. Resende, J. Silva, N. Tomada,<br />
P. Diniz, F. Cruz, P. Vendeira<br />
P-11-010<br />
P-11-011<br />
P-11-012<br />
P-11-013<br />
P-11-014<br />
P-11-015<br />
Gold standards in penile reconstructive<br />
surgery<br />
Nicolas Morel Journel, France<br />
F. Courtois, P. Brassard, M. Blamoutier,<br />
C. Leriche<br />
Our experience in <strong>the</strong> management<br />
<strong>of</strong> penile fracture<br />
Mehmet Ekinci, Turkey<br />
M. B. Hoşcan, A. Tunçkıran<br />
Reconstructive surgery in penile cancer<br />
and benign penile disease with<br />
skin grafting<br />
Alvaro Gomez-Ferrer, Spain<br />
J. Rubio, E. Solsona<br />
Surgical reconstruction <strong>of</strong> severe genital<br />
injury: Litectomy in urethral diverticulum<br />
and Fournier‘s gangrene<br />
Oscar Gorria, Spain<br />
J. Aldave<br />
Urethral injuries with concomitant<br />
rupture <strong>of</strong> <strong>the</strong> corpus cavernosum<br />
Marco Grasso, Italy<br />
S. Blanco, F. Berardinelli, F. Antomarchi,<br />
F. Torelli<br />
Dynamics <strong>of</strong> morphological structure<br />
changes <strong>of</strong> <strong>the</strong> penis in patients with<br />
peyronie‘s disease<br />
Yurii Gurzhenko, Ukraine<br />
M. Romaniuk<br />
P-11-017<br />
P-11-018<br />
The use <strong>of</strong> vacuum drainage in twostage<br />
scrotal flap penile reconstructive<br />
surgery in penile sclerosing<br />
granuloma patient to reduce subcutaneous<br />
haematoma: A case study<br />
Boyke Soebhali, Indonesia<br />
A. Susilo, H. Nusaly, I. Anggraini<br />
Modified Nesbit technique in <strong>the</strong> surgical<br />
treatment <strong>of</strong> penile curvature:<br />
Our experience<br />
Wojciech Zachalski, Poland<br />
M. Matuszewski, J. Michajlowski, K. Krajka<br />
P-12 Posters<br />
Ejaculatory disorders<br />
P-12-001<br />
P-12-002<br />
P-12-003<br />
P-12-004<br />
Premature and delayed ejaculation:<br />
Two ends <strong>of</strong> a single continuum influenced<br />
by hormonal milieu<br />
Giovanni Corona, Italy<br />
E. Jannini, F. Lotti, V. Boddi, G. de Vita,<br />
G. Forti, A. Lenzi, E. Mannucci, M. Maggi<br />
Impact <strong>of</strong> premature ejaculation (PE)<br />
on men and <strong>the</strong>ir partners: Results<br />
from <strong>the</strong> ‘PE Confidential’ online<br />
survey<br />
Irem Hattat, Spain<br />
I. Banks, M. Berner, S. Pirnay-Kromer,<br />
I. Mon cada, A. Morales<br />
Prevalence <strong>of</strong> ejaculatory disorders in<br />
45 – 75 year old males with erectile<br />
dysfunction. Influence <strong>of</strong> testosterone<br />
deficiency syndrome<br />
Luis Labairu Huerta, Spain<br />
J. L. Arrondo Arrondo, I. Losada Álvarez, A.<br />
Teyrouz Belliot, O. Gorría Cardesa, M. Ponz<br />
González, J. Iriarte Aristu, A. Solchaga<br />
Martínez<br />
The correlation between erectile dysfunction<br />
and premature ejaculation<br />
in urologic patients who complain <strong>of</strong><br />
LUTS<br />
Ki Hak Moon, Republic <strong>of</strong> Korea<br />
P. H. Song, J. M. Kim, H. T. Kim, J. S. Hyun<br />
P-11-016<br />
Role <strong>of</strong> urgent surgical intervention<br />
in <strong>the</strong> management <strong>of</strong> fracture penis<br />
Hussein Hussein, Egypt<br />
A. Hussein<br />
www.essm.org<br />
51
poster presentations<br />
P-12-005<br />
P-12-006<br />
P-12-007<br />
P-12-008<br />
P-12-009<br />
P-12-010<br />
P-12-011<br />
The comparison <strong>of</strong> premature ejaculation<br />
assessment questionnaires in four<br />
premature ejaculation syndromes: Results<br />
from <strong>the</strong> Turkish Society <strong>of</strong> Andrology<br />
Sexual Health Survey<br />
Ege Can Serefoglu, Turkey<br />
O. Yaman, S. Cayan, R. Asci, I. Orhan,<br />
M. F. Usta, O. Ekmekcioglu, M. Kendirci,<br />
B. Semerci, A. Kadioglu<br />
Prevalence <strong>of</strong> <strong>the</strong> four premature<br />
ejaculation syndromes: Results from<br />
<strong>the</strong> Turkish Society <strong>of</strong> Andrology Sexual<br />
Health Survey<br />
Ege Can Serefoglu, Turkey<br />
O. Yaman, S. Cayan, R. Asci, I. Orhan, M.<br />
F. Usta, O. Ekmekcioglu, M. Kendirci, B.<br />
Semerci, A. Kadioglu<br />
Clinical observation <strong>of</strong> citalopram on<br />
<strong>the</strong> treatment <strong>of</strong> premature ejaculation<br />
Xuejun Shang, China<br />
X. Xia, Y. Shao, Y. Huang<br />
Mechanisms which increase erection<br />
inhibit premature ejaculation. Retrospective<br />
analysis <strong>of</strong> effect <strong>of</strong> 5-PDE<br />
inhibitors, used <strong>for</strong> erectile dysfunction,<br />
on premature ejaculation<br />
Crisitina Dana Staicu, Romania<br />
M. Carsote, C. Poiana, D. Peretianu<br />
Effects <strong>of</strong> PFE5 inhibitors on semen in<br />
men with premature ejaculation<br />
Panagiota Tsounapi, Japan<br />
S. Tsampalas, D. Baltogiannis, D. Giannakis,<br />
N. Kolitsas, S. Koukos, K. Kotsonas, N. Kanakas,<br />
F. Dimitriadis, A. Takenaka, N. S<strong>of</strong>ikitis<br />
Premature Ejaculation (PE) and its associated<br />
conditions in Korean male<br />
sexual health survey<br />
Sang-Kuk Yang, Republic <strong>of</strong> Korea<br />
S. W. Lee, J. K. Park, K. Park, K. J. Oh,<br />
H. J. Park, S.-W. Kim, D. Y. Yang, K.-H.<br />
Moon, J. S. Hyun, K.-S. Min<br />
The applicability <strong>of</strong> PEPP <strong>for</strong>ms in our<br />
country<br />
Ertan Can, Turkey<br />
O. Demir, B. Gumus, T. Değirmenci, A.<br />
Bo lukbasi, M. Basar, C. Akbal, K. Ozgur,<br />
B. Alici, K. Inci, A. Esen<br />
P-13 Posters<br />
Homosexuality and gender identity disorders<br />
P-13-001<br />
P-13-002<br />
P-13-003<br />
P-13-004<br />
P-13-005<br />
P-13-006<br />
P-13-007<br />
Risk <strong>of</strong> venous thromboembolism<br />
(VTE) in estrogen-treated male-to-female<br />
transsexuals: Review <strong>of</strong> literature<br />
and observations from 9 European<br />
centers <strong>for</strong> Gender Dysphoria<br />
Henk Asscheman, The Ne<strong>the</strong>rlands<br />
G. T´Sjoen, A. Lemaire, M. Mas, C. Meriggiola,<br />
A. Mueller, J. Buffat, A. Kuhn,<br />
C. Dhejne, N. Morel Journel, L. Gooren<br />
Parenthood wishes and attitudes <strong>of</strong><br />
transgendered people<br />
Delia Baez, Spain<br />
P. Hernandez, P. Gutierrez, M. Mas<br />
Traumatic childhood experiences in<br />
subjects with male to female gender<br />
identity disorder<br />
Elisa Bandini, Italy<br />
F. Lotti, V. Ricca, M. C. Meriggiola, E. A.<br />
Jan nini, C. Manieri, G. Corona, J. Ristori,<br />
E. Fanni, M. Maggi<br />
Prevalence <strong>of</strong> hyperandrogenism, polycystic<br />
ovary syndrome and metabolic<br />
syndrome in female-to-male<br />
transsexuals<br />
Gilberto Pérez-López, Spain<br />
A. Becerra, M. Menacho, G. Rubalcava,<br />
E. Chiquete, M. J. Lucio, J. M. Rodriguez-<br />
Molina, N. Asenjo, J. F. Martín-Lázaro, M.<br />
V. Aguilar<br />
Effects <strong>of</strong> testosterone treatment on<br />
cardiovascular risk and insulin resistance<br />
in female-to-male transsexuals<br />
Antonio Becerra, Spain<br />
G. Pérez-López, M. Menacho, G. Rubalcava,<br />
E. Chiquete, M. J. Lucio, J. M. Rodriguez-<br />
Molina, N. Asenjo, J. F. Martín-Lázaro, M.<br />
V. Aguilar<br />
Sexual preferences and behavior <strong>of</strong><br />
transsexual patients<br />
Mireille Bonierbale, France<br />
A. Gorin-Lazard, A. Maquigneau<br />
The neurobiology <strong>of</strong> sexual orientation<br />
Jerome Goldstein, USA<br />
52
poster presentations<br />
P-14 Posters<br />
Women‘s sexual health<br />
P-14-001 Incidence <strong>of</strong> sexual dysfunction:<br />
A prospective survey in ghanaian females<br />
Nafiu Amidu, Ghana<br />
W. K. B.A. Owiredu, E. Woode, O. Addai-<br />
Mensah, A. Alhassan, E. A. Tagoe<br />
P-14-010<br />
P-14-011<br />
Do females respond differently to<br />
sexual stimuli across <strong>the</strong>ir monthly<br />
hormonal cycle Preliminary results<br />
using eevent related potential analysis<br />
(P300)<br />
Ilan Gruenwald, Israel<br />
Y. Granovsky, L. Lowenstein, Y. Vardi<br />
Sexual debut<br />
Ekaterina Kulchavenya, Russia<br />
P-14-002<br />
P-14-003<br />
P-14-004<br />
P-14-006<br />
P-14-007<br />
P-14-008<br />
P-14-009<br />
Physiological versus surgical menopause<br />
– impact <strong>of</strong> female sexual satisfaction<br />
Dana Bucuras, Romania<br />
D. Anastasiu, M. Craina<br />
Effect <strong>of</strong> sustained weight loss on hiperandrogenemia<br />
and body image –<br />
conections with sexual satisfaction<br />
Dana Bucuras, Romania<br />
M. Craina, D. Anastasiu, D. Anastasiu<br />
Anxious attachment is associated<br />
with lesser vaginal orgasm consistency<br />
Rui Costa, United Kingdom<br />
S. Brody<br />
Sexual dysfunction in Greek women<br />
with type 1 diabetes: A comparative<br />
study<br />
Konstantinos Dimitropoulos, Greece<br />
A. Bargiota, I. Zachos, G. Koukoulis, M. Melekos,<br />
V. Tzortzis<br />
Treatment <strong>of</strong> Hypoactive Sexual Desire<br />
Disorder (HSDD) in women with<br />
Major Depression (MDD) – What factors<br />
constitute clinical improvement<br />
Louis F Fabre, USA<br />
S. J. Kramer, L. C. Smith<br />
Gepirone-ER: Is <strong>the</strong> anxiolytic effect<br />
in women with Major Depressive Disorder<br />
(MDD) responsible <strong>for</strong> improvement<br />
in sexual function<br />
Louis F Fabre, USA<br />
S. J. Kramer, L. C. Smith<br />
Vaginal reconstruction with ileum<br />
and uterus-neovaginal anastomosis<br />
in patient with variant <strong>of</strong> rokitansky<br />
syndrome<br />
Dario Fontana, Italy<br />
L. Galletto, L. Rolle, M. Timpano, E. Galletto,<br />
C. Ceruti, O. Sedigh, C. Negro<br />
P-14-012<br />
P-14-013<br />
P-14-014<br />
P-14-015<br />
P-14-016<br />
P-14-017<br />
P-14-021<br />
Good contraception as a base <strong>of</strong> sexual<br />
satisfaction<br />
Ekaterina Kulchavenya, Russia<br />
Sexuality: A vulnerable dimension in<br />
life<br />
Birgitte Schantz Laursen, Denmark<br />
K. Overvad, A. S. Olesen, C. Delmar, L.<br />
Arendt-Nielsen<br />
Update in first line treatment <strong>of</strong> female<br />
urethral stricture: Vaginal inlay<br />
urethroplasty<br />
Sinasi Yavuz Onol, Turkey<br />
F. F. Onol, O. Kurt, O. Kose, M. R. Erdem<br />
Female and male sexual behavior and<br />
satisfaction on <strong>the</strong> middle-east Hungarian<br />
region<br />
Marta Rakos, Hungary<br />
E. Holman, L. Parducz<br />
The role <strong>of</strong> metabolism <strong>of</strong> nitric oxide<br />
in <strong>the</strong> <strong>for</strong>mation <strong>of</strong> female sexual<br />
dysfunctions in menopause<br />
Oksana Romashchenko, Ukraine<br />
A. Soloviev, S. Melnykov, V. Bilogolovskaya,<br />
V. Kyslova<br />
Self-assessment <strong>of</strong> genital anatomy,<br />
sexual sensitivity and function in<br />
women focusing on <strong>the</strong> labia <strong>for</strong> surgical<br />
implications<br />
Justine Schober, USA<br />
J. Chan, L. Mayoglou, H. Meyer-Bahlburg<br />
Sexual pain disorders: A mystery<br />
through history<br />
Marianna Tsatali, Greece<br />
V. Stergiou<br />
www.essm.org<br />
53
poster presentations<br />
P-15 Posters<br />
Miscellaneous<br />
P-15-001<br />
P-15-002<br />
P-15-003<br />
P-15-004<br />
P-15-005<br />
P-15-006<br />
P-15-007<br />
P-15-008<br />
P-15-009<br />
P-15-010<br />
Necrotizing fasciitis; Our experience<br />
during <strong>the</strong> last 10 years<br />
Javier Aldave, Spain<br />
O. Gorria<br />
Analysis <strong>of</strong> <strong>the</strong> sexual problems <strong>of</strong><br />
HIV positive individuals cared <strong>for</strong> in a<br />
London genitourinary medicine clinic<br />
Jane Ashby, United Kingdom<br />
N. Pickwoad, J. Vaneyk, A. Mears, D. Goldmeier<br />
The effects <strong>of</strong> repeating TESE on testes<br />
Mehmet Tahmaz, Turkey<br />
K. Erten, M. Dayanc<br />
Chronic penile edema due to compulsive<br />
masturbation<br />
Rocco Salvatore Calabrò, Italy<br />
A. Galì, E. Ferlazzo, G. Gervasi, F. Quattrini,<br />
S. Marino, P. Bramanti<br />
Desire <strong>for</strong> penile girth enhancement<br />
and <strong>the</strong> effects <strong>of</strong> self hyaluronic acid<br />
gel injection<br />
Enis Rauf Coskuner, Turkey<br />
B. Ozkan<br />
Seminal vesicle cyst presenting as<br />
pelvic abscess<br />
Péter Dombóvári, Hungary<br />
S. Mavrogenis, K. Borka, P. Bata, P. Nyirády<br />
Osteoporosis in males with Klinefelter’s<br />
syndrome and hypogonadothropic<br />
hypogonadism<br />
Abdullah Demirtas, Turkey<br />
A. Gokce, E. Akinsal, O. Ekmekcioglu<br />
Varicoceles and infertility – a systematic<br />
review<br />
Mikkel Fode, Denmark<br />
J. Sønksen<br />
Penile morphology in Egyptian men<br />
Khaled Gadalla, Egypt<br />
Aromatase inhibitors <strong>for</strong> <strong>the</strong> treatment<br />
<strong>of</strong> infertile men with obesity<br />
Safail Gamidov, Russia<br />
O. Tazhetdinov, R. Ovchinnikov, A. Pav lovichev<br />
P-15-012<br />
P-15-013<br />
P-15-014<br />
P-15-016<br />
Rare case <strong>of</strong> atypical epi<strong>the</strong>lioid hemangioma<br />
<strong>of</strong> penis evidenced with<br />
elastosonography<br />
Marco Grasso, Italy<br />
S. Blanco, F. Berardinelli, N. Zucchini, G.<br />
Bovo<br />
Sexual behaviour in young European<br />
holidaymakers visiting Mediterranean<br />
resorts<br />
Karen Hughes, United Kingdom<br />
N. Blay, M. Bellis, A. Calafat<br />
Gender differences in <strong>the</strong> prevalence<br />
<strong>of</strong> sexual dysfunction and attitudes<br />
towards sexuality among general<br />
population in Bulgaria<br />
Zdravko Asenov Kamenov, Bulgaria<br />
R. Georgieva<br />
Characteristics <strong>of</strong> gonorrhoea patients<br />
in Prague<br />
Martina Kojanova, Czech Republic<br />
I. Kuklova, P. Velcevsky, J. Belacek, M.<br />
Novak<br />
P-15-017 History <strong>of</strong> mental health issues in 159<br />
patients presenting to a genitourinary<br />
medicine clinic following sexual<br />
assault<br />
Emma Mccarty, United Kingdom<br />
S. Quah, R. Maw, W. Dinsmore, C. Emerson<br />
P-15-018<br />
P-15-019<br />
P-15-020<br />
History <strong>of</strong> mental health issues in<br />
159 pa tients presenting after sexual<br />
assault at a genitourinary medicine<br />
clinic<br />
Emma Mccarty, United Kingdom<br />
W. DIinsmore, S. Quah, R. Maw, C.<br />
Emerson<br />
Dexamethasone treatment <strong>of</strong> pregnan<br />
cies at risk <strong>for</strong> congenital adrenal<br />
hyperplasia diminishes behavioral<br />
mas culinization / defeminization <strong>of</strong> <strong>of</strong>fspring<br />
in adolescence and young adulthood<br />
Heino F L Meyer-Bahlburg, USA<br />
C. Dolezal, B. Kassai, P. Chatelain, M. G.<br />
Forest, M. I. New<br />
Could transmission <strong>of</strong> sexual diseases<br />
affect youth’s sexual behaviors<br />
Evangelia Nakopoulou, Greece<br />
S. Papaharitou, S. Batalama, E. Logo<strong>the</strong>ti,<br />
M. Tsiouprou, D. Hatzichristou<br />
54
poster presentations<br />
P-15-021<br />
P-15-022<br />
P-15-023<br />
Unusual case <strong>of</strong> penile hematoma<br />
Djordje Nale, Serbia<br />
N. Bojanic<br />
Introducing a new index parameter<br />
and HBA assay <strong>for</strong> monitoring <strong>the</strong><br />
fertility potential during a complex<br />
food supplement administration<br />
Péter Osváth, Hungary<br />
M. Szűcs<br />
Comparison <strong>of</strong> female sexual problems<br />
in three mediterranean countries<br />
Stamatis Papaharitou, Greece<br />
E. Nakopoulou, J. Martinez Salamanca,<br />
M. Lemos, C. Martinez, I. Hattat, E. Akkus,<br />
H. Hattat, D. Hatzichristou<br />
P-15-024<br />
P-15-025<br />
P-15-026<br />
P-15-028<br />
How painful is a circumcision – A prospective<br />
study<br />
Bhavan Prasad Rai, United Kingdom<br />
A. Qureshi, N. Kadi, R. Donat<br />
Perceptions <strong>of</strong> women and <strong>the</strong>ir partners<br />
on <strong>the</strong> impact <strong>of</strong> erectile dysfunction:<br />
A qualitative study<br />
Derek Ru<strong>the</strong>r<strong>for</strong>d, United Kingdom<br />
Sexual healing through orgasm<br />
Pia Struck, Denmark<br />
Sexological counselling in patients<br />
with prostate cancer<br />
Birgitte Schantz Laursen, Denmark<br />
A. Højer Mikkelsen<br />
www.essm.org<br />
55
Reference<br />
1. Dean J et al.<br />
Rev Urol 2004;6(Suppl 6):S22-29.<br />
Prescribing In<strong>for</strong>mation: Testim 50mg Gel.<br />
Testim is a clear to translucent gel. One tube <strong>of</strong><br />
5 g gel contains 50 mg testosterone Indication:<br />
Testosterone replacement <strong>the</strong>rapy <strong>for</strong> male hypogonadism<br />
when testosterone defi ciency has been confi rmed by<br />
clinical features and biochemical tests. Dosage and<br />
administration: Recommended starting dose: One tube<br />
<strong>of</strong> 5 g gel daily. If serum testosterone levels are below <strong>the</strong><br />
normal range, <strong>the</strong> dose may be increased from 50 mg (one<br />
tube) to 100 mg (two tubes) once daily. Once opened apply<br />
<strong>the</strong> entire content <strong>of</strong> <strong>the</strong> tube immediately to clean dry<br />
intact skin <strong>of</strong> <strong>the</strong> shoulders and/or upper arms, preferably<br />
in <strong>the</strong> morning. Wash hands immediately after use. Do<br />
not apply to <strong>the</strong> genital area. Not <strong>for</strong> use in children. Not<br />
clinically evaluated in males less than 18 years <strong>of</strong> age.<br />
Contraindications: Androgens are contraindicated in<br />
men with carcinoma <strong>of</strong> <strong>the</strong> breast or known or suspected<br />
carcinoma <strong>of</strong> <strong>the</strong> prostate. Hypersensitivity to testosterone<br />
(syn<strong>the</strong>sised from soy) or to any <strong>of</strong> <strong>the</strong> excipients.<br />
Pregnancy and lactation: Testim is not indicated <strong>for</strong><br />
women and must not be used in pregnant or breastfeeding<br />
women. Pregnant women must avoid skin contact with<br />
Testim application sites. Warnings and precautions: Prior<br />
to <strong>the</strong>rapy, <strong>the</strong> risk <strong>of</strong> prostate cancer must be excluded.<br />
Examine breast and prostate gland at least yearly and<br />
twice yearly in elderly or at risk patients (those with<br />
clinical or familial factors). Monitor serum calcium levels in<br />
patients with skeletal metastases at risk <strong>of</strong> hypercalcaemia/<br />
hypercalcuria. Testosterone may cause oedema with or<br />
without congestive cardiac failure in patients with severe<br />
cardiac, hepatic or renal insufficiency. In this case, stop<br />
treatment immediately. Use with caution in patients with<br />
hypertension, ischemic heart disease, epilepsy, and migraine.<br />
Possible increased risk <strong>of</strong> sleep apnoea in patients who<br />
are obese or with chronic respiratory disease. Improved<br />
insulin sensitivity may occur. Irritability, nervousness,<br />
weight gain, prolonged or frequent erections may indicate<br />
excessive androgen exposure requiring dosage adjustment.<br />
If severe application site reaction occurs, discontinue<br />
treatment if necessary. Periodically monitor testosterone<br />
concentrations, full blood count, lipid pr<strong>of</strong>ile, and liver<br />
function. Testosterone may produce a positive reaction in<br />
an anti-doping test. Not <strong>for</strong> use in women. The gel may be<br />
transferred to o<strong>the</strong>rs by skin to skin contact, which could<br />
lead to adverse reactions (inadvertent androgenisation)<br />
by repeated contact. In<strong>for</strong>m <strong>the</strong> patient about <strong>the</strong> transfer<br />
risk, which can be prevented by covering or washing <strong>the</strong><br />
site be<strong>for</strong>e contact. Testim gel should not be prescribed<br />
<strong>for</strong> patients who may not comply with safety instructions<br />
(e.g. severe alcoholism, drug abuse, severe psychiatric<br />
disorders). The content <strong>of</strong> <strong>the</strong> tube is flammable. Testim<br />
contains propylene glycol which may cause skin irritation.<br />
Interactions: Interactions have been reported with oral<br />
anticoagulants, ACTH, corticosteroids and propranolol.<br />
Laboratory tests have shown that androgens may decrease<br />
levels <strong>of</strong> thyroxine-binding globulin. Undesirable effects:<br />
Common (1% to
List <strong>of</strong> Exhibitors – exhibition map<br />
Exhibitors A – Z<br />
American Medical Systems Europe B.V. 8<br />
ASESA – Associación Española de 12<br />
Andrología Medicina Sexual y<br />
Reproductiva<br />
Coloplast A / S 9<br />
Eli Lilly & Company 3<br />
<strong>ESSM</strong> – European Society <strong>for</strong> Sexual 7<br />
Medicine<br />
ESHA – European Sexual Health 5<br />
Alliance<br />
ISSM – International Society <strong>for</strong> Sexual 6<br />
Medicine<br />
Itamar Medical Ltd. 11<br />
Medispec Ltd 10<br />
Nature Publishing Group 4<br />
Pfizer 1<br />
Booth No.<br />
Booth No.<br />
1 Pfizer<br />
Exhibitors<br />
3 Eli Lilly & Company<br />
4 Nature Publishing Group<br />
5 ESHA – European Sexual Health<br />
Alliance<br />
6 ISSM – International Society <strong>for</strong> Sexual<br />
Medicine<br />
7 <strong>ESSM</strong> – European Society <strong>for</strong> Sexual<br />
Medicine<br />
8 American Medical Systems Europe B.V.<br />
9 Coloplast A / S<br />
10 Medispec Ltd<br />
11 Itamar Medical Ltd.<br />
12 ASESA – Associación Española de<br />
Andrología Medicina Sexual y<br />
Reproductiva<br />
Pavillion 1– Exhibition Area<br />
4 5 6 7 8 9 10 11<br />
12<br />
Internet<br />
Centre<br />
Working Area<br />
3 Catering<br />
Poster Exhibition<br />
1<br />
Highlighted<br />
Poster Area<br />
Catering<br />
Entrance from<br />
Meeting Rooms<br />
Restaurant<br />
www.essm.org<br />
57
List <strong>of</strong> chairpersons and presenters<br />
Name Page Name Page<br />
A<br />
Abdel-Hamid, I. A..................................................... 34<br />
Aggelis, A...........................................................44, 45<br />
Akkus, E.............................................................33, 37<br />
Albersen, M........................................................38, 42<br />
Aldave, J................................................................... 54<br />
Alemida de Araujo Goes, P........................................ 47<br />
Amar, Edouard......................................................... 31<br />
Amidu, N.................................................................. 53<br />
Anderson, B.............................................................. 43<br />
Anderson, P.............................................................. 26<br />
Andrew, G................................................................ 29<br />
Andrianne, R............................................................ 31<br />
Angulo, J............................................................28, 32<br />
Arrondo Arrondo, J................................................... 26<br />
Ashby, J.................................................................... 54<br />
Askitis, A.................................................................. 40<br />
Asscheman, H........................................................... 52<br />
Astobieta Odriozola, A.............................................. 26<br />
Aversa, A.................................................................. 29<br />
Aydogdu, O........................................................36, 42<br />
B<br />
Baez, D..................................................................... 52<br />
Bajory, Z................................................................... 50<br />
Baldo, O................................................................... 37<br />
Bandini, E...........................................................34, 52<br />
Becerra, A................................................................. 52<br />
Beggi, M................................................................... 28<br />
Bekker, M................................................................. 40<br />
Bellis, M. A......................................................... 28, 32<br />
Berner, M............................................................35, 40<br />
Bettocchi, C............................................26, 30, 33, 35<br />
Bitzer, J.............................................29, 33, 35, 38, 40<br />
Bizic, M.................................................................... 35<br />
Boddi, V.................................................................... 47<br />
Bolyakov, A............................................................... 41<br />
Bonierbale, M........................................................... 52<br />
Bosinski, H..........................................................32, 35<br />
Bozkurt, O................................................................ 38<br />
Bratsas, K................................................................. 48<br />
Brody, S..............................................................30, 31<br />
Bronselaer, G............................................................ 32<br />
Bucuras, D....................................................37, 40, 53<br />
Bucuras, V................................................................. 48<br />
Bunker, C.................................................................. 29<br />
Burgu, B................................................................... 36<br />
Burri, A..................................................................... 40<br />
C<br />
Calabrò, R. S............................................................. 54<br />
Calomfirescu, N........................................................ 37<br />
Can, E...................................................................... 52<br />
Canguven, O.......................................................43, 45<br />
Carvalheira, A...............................................40, 41, 48<br />
Castela, A...........................................................39, 42<br />
Castiglione, F............................................................. 38<br />
Cayan, S.............................................................35, 40<br />
Chen, J...............................................................36, 40<br />
Chiang, P.-K.............................................................. 44<br />
Claes, H.................................................................... 48<br />
Colombo, F................................................... 28, 36, 49<br />
Cormio, L. C............................................................. 38<br />
Corona, G.............................31, 33, 34, 37, 45, 46, 51<br />
Cortada, J................................................................. 44<br />
Coskuner, E. R........................................................... 54<br />
Costa, C..............................................................32, 38<br />
Costa, R.................................................................... 53<br />
Courtois, F..........................................................33, 48<br />
Crnomarkovic, D....................................................... 50<br />
Cruz Navarro, N.................................................. 26, 31<br />
Cuzin, B.................................................................... 29<br />
D<br />
Darabi Mahboub, M. R.......................................31, 44<br />
Dean, J.........................................................27, 32, 41<br />
Debruyne, F...................................................31, 37, 46<br />
Demir, O................................................................... 42<br />
Demirtas, A.............................................................. 54<br />
de Quiroga, S........................................................... 37<br />
DeRogatis, L............................................................. 46<br />
Dimitropoulos, K....................................................... 53<br />
Dinsmore, W. W........................................................ 32<br />
Di Pierro, E. D........................................................... 29<br />
Djinovic, R................................................................ 26<br />
Djordjevic, M. L...................................................37, 38<br />
Dombóvári, P............................................................ 54<br />
Doumas, M............................................................... 34<br />
E<br />
Eardley, I.............................................................36, 37<br />
Edhem, I................................................................... 49<br />
Egui, A..................................................................... 36<br />
Egydio, P. H.............................................................. 38<br />
Ekinci, M.................................................................. 51<br />
Emmanuele di Villa, B. d’.......................................... 41<br />
Ergul, A.................................................................... 29<br />
Erol, B................................................................34, 37<br />
F<br />
Fabre, L. F...........................................................46, 53<br />
Faix, A................................................................35, 50<br />
Fekete, F.................................................................... 43<br />
Ferenidou, F.............................................................. 35<br />
Ferran García, J......................................................... 26<br />
Fica, S....................................................................... 46<br />
58
List <strong>of</strong> chairpersons and presenters<br />
Name Page Name Page<br />
Fisher, A.D................................................................ 31<br />
Fode, M..............................................................26, 54<br />
Fontana, D................................................................ 53<br />
Foster, M.................................................................. 49<br />
Fotas, A.................................................................... 49<br />
Fragasso, G............................................................... 29<br />
Franco, G.................................................................. 41<br />
Fugl-Meyer, K............................................................ 41<br />
G<br />
Gadalla, K................................................................. 54<br />
Galesanu, C.............................................................. 47<br />
Gamidov, S.........................................................49, 54<br />
Garaffa, G................................................................ 30<br />
García Cruz, E........................................................... 26<br />
Gelez, H................................................................... 30<br />
Georgiadis, J............................................................. 30<br />
Giraldi, A..........................................29, 30, 31, 38, 40<br />
Giuliano, F..........................................................36, 37<br />
Goldmeier, D............................................................ 28<br />
Goldstein, I............................................................... 27<br />
Goldstein, J............................................................... 52<br />
Gomez-Ferrer, A........................................................ 51<br />
Gontero, P................................................................ 50<br />
Gonzalez-Cadavid, N. F............................................. 33<br />
Gorpynchenko, I...........................................35, 46, 50<br />
Gorria, O.................................................................. 51<br />
Graefen, M............................................................... 30<br />
Grasso, A.................................................................. 42<br />
Grasso, M.....................................................50, 51, 54<br />
Gratzke, C................................................................ 32<br />
Greenfield, D. M....................................................... 40<br />
Greggain, J............................................................... 30<br />
Gruenwald, I.......................................................28, 53<br />
Gurzhenko, Y............................................................ 51<br />
Gvasaliya, B.............................................................. 50<br />
H<br />
Hackett, G................................................................ 36<br />
Hamann, S............................................................... 35<br />
Hassan, A................................................................. 43<br />
Hattat, I........................................................41, 44, 51<br />
Hatzichristou, D..................................................28, 32<br />
Hatzimouratidis, K.................................................... 31<br />
Hedlund, P.................................................... 32, 34, 38<br />
Hellstrom, W.................................................33, 34, 38<br />
Ho, C.-H................................................................... 33<br />
Holman, E................................................................ 53<br />
Hughes, K................................................................. 54<br />
Hussein, H..........................................................49, 51<br />
Hyun, J.-S................................................................. 32<br />
I<br />
Iacono, F................................................................... 48<br />
Ioakeimidis, N.....................................................34, 42<br />
Izumi, K.................................................................... 47<br />
J<br />
Jackson, G................................................................ 34<br />
Jang, S.-Y.................................................................. 51<br />
Janjgava, S................................................................ 37<br />
Jannini, E......................................................28, 30, 36<br />
Jern, P.................................................................33, 36<br />
K<br />
Kadioglu, A........................................................26, 37<br />
Kamenov, Z. A..............................................34, 48, 54<br />
Kartsaklis, P............................................................... 50<br />
Kawanishi, Y............................................................. 49<br />
Kayigil, Ö............................................................49, 50<br />
Kell, P........................................................................ 32<br />
Kendirci, M............................................................... 31<br />
Khademi, A.............................................................. 41<br />
Khera, M.................................................................. 36<br />
Kim, S. J.............................................................30, 42<br />
Király, I. E.................................................................. 42<br />
Kojanova, M............................................................. 54<br />
Kojovic, V.................................................................. 50<br />
Kopa, Z..................................................................... 44<br />
Korda, Beate............................................................. 35<br />
Koyuncu, H............................................................... 33<br />
Krüger, Tillmann H.................................................... 41<br />
Kulchavenya, E.......................................................... 53<br />
L<br />
Labairu Huerta, L..........................................44, 46, 51<br />
La Fuente, J. M...................................................30, 38<br />
Laursen, B. S.......................................................53, 55<br />
Lee, D. M.................................................................. 40<br />
Lee, E....................................................................... 34<br />
Liaw, R. L.................................................................. 39<br />
Lopes,T..................................................................... 51<br />
Louro, Nuno............................................................. 26<br />
Luis, S.J................................................................... 30<br />
M<br />
Maggi, M...............................................29, 36, 40, 41<br />
Majstorovic, M.......................................................... 50<br />
Maniglio, R............................................................... 32<br />
Martin-Alguacil, N.................................................... 43<br />
Martinez Jabaloyas, J. M...............................32, 44, 46<br />
Martínez-Salamanca, J. I......................... 26, 34, 35, 36<br />
Martin Morales, A.........................................26, 28, 37<br />
www.essm.org<br />
59
List <strong>of</strong> chairpersons and presenters<br />
Name Page Name Page<br />
Mas, Manuel................................................26, 29, 31<br />
Mccarty, E...........................................................48, 54<br />
McMahon, C......................................................28, 31<br />
Melchor Galán, A...................................................... 49<br />
Melon, S................................................................... 28<br />
Meyer-Bahlburg, H. F. L............................................. 54<br />
Mihalca, R................................................................ 46<br />
Minhas, S.....................................................26, 28, 36<br />
Mirkin, Y................................................................... 49<br />
Mirone, V.................................................................. 37<br />
Moncada, I.....................26, 28, 31, 35, 41, 47, 48, 49<br />
Montorsi, F...................................................30, 31, 32<br />
Moon, D. G..................................................42, 43, 48<br />
Moon, I.................................................................... 46<br />
Moon, K. H............................................................... 51<br />
Moossa, F................................................................. 44<br />
Morel Journel, N....................................................... 51<br />
Muller, A.................................................................. 39<br />
Muneer, A................................................................ 29<br />
N<br />
Nakopoulou, E....................................................31, 54<br />
Nale, D.........................................................43, 50, 55<br />
Nappi, R.......................................................29, 33, 41<br />
Nigam, R.................................................................. 46<br />
Noori, S.................................................................... 43<br />
Nowosielski, K.......................................................... 35<br />
Nugent, B................................................................. 35<br />
O<br />
Ohl, D...................................................................... 26<br />
Okwun, C. K............................................................. 43<br />
Onol, S. Y......................................................46, 49, 53<br />
Opsomer, R............................................................... 48<br />
Osváth, P.................................................................. 55<br />
Oudot, A.................................................................. 42<br />
P<br />
Pacholski, M............................................................. 43<br />
Paduch, D........................................................... 41, 48<br />
Palma Ceppi, C......................................................... 36<br />
Palminteri, E............................................................. 37<br />
Papaharitou, S.......................................................... 55<br />
Park, H.-J............................................................44, 50<br />
Park, J. K................................................................... 42<br />
Park, K...................................................................... 42<br />
Pasqualotto, F........................................................... 41<br />
Paulino, E................................................................. 32<br />
Peretianu, D........................................................37, 45<br />
Pérez-López, G.......................................................... 52<br />
Pezzoni, F.................................................................. 50<br />
Philippsohn, S........................................................... 31<br />
Pomerol Montseny, J. Mª.......................................... 26<br />
Porst, H............................................28, 35, 36, 37, 48<br />
Prieto Castro, R......................................................... 26<br />
Puigvert Martínez, A........................................... 26, 41<br />
Q<br />
Quattrini, F................................................................ 50<br />
R<br />
Radwan, D................................................................ 42<br />
Rai, B. P.................................................................... 55<br />
Rakos, M.................................................................. 53<br />
Ralph, D...........................................26, 30, 35, 37, 38<br />
Raynaud, J. P.......................................................34, 47<br />
Rees, C. A................................................................. 32<br />
Reisman, Y....................................................36, 40, 49<br />
Rocha Mendes, J....................................................... 26<br />
Rodríguez Vela, L...................................................... 26<br />
Rokkas, K......................................................34, 39, 47<br />
Romaniuk, M............................................................ 36<br />
Romashchenko, O..................................................... 53<br />
Romero-Otero, J....................................................... 33<br />
Rosenbaum, T.....................................................30, 40<br />
Rosen, R...........................................28, 32, 33, 34, 47<br />
Roumeguere, T.......................................................... 31<br />
Ru<strong>the</strong>r<strong>for</strong>d, D........................................................... 55<br />
S<br />
Salonia, A...............................................27, 40, 45, 47<br />
Sancaktutar, A. A...................................................... 44<br />
Sand, M.............................................................32, 34<br />
Sandner, P................................................................. 32<br />
Sarquella, J............................................................... 45<br />
Schober, J................................................................. 53<br />
Schulman, C............................................................. 36<br />
Schul<strong>the</strong>iss, D........................................................... 29<br />
Schwenkhagen, A...............................................29, 33<br />
Sedigh, O................................................................. 26<br />
Serefoglu, E. C....................................................36, 52<br />
Shaeer, O. K. Z. M..................................................... 38<br />
Shamsodini, A.......................................................... 26<br />
Shang, X.................................................................. 52<br />
Shechter, A............................................................... 43<br />
Simonelli, C.............................................................. 32<br />
Simonsen, U............................................................. 29<br />
Simsek, K.................................................................. 48<br />
Soebhali, B............................................................... 51<br />
S<strong>of</strong>ikitis, N................................................................ 28<br />
Sonksen, J.......................................................... 26, 33<br />
Sorokin, I.................................................................. 41<br />
Sorsaburu, S............................................................. 45<br />
Spillings, A............................................................... 35<br />
60
List <strong>of</strong> chairpersons and presenters<br />
Name Page Name Page<br />
Sramkova, T.............................................................. 45<br />
Staicu, C. D............................................................... 52<br />
Stanislavov, R............................................................ 47<br />
Startsev, V................................................................. 47<br />
Struck, P................................................................... 55<br />
Sultan, R................................................................... 46<br />
Sutory, M.................................................................. 37<br />
Symonds, T............................................................... 32<br />
T<br />
Tahmaz, M.........................................................44, 54<br />
Teimourpour, N......................................................... 40<br />
Terentes-Printzios, D.................................................. 47<br />
Tereso, A.................................................................. 47<br />
Tok, A....................................................................... 47<br />
Tomada, N................................................................ 45<br />
Tsatali, M.................................................................. 53<br />
Tsounapi, P................................................................ 52<br />
Tuiten, A................................................................... 32<br />
Tunçkiran, A.......................................................44, 45<br />
U<br />
Usai, P...................................................................... 50<br />
Usta, M. F...........................................................30, 36<br />
V<br />
Vardi, Y...............................................................31, 33<br />
Vendeira, P. S............................................................ 34<br />
Vignozzi, L..........................................................38, 43<br />
Viigimaa, M.............................................................. 29<br />
Virag, R..............................................................41, 49<br />
Vlachopoulos, C......................................29, 41, 43, 44<br />
W<br />
Waldinger, M. D.................................................33, 35<br />
Wimpissinger, F......................................................... 49<br />
Wylie, K..............................................................30, 41<br />
Y<br />
Yang, D. Y................................................................. 43<br />
Yang, S.-K................................................................. 52<br />
Yoo, S....................................................................... 49<br />
Z<br />
Zachalski, W.............................................................. 51<br />
Zachos, I................................................................... 53<br />
Zaitsev, V.................................................................. 33<br />
Zitzmann, M.......................................................32, 40<br />
www.essm.org<br />
61
Membership New and<br />
Renewal Application<br />
The European Society <strong>for</strong> Sexual Medicine welcomes new applications<br />
<strong>for</strong> membership from individuals who are interested in <strong>the</strong> field<br />
<strong>of</strong> sexual medicine.<br />
becoming essM member automatically means becoming issM<br />
member and receiving <strong>the</strong> issM <strong>of</strong>ficial journal JsM, receiving<br />
<strong>the</strong> essM newsletter essM today and free access to <strong>the</strong> essM<br />
website restricted Members’ area.<br />
The following membership categories are available:<br />
■ full membership is open to all pr<strong>of</strong>essionals, citizens <strong>of</strong> any European<br />
country, or country whose citizens have <strong>for</strong>merly been accepted <strong>for</strong> membership, or<br />
non-European citizens working permanently in Europe, with specific interest in <strong>the</strong><br />
area <strong>of</strong> sexual medicine and who have an appropriate qualification in <strong>the</strong>ir<br />
discipline. A candidate <strong>for</strong> full membership will be required to make <strong>for</strong>mal<br />
application to <strong>the</strong> <strong>ESSM</strong>. The mechanism <strong>for</strong> appointment to membership is<br />
<strong>the</strong> responsibility <strong>of</strong> <strong>the</strong> Executive Committee. The candidate may be asked to<br />
show evidence that his/her training and pr<strong>of</strong>essional activities embrace <strong>the</strong> field<br />
<strong>of</strong> sexual medicine. Full members, elsewhere referred to as “eligible members”,<br />
are entitled to vote at <strong>the</strong> Business Meeting.<br />
■ associate membership may be requested by any person who does not fulfil<br />
<strong>the</strong> above criteria, such as non-European citizens not working permanently in Europe,<br />
people in training, industry etc. Associate members cannot vote in ballots <strong>of</strong> <strong>the</strong><br />
Society or hold <strong>of</strong>fice in <strong>the</strong> Society.<br />
For fur<strong>the</strong>r in<strong>for</strong>mation feel free to visit <strong>the</strong> website www.essm.org or contact<br />
<strong>the</strong> Secretariat at:<br />
essM secretariat<br />
c/o AIM CONGRESS – AIM Group<br />
Via G. Ripamonti 129<br />
20141 Milano, Italy<br />
Phone: +39 – 02 – 56 60 12 89<br />
Fax: +39 – 02 – 70 04 85 77<br />
Email: admin@essm.org
<strong>Congress</strong> and Exhibition Office<br />
CPO HANSER SERVICE<br />
Hanser & Co GmbH<br />
Zum Ehrenhain 34<br />
22885 Barsbüttel • Germany<br />
Phone: +49 – 40 – 670 88 20<br />
Fax: +49 – 40 – 670 32 83<br />
Email: essm@cpo-hanser.de<br />
www.essm.org
Change language